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Introduction
1Introduction
Cardiovascular disease is the second-leading cause of death in the Netherlands with 
approximately 38.000 deaths a year.1 In addition, stroke is the leading cause of dis-
ability. A stroke is a sudden loss of neurological function due to an interruption of 
blood flow to the brain or extravasation of blood in the brain. The majority of strokes 
is of ischemic origin (87%)2 in which a blood clot occludes one of the arteries of 
the brain. In a transient ischemic attack (TIA), this interruption and the subsequent 
symptoms are only temporary, mostly hours, and do not lead to a permanent deficit.3 
Ischemic stroke and TIA have similar causes and their clinical management is identi-
cal as atherosclerosis plays an important causal role in both.2 
Atherosclerosis is a chronic inflammatory disease of especially large arteries with 
thickening of the arterial vessel wall which progresses into plaque development and 
stenosis of the vessel lumen. There are different stages of atherosclerotic plaque 
development4, 5; first deposition of lipids in the artery wall, followed by the influx of 
different cells in the lesion like macrophages, inflammatory cells and foam cells. 
Eventually this process can lead to a complicated plaque with a lipid-rich necrotic 
core, intraplaque hemorrhage, calcifications, inflammatory cells and an overlying 
fibrous cap. One of the major hazards of the atherosclerotic plaque is that it can 
rupture. Thrombogenic components of the plaque then come into contact with blood 
and a thrombus develops. This thrombus may generate distal emboli that occlude an 
artery of the brain, leading to an ischemic stroke. However, not all plaque ruptures 
lead to a clinical event.4, 6, 7 
Blood coagulation plays a role in atherosclerosis and the development of ischemic 
events. Previous studies have shown an association between plasma levels of impor-
tant coagulation factors (Von Willebrand Factor (VWF), A Disintegrin And Metallo-
protease with Thrombo Spondin motif repeats 13 (ADAMTS13)) and cardiovascular 
disease risk.8, 9 However, the exact interaction between these coagulation factors and 
ischemic events is unclear; one of the candidate mechanism underlying this associa-
tion may be atherosclerosis. Previous studies suggest that atherosclerosis (and not 
only thrombus formation) is a determinant of VWF levels.10 On the other hand, in 
vitro and in vivo studies suggest that VWF might contribute to the pathogenesis of 
atherosclerosis.11 In addition, studies on animals with a VWF deficiency suggest that 
VWF deficiency has a protective effect against atherosclerosis and VWF may be a 
determinant of atherosclerosis.11-13 When taking all these studies together, the data 
on this topic are inconclusive.11, 14, 15 Detailed analyses of the atherosclerotic plaque 
in vivo by new imaging biomarkers may help unravel the association between these 
coagulation factors and atherosclerosis. 
The last few decades have witnessed a rapidly growing evaluation of imaging tech-
niques for the assessment of imaging biomarkers of atherosclerosis. Carotid intima-
media thickness (CIMT), the combined thickness of the intimal and medial layers 
of the carotid artery, assessed by means of ultrasound (US), was the first imaging 
ELRPDUNHUZLGHO\XVHGLQUHVHDUFKRQDWKHURVFOHURVLV$&,07RIPPRU!
of the surrounding IMT is indicative for an atherosclerotic plaque.16, 17 Advantages 
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of US are its noninvasive nature, low costs and wide availability. Drawbacks are its 
high operator variability, loss of signal behind calcifications, and limited information 
on plaque composition. Furthermore, the development of other image modalities like 
multidetector-row computed tomography angiography (MDCTA) and magnetic reso-
nance imaging (MRI), have shifted interest from US to these image techniques.17, 18 
MDCTA is a fast, widely available and minimally invasive imaging modality. However, 
disadvantages of MDCTA are radiation exposure and limited soft-tissue contrast.17, 
18 Histological studies have shown that imaging biomarkers like degree of carotid 
artery stenosis, carotid plaque burden, plaque component volumes (especially cal-
cifications), and plaque ulcerations, can be evaluated well with MDCTA.19-21 MRI is 
currently one of the most promising imaging modalities for plaque imaging due to 
its excellent soft-tissue contrast, the use of multiple contrast weightings each provid-
ing additional information, minimally invasive nature and no ionizing radiation.17, 
18 Histological studies have shown that imaging biomarkers like carotid plaque bur-
den, plaque component volumes (especially intraplaque hemorrhage) and fibrous 
cap status, can be correctly evaluated with MRI.6, 22, 23 However, MRI is less available, 
contra-indicated in patients with claustrophobia, pacemakers, defibrillators or other 
implanted electronic devices and has a relative long scan time.17, 18 
Currently, patients with acute ischemic stroke are treated with intravenous thrombo-
lytic drugs if possible or intra-arterial thrombectomy in case of an intracranial arterial 
occlusion. Following the acute phase, patients with ischemic stroke or TIA are treated 
with antiplatelet therapy and statins, antihypertensive and/or antidiabetic drugs if indi-
cated, resulting in a significant reduction of recurrent stroke risk.24 In addition, carotid 
endarterectomy (CEA) is indicated in men with a stenosis of 50-99% and in women 
with a 70-99% carotid artery stenosis, preferably performed within two weeks after 
the stroke or TIA.25, 26 However, selection for CEA based primarily on the degree of 
carotid stenosis is suboptimal in light of the current knowledge of the pathophysiology 
of atherosclerosis. Histological studies have identified several plaque characteristics 
associated with an increased risk of plaque rupture; the so-called ‘vulnerable plaque’ 
characteristics. Examples of vulnerable plaque characteristics are a large necrotic 
core, a thin overlying fibrous cap, many inflammatory cells, neovascularization and 
intraplaque hemorrhage.27 Visualizing and measuring these vulnerable plaque char-
acteristics could help identify patients with an increased risk for recurrent stroke who 
may also benefit from a CEA or reduce the number of unnecessary interventions.28 
To investigate if plaque imaging indeed enables us to better identify patients in the 
30-69% carotid stenosis group with an increased stroke risk, a large multicenter co-
hort study was started in 2010 by the multicenter Plaque At RISK (PARISK) consor-
tium.29
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1Outline of this thesis
The focus of my thesis is the imaging of the atherosclerotic plaque in the carotid 
artery using US, MDCTA and MRI and how we can use imaging biomarkers to better 
understand atherosclerotic plaque pathophysiology and the role of blood coagula-
tion. In addition, I aimed to evaluate which image modality and which imaging bio-
markers can be valuable in the clinical setting.
In Chapter 2, I investigate the relationship between two important coagulation 
factors (VWF, ADAMTS13) and imaging biomarkers to try and unravel the underlying 
mechanisms of the association between the blood biomarkers and cardiovascular 
disease risk.
All imaging modalities have different advantages and limitations and it is not 
clear yet how the different modalities are interrelated. In Chapter 3, I assess the ac-
curacy of contrast-enhanced US to detect plaque ulcerations compared to MDCTA, 
investigate the association between intraplaque hemorrhage on MRI and plaque sur-
face on MDCTA, and finally, compare the performance of MRI and MDCTA in the 
detection and quantification of plaque calcifications. 
In Chapter 4, I present examples of the use of imaging biomarkers in the clini-
cal setting. First, I evaluate the calcifications in the aortic arch and carotid artery in 
a large cohort of patients with ischemic stroke and assess the differences between 
nonlacunar and lacunar ischemic strokes. In addition, I describe the study design of 
the PARISK study, a multicenter cohort study focusing on the identification of patients 
with an increased stroke risk in a group of patients with a recent stroke or TIA and a 
non-significant carotid stenosis, using plaque imaging.
Finally, in Chapter 5, I discuss all findings, methodological aspects, implications 
and future directions.
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Chapter 2.1
Abstract
Background: Large population studies have revealed that increased von Willebrand 
Factor (VWF) levels are associated with an increased risk of ischemic stroke. In previ-
ous studies VWF was associated with atherosclerosis in healthy individuals. However, 
it is yet unknown what the association is between atherosclerosis and VWF levels in 
patients with ischemic stroke.
Objectives: The aim of our study was to determine the association of atherosclerosis, 
measured with recent developed techniques, and VWF levels in a large, well char-
acterized, cohort of ischemic stroke patients and to determine the prognostic value.
Methods: We included 925 consecutive patients with transient ischemic attack (TIA) 
or ischemic stroke. Calcification volumes (mm3) were scored in the aortic arch and 
both carotid arteries using multidetector computed tomography (CT) angiography. 
VWF antigen (VWF:Ag) levels were measured using ELISA. 
Results: Mean VWF:Ag levels were significantly higher in the presence of calcification 
in either the aortic arch (1.47 vs. 1.37 IU/ml [P = 0.039]) or the carotid arteries (1.49 
vs. 1.34 IU/ml [P = 0.001]). Patients with a large artery atherosclerosis ischemic 
stroke had significantly higher VWF:Ag levels then the other TOAST subtypes (P < 
0.0001). High VWF:Ag levels were associated with an unfavorable outcome (modi-
ILHG5DQNLQ6FDOH!YVYV,8PO>3@
Conclusion: Our study showed a strong association between the extent of atheroscle-
rosis in both the aortic arch and the carotid arteries and VWF levels in patients with 
TIA or ischemic stroke. Higher VWF levels are found in large artery atherosclerosis 
and are associated with a poor outcome.
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2.1
Introduction
Von Willebrand Factor (VWF) plays a crucial role in platelet adhesion and aggrega-
tion, the initial steps in thrombus formation. VWF is a multimeric plasma protein 
that is produced by endothelial cells and megakaryocytes.1 Since VWF plasma levels 
increase as the result of endothelial damage, VWF levels can be used as a marker of 
endothelial dysfunction.2
Previous studies have shown a positive association between levels of VWF and 
risk of coronary heart disease and stroke.3-6 In ischemic stroke, a particular associa-
tion of VWF levels with etiologic subtypes, such as large artery atherosclerosis and 
cardioembolic stroke, was found.7 Despite the fact that prospective studies have iden-
tified VWF levels as a predictor of ischemic stroke, the mechanism by which increased 
VWF levels are related to stroke is still unclear.8-10
We have previously shown that genetic variation strongly determines VWF levels, 
however these genetic variations are not or minimally associated with ischemic stroke 
risk.11,12 Therefore it has been suggested that the VWF levels may predominantly be 
determined by endothelial dysfunction and atherosclerosis.13
Endothelial dysfunction is the first phase in the development of atherosclerotic 
plaques. Because endothelial activation is related to atherosclerosis and an associa-
tion of VWF with ischemic stroke has been found, atherosclerosis may be a determi-
nant of VWF levels.14 Previous studies have shown a significant association between 
atherosclerosis, measured by the ankle-brachial index and intima- media thickness, 
and increased VWF levels in healthy individuals.15,16
In recent years, new techniques have been developed to study the extent of 
atherosclerosis more precisely. Calcification volume is an important indicator of ath-
erosclerosis severity and may have a strong association with VWF levels.17-19 
We hypothesized that a higher degree of calcification volume, measured both in 
the aortic arch and carotid arteries, is associated with higher levels of VWF in patients 
with ischemic stroke, which may provide more insight in the relationship between 
VWF levels and ischemic stroke risk and the prognostic value of VWF.
Materials and methods
Study population
We studied 925 consecutive patients with TIA or ischemic stroke from the Erasmus 
Stroke Study, an ongoing registry of patients with cerebrovascular diseases treated at 
our hospital, from December 2005 until December 2010 of whom plasma, DNA and 
a CT angiography was available.20 TIA was defined as a focal neurological deficit of 
presumed vascular origin lasting less than 24 h, with imaging studies showing no ab-
normalities. Ischemic stroke was defined as a focal neurological deficit of presumed 
YDVFXODURULJLQODVWLQJKZLWKEUDLQLPDJLQJVWXGLHVVKRZLQJQRDEQRUPDOLWLHV
or typical signs of infarction. Patients were classified according to the Trial of Org 
10172 in Acute Stroke Treatment (TOAST) criteria and additionally to a phenotypic 
classification which is a variant of the A-S-C-O score.21,22 This score is characterized 
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by 9 categories: definite lacunar stroke, definite atherothrombotic stroke, probable 
atherothrombotic stroke, definite cardiac cause, possible cardiac cause, definite he-
matologic cause, possible hematologic cause, other cause of stroke and unknown 
cause of stroke. Definitions are described in the supplementary information. Patients 
who have multiple causes of stroke did not fit into one of the categories and are 
therefore excluded from the analysis (N = 125). Hypertension and hypercholester-
olemia were defined as the use of antihypertensive or cholesterol lowering drugs, 
respectively, before the inclusion event. Diabetes mellitus was defined as the use of 
oral and/or parenteral antidiabetic drugs before the event. Smoking status (smoking 
versus non-smoking) was assessed at the time of the event. Patients were considered 
to have a history of ischemic heart disease when they had a documented myocardial 
infarction, angina pectoris or cardiac revascularization therapy. Peripheral arterial 
disease was defined as a history of intermittent claudication or peripheral vascular 
surgery or amputation due to lower limb ischemia. A history of cardiovascular disease 
indicates a history of ischemic heart disease and/or peripheral arterial disease and/
or atrial fibrillation and/or TIA or ischemic stroke. The National Institutes of Health 
Stroke Scale (NIHSS) was assessed at admission from the stroke unit or outpatient 
clinic.23 The functional outcome was assessed using the modified Rankin scale (mRS) 
DWGLVFKDUJHDQGZDVGLFKRWRPL]HGDVIDYRUDEOHRUXQIDYRUDEOH!RXWFRPH24
All participants provided written informed consent. The study was approved by 
the Medical Ethics Committee of the Erasmus University Medical Center.
MDCTA angiography
A multidetector CT angiography (MDCTA) was performed routinely according to a 
standard protocol. MDCTA was performed at a median of 5 days (interquartile range 
2-14 days) after onset of symptoms. Image acquisition was performed using a 16, 64 
or 128 slice multidetector CT system (Sensation 16, Sensation 64, Definition, Defini-
tion AS+ or Definition flash, Siemens Medical Solutions, Erlangen, Germany) using 
a standardized optimized contrast- enhanced protocol (120 kVp, 180-200 mAs, col-
limation 16 x 0.75 mm; 32 x 2 x 0.6 mm; 64 x 2 x 0.6 mm, pitch <1). The scan range 
extended from the ascending aorta to the intracranial circulation. All patients re-
ceived 80 ml of contrast agent (320 mg/mL iodixanol, Visipaque, Amersham Health, 
Little Chalfont, UK), followed by 45 ml saline bolus chaser, both at an injection rate 
of 4 or 5 ml/s. Real-time bolus tracking at the level of the ascending aorta was used 
to synchronize passage of contrast agent and data acquisition. Image reconstructions 
were made with field of view of 120 mm, matrix size 512 x 512, slice thickness 0.75 or 
1.0 mm, increment 0.4-0.6 mm and with an intermediate reconstruction algorithm. 
All MDCTA studies were evaluated by trained readers blinded for clinical data. Dedi-
cated commercially available software (Syngo Calcium Scoring, Siemens) was used to 
quantify calcifications at the aortic arch and the carotid arteries; expressed as calcifi-
cation volume in mm3. The aortic arch was defined as the origin of the aortic arch to 
the first 1 cm of the common carotid arteries, the vertebral arteries and the subclavian 
arteries beyond the origin of the vertebral arteries. Both carotid arteries were scored 
within 3 cm proximal and distal of the bifurcation and calcification volume of both 
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carotid arteries was added. A threshold of 600 Hounsfield units (HU) was used to dif-
ferentiate calcifications from contrast material in the lumen. A detailed description of 
the measurement is provided elsewhere.17,25
Reasons for not performing MDCTA were poor renal function, significant comor-
bidity with resultant very short life expectancy and very severe stroke with likely fatal 
outcome. Patients with a time interval between event and MDCTA of more than 180 
days were excluded (n = 20). Because of poor image quality of both the aortic arch 
and the carotid arteries caused by artifacts, 17 scans were not gradable. In 7 patients 
the aortic arch and in 10 patients the carotid arteries could not be analyzed due to 
dissection of the carotid artery, presence of artifacts or stents.
Blood samples, VWF measurement and blood group assessment
Blood sampling was performed at a median of six days (interquartile range 3-14 days) 
after onset of symptoms. There was no significant correlation between VWF levels 
and time from event till blood sampling ( -0,0001 IU/ml per day; P = 0.33).
Citrated blood was centrifuged at 1700 xg for 15 min at room temperature, 
and stored at -80 °C within 2 h from collection. DNA was isolated from blood using 
MagNA Pure (Roche Diagnostics) and stored at -80 °C. VWF antigen (VWF:Ag) levels 
were determined with an in-house ELISA, using rabbit anti-human VWF antibodies 
(DakoCytomation, Glostrop, Denmark) for catching and tagging. Reference standard 
plasma, calibrated against the international standard (Cryocheck Reference, Kordia, 
Leiden, the Netherlands), was used as a calibrator. The intra-assay coefficient of 
variation was 3.2%. Blood groups were assessed with a standard test of blood group 
antibodies in 572 patients. In the remaining 353 patients, we genotyped rs687289, 
which can be used to discriminate blood group O from non-O status, using custom 
TaqMan Genotyping Assays (Applied Biosystems, Foster City, CA, USA)26 Genotyping 
was successful in 99% of all patients.
Statistical analysis
Levels of VWF:Ag and the calcification volumes in the aortic arch and carotid arteries 
were normalized by logarithmic trans- formation. The data are presented as geomet-
ric means and 95% confidence interval (CI). Correlation between two groups was 
assessed with Spearman rank correlation. The aortic arch and carotid calcification 
volume were divided into four subgroups. The first group consists of all patients with 
a calcification volume of 0 mm3, the remaining patients were divided into tertiles. 
9:)$JOHYHOVZHUHGLYLGHGLQWRWZRFDWHJRULHVORZOHYHOEHORZWKHPHGLDQ
,8PODQGKLJKOHYHODERYHWKHPHGLDQ!,8PO*URXSVZHUHFRPSDUHGXVLQJ
independent T-tests or ANOVA with Bonferroni correction. Linear regression analy-
sis was used to analyze the relationship between calcification volume with VWF:Ag 
levels. All analyses were adjusted for potential con- founders: age, sex, ABO blood 
group, smoking, hypertension, hypercholesterolemia, diabetes mellitus and a history 
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of cardiovascular disease. Only confounders that were significantly associated with 
VWF:Ag levels were used in the multivariate analyses. All analyses were performed 
using SPSS version 20.0 (IBM, Somers, NY, USA). A P value <0.05 was considered 
to indicate statistical significance.
Results
Baseline characteristics of the 925 patients in this study are shown in Table 1. Mean 
age was 62 ± 13.6 years and 47% were females. As expected in our cohort of pa-
tients with TIA or ischemic stroke, they frequently suffered from hypertension, hy-
percholesterolemia and the majority of patients smoked. The geometric mean of 
the VWF:Ag levels in our patients was 1.43 IU/ml (95% CI 0.63-3.24). Patients with 
ischemic stroke had significantly higher levels of VWF than patients with TIA (1.50 vs. 
1.35 IU/ml; P < 0.0001). Patients with blood group O had significantly lower levels 
of VWF:Ag compared with patients with non-O blood groups (1.24 vs 1.62 IU/ml, p 
< 0.0001). 113 patients had a time interval between event and MDCTA of more than 
one month. The results of the study did not change, when excluding those patients.
9D;AÍ;9LAGFNGDME=G>L@=9GJLA;9J;@9F<./?D=N=DK
The geometric mean calcification volume of the aortic arch of the total group was 
17.59 mm3 (95% CI 0-3374.8 mm3). Patients with calcifications in the aortic arch (n 
= 593) had significantly higher VWF:Ag levels compared with patients without calci-
fications in the aortic arch (n = 325; 1.47 vs. 1.37 IU/ml, P = 0.039). VWF:Ag levels 
increased linearly with increasing groups of the aortic calcification volume (P for trend 
0.003; Fig. 1a). After multivariate adjustment, age and blood group were significantly 
associated with levels of VWF:Ag (P < 0.0001; P < 0.0001; respectively). Patients 
with blood group O, with mean VWF:Ag levels of 1.24 IU/ml, had similar aortic cal-
cification volume compared with patients with blood group non-O, who had a mean 
VWF:Ag level of 1.62 IU/ml (17.2 vs. 18.0 mm3, P = 0.80). The association between 
the calcification volume and VWF:Ag levels was seen both in blood group O and non-
O and this was not statistically significant different (P for indication = 0.49).
9D;AÍ;9LAGFNGDME=G>L@=;9JGLA<9JL=JA=K9F<./?D=N=DK
The geometric mean of the carotid calcification volume of the total group was 5.7 
mm3 (95% CI 0.0-396.9 mm3). Patients with calcifications (n = 529) had significantly 
higher levels of VWF:Ag compared with those without calcifications (n = 386; 1.49 
vs 1.34 IU/ml, P = 0.001).
VWF:Ag levels increased linearly in increasing groups of the calcification volume 
(P for trend <0.0001; Fig. 1b). Age and blood group were significantly associated 
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with levels of VWF:Ag after multivariate analysis (P < 0.0001; P < 0.0001, respec-
tively). Patients with blood group O, with a mean VWF:Ag levels of 1.24 IU/ ml, had a 
similar carotid calcification volume compared with patients with blood group non-O, 
with a mean VWF:Ag level of 1.61 IU/ml (6.4 vs. 5.3 mm3, P = 0.25).
Calcification volume of the aortic arch and of the carotid arteries were highly 
correlated (R = 0.69; P < 0.0001). Patients with calcifications in both arteries were 
older (67 vs. 49 years, P < 0.0001) and had more cardiovascular risk factors than 
those without calcifications (Table 1). This was similar in the separate arteries. As-
sessing the mean VWF:Ag level in patients using both calcification volume, showed 
the highest levels in patients with both the highest calcification volume (Fig. 2). The 
association between the calcification volume and VWF:Ag levels was seen both in pa-
tients with blood group O and non-O and this was not statistically significant different 
(P for interaction = 0.11).
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Figure 1. Levels of mean VWF:Ag per group of calcification volume. A. Mean and standard error (SE) 
VWF:Ag levels (in IU/ml) in the aortic arch calcification volume groups (*P = 0.006 compared with the 
first group; †P < 0.0001 compared with the first group). B. Mean and standard error (SE) VWF:Ag levels 
(in IU/ml) in the carotid calcification volume groups (*P = 0.001 compared with the first group; †P < 
0.0001 compared with the first group).
Figure 2. Relationship between aortic arch and 
carotid calcification volume and mean VWF:Ag 
levels The relation between aortic arch and 
carotid calcification volume groups and mean 
VWF:Ag levels (IU/ml).
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LAGDG?A;KM:LQH=KG>,!GJKLJGC=9F<D=N=DKG>./?
Levels of VWF:Ag differed significantly between etiologic subtypes of TIA and isch-
emic stroke (P = 0.006; Fig. 3). Levels of VWF:Ag were significantly increased in 
patients with a large artery atherosclerosis of TIA or ischemic stroke, compared with 
the other subtypes (1.59 vs. 1.40 IU/ml, P < 0.0001). Patients with a small vessel 
occlusion etiology had significantly lower levels of VWF:Ag compared with the other 
patients (1.34 vs. 1.45 IU/ml, P = 0.009).
Patients with a definite atherothrombotic stroke using the A-S- C-O score vari-
ant had significantly higher VWF:Ag levels (1.58 IU/ ml) compared with patients with 
a probable atherothrombotic stroke (1.40 IU/ml; P = 0.001), other cause of stroke 
(1.24 IU/ml; P = 0.009) and unknown cause of stroke (1.32 IU/ml; P < 0.0001). 
Patients with a definite lacunar stroke had significantly higher VWF:Ag levels (1.66 
IU/ml) compared with probable atherothrombotic (P = 0.04), other cause of stroke 
(P = 0.013) and with unknown cause of stroke (P = 0.009).
VWF levels were significantly correlated with the NIHSS score at admission (R 
= 0.183, P < 0.0001) and with functional outcome of the patients, as determined 
by the modified Rankin Scale (mRS) at discharge (R = 0.222, P < 0.0001). Patients 
ZLWKDQXQIDYRUDEOHRXWFRPHP56!KDGVLJQLILFDQWO\KLJKHU9:)$JOHYHOVFRP-
SDUHGZLWKSDWLHQWVZLWKDIDYRUDEOHRXWFRPHP56,8POYV,8PO
P < 0.0001). However, these patients did not have a significant higher calcification 
volume in both the aortic arch (23.1 vs. 17.0 mm3, P = 0.17) and carotid arteries 
(6.6 vs. 5.6 mm3, P = 0.45), compared with patients with a favorable outcome. Pa-
WLHQWVZLWKDKLJK9:)$JOHYHO!,8POKDGDKLJKHUULVNRIDQXQIDYRUDEOH
RXWFRPHFRPSDUHGZLWKSDWLHQWVZLWKDORZ9:)$JOHYHO,8PO253
< 0.0001) and this difference remained after additionally adjustment for aortic arch 
and carotid calcification volume. However, there was no significant difference in out-
come between patients with blood group O and non-O (OR 0.95, P = 0.40) Table 2.
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Figure 3. Levels of mean VWF:Ag per etiologic 
subtypes of TIA and ischemic stroke. Mean and 
standard error (SE) VWF:Ag levels (IU/ml) in the 
etiologic subtypes of TIA and ischemic stroke 
according to the TOAST criteria. * indicates P 
< 0.0001; †P < 0.05. LAA indicates large ar-
tery atherosclerosis; CE, cardio embolism; SVO, 
small vessel occlusion; Other, stroke of other 
determined etiology; Undetermined, cerebral 
ischemia of undetermined etiology.
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Discussion
The main result of our study is a strong positive association between the extent of 
atherosclerosis, determined by the calcification volume in both the aortic arch and 
the carotid arteries, and VWF:Ag levels in patients with ischemic stroke. In addition, 
we observed that levels of VWF were significantly higher in patients with a large artery 
atherosclerosis type of ischemic stroke compared to other stroke subtypes.
To the best of our knowledge, our study is the first to investigate the extent of 
atherosclerosis, using newly developed quantitative measurements, and VWF levels 
in patients with TIA or ischemic stroke. We found similar positive associations in both 
aortic arch calcification volume and carotid calcification volume with VWF:Ag levels. 
Furthermore, patients with the highest score for both the aortic arch calcification vol-
ume and carotid calcification volume had the highest VWF:Ag levels. VWF:Ag levels 
were strongly associated with large artery atherosclerosis.
It is still debated whether VWF itself plays a pathogenetic role in atherogenesis. 
Despite the fact that several animal models indicated that VWF may lead to a reduc-
tion of atherosclerosis, multiple human studies failed to confirm this observation.27,28 
In these studies a similar extent of atherosclerosis in individuals with severe von Will-
ebrand disease (VWD), characterized by reduced levels of VWF, was shown compared 
with controls.29-33
It is well known that genetic variations, both within the VWF gene and outside 
the VWF gene, strongly determine VWF levels.11,12,34-36 One of the main genetic de-
terminants of VWF levels is the ABO blood group, resulting in 25-30% lower levels 
in individuals with blood group O compared to non-O.37 Also in our study, ischemic 
stroke patients with blood group O had 30% lower VWF:Ag levels compared to pa-
Mean VWF:Ag levels (mean ± SE) per calcification volume subgroup. 
Model 1: univariate. Model 2: adjusted for age, sex, blood group and cardiovascular risk factors.
Calcification 
volume (mm3)
Mean VWF:Ag
(IU/ml) model 1
Mean VWF:Ag
(IU/ml) model 2
Aortic arch
 0
 0.01-41
 41.01-257.4
 !
P for trend 
1.26 ± 0.03
1.42 ± 0.04
1.54 ± 0.04
1.67 ± 0.04
<0.0001 
1.36 ± 0.03
1.41 ± 0.04
1.48 ± 0.04
1.54 ± 0.05
0.03
Carotid artery
 0
 0.01-10.1
 10.11-63.9
 !
P for trend 
1.27 ± 0.03
1.47 ± 0.04
1.49 ± 0.05
1.73 ± 0.05
<0.0001
1.34 ± 0.03
1.43 ± 0.04
1.46 ± 0.04
1.61 ± 0.05
<0.0001
Table 2. Association between calcification volume and VWF:Ag levels.
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tients with blood group non-O, but did not have lower calcification volumes. This 
finding suggests that VWF levels do not have a major pathogenetic role in atheroscle-
rosis. In addition, it is still debatable whether blood group is a risk factor for ischemic 
stroke.38,39 An earlier study of our group already showed that, despite the fact that 
several genetic variations were strongly associated with VWF levels, the genetic varia-
tions did not influence the risk of ischemic stroke.11 This suggests that VWF levels 
are merely a marker of atherosclerosis and thereby determine the previously found 
association between increased VWF:Ag levels and risk of stroke, as atherosclerosis is 
a well-known important risk factor for TIA and ischemic stroke.
Patients with a small vessel occlusion ischemic stroke had lower levels of 
VWF:Ag than the other stroke patients. This was comparable with another study, 
which showed that patients with a small vessel disease type of stroke, had lower VWF 
levels compared with the large vessel disease and cardio embolism group.7 These 
lower VWF levels may be explained by the fact that in these patients atherosclerosis 
does not play a major role in the etiology of stroke. However, the small arterioles of 
the brain are presumed to be affected by various vascular risk factors.40 This may also 
lead to endothelial activation, but only to certain subtypes of lacunar infarcts.41 How-
ever, lacunar stroke described in the A-S-C-O score variant was associated with high 
VWF:Ag levels. This might be explained by the difference in the number of patients (N 
= 22 A-S- C-O score, N = 183 TOAST classification) and a difference in definition. 
In this study, VWF:Ag levels were associated with stroke severity, determined by the 
NIHSS at admission and with poor outcome, determined by the mRS at discharge. 
This is in agreement with one previous study in patients with acute ischemic and 
hemorrhagic stroke in which high VWF levels were associated with a poor modified 
Rankin score.42 Recently we showed in the prospective population-based Rotterdam 
study that increased VWF levels are a predictor of stroke.9 In this study we have shown 
that increased VWF levels and not blood group are a predictor of stroke outcome sug-
gesting that VWF levels could serve as a risk marker of stroke outcome. Additionally, 
because levels of VWF are increased due to presence of atherosclerosis, VWF could 
also serve as a useful marker of atherosclerosis and thereby as a risk marker of stroke.
Some methodological issues have to be addressed. Strengths of our study are 
the large number of ischemic stroke patients of all ages, with availability of well-
GRFXPHQWHG FOLQLFDO LQIRUPDWLRQ H[WHQVLYH VFRULQJ !RI0'&7DQJLRJUDSK\
of the aortic arch and the carotid arteries, and the availability of plasma of nearly all 
consecutive patients.
Furthermore, we determined calcifications of the aortic arch and carotid arter-
ies using dedicated commercially available software in which calcifications of the 
aortic arch and carotid arteries can be reproducible quantified in a specified range. 
So far only limited data was available regarding calcifications in the carotid arteries 
as a marker of atherosclerosis. In this study, we found a significantly higher preva-
lence of cardiovascular risk factors in patients with calcifications in the aortic arch 
and carotid arteries than in patients without calcifications. This is in agreement with 
another study, which showed an independent relationship between several cardio-
vascular risk factors and carotid calcifications and similar risk factor profiles were 
found in different vessel beds including the coronary arteries, aortic arch and carotid 
arteries.17 Calcifications in the aortic arch and carotid arteries were associated with 
the presence of stroke and luminal stenosis in previous studies.18,19,43,44 This all shows 
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that calcifications in the aortic arch and carotid arteries can be used as a marker of 
atherosclerosis.
A potential drawback of our study is that calcifications below the threshold of 
600 HU or outside the scan range were not detected. Another possible limitation 
concerns the fact that calcifications are one of the components of an atherosclerotic 
plaque and a soft atherosclerotic plaque that contains no calcification is therefore 
not detected.43 However, it has been shown that the majority (82%) of atherosclerotic 
plaques contains some calcifications and therefore this would only minimally affect 
our results.25 In addition, time between stroke and blood sampling was variable. How-
ever, there was no significant correlation between VWF levels and time from event 
till blood sampling. This suggests that the time of blood drawn did not influence the 
levels of VWF. Furthermore, patients with significant comorbidity, very severe stroke 
or those who died within 24 h were not included in this study, resulting in a relatively 
less severely affected cohort.
Conclusion
In conclusion, our study in patients with TIA or ischemic stroke indicates that the 
extent of atherosclerosis, determined by calcifications in the aortic arch and carotid 
arteries, is strongly associated with VWF levels. In addition, highest VWF levels are 
found in large vessel disease, whereas the levels are lower in small vessel disease. 
Furthermore, our study suggests that VWF may have prognostic value in patients with 
ischemic stroke.
Processed on: 2-12-2016
506902-L-sub01-bw-vanDijk

VWF and calcifications of the carotid artery and aortic arch
2.1
Supplementary information
Lacunar stroke is defined as a small deep infarct on scan <15 mm in the territory 
corresponding to symptoms in a patient with a clinical syndrome compatible with 
small deep infarct. Definite atherothrombotic stroke is defined by (1) an ipsilateral 
LQWHUQDOFDURWLGVWHQRVLVRUDQLSVLODWHUDOVWHQRVLVLQDQRWKHULQWUD
extracranial artery (also in vertebrobasilar system if applicable), or (3) mobile throm-
bus in the aortic arch. Probable atherothrombotic stroke is defined as patients with 
ipsilateral internal carotid or other intra/extracranial artery <50% stenosis, contra-
ODWHUDO VWHQRVLVSDWLHQWVZLWKRI WKH IROORZLQJ ULVN IDFWRUV IRUDWKHURWKURPERWLF
disease: hypertension (as defined above), diabetes mellitus, smoking at time of event, 
high cholesterol. Definite cardiac cause is defined as patients with atrial fibrillation, 
atrial flutter, sick sinus syndrome, prosthetic valve, mitral stenosis, recent myocardial 
infarction (<6 weeks), left ventricular thrombus, atrial myxoma, infective endocar-
ditis, non-ischemic dilating cardiomyopathy, non-bacterial thrombotic endocarditis. 
Possible cardiac cause is defined by patients with calcific aorta stenosis, mitral valve 
prolaps, mitral annulus calcification, patent foramen ovale, atrial septal aneurysm, 
ventricular aneurysm, ventricular septal defect, other structural cardiac abnormalities 
not mentioned above. Definite hematologic cause is defined as patients with dis-
seminated intravascular coagulation, myeloproliferative disorders, essential throm-
bocythemia, polycythemia vera and antiphospholipid syndrome (the full syndrome). 
Possible hematologic cause is defined as patients with protein C deficiency, protein 
S deficiency, antithrombin deficiency, factor V Leiden, isolated lupus anticoagulans, 
single increased antiphospholipid antibodies (not confirmed with second increased 
measurement), and other hematologic causes. In other causes  of stroke carotid 
or vertebral dissection, vasculitis, AVMs, Moyamoya, Fabry, other vascular causes, 
hemodynamic stroke, migrainous stroke, neoplasm and miscellaneous causes are 
included. Unknown cause stroke is defined as patients whom, based on all available 
data, cannot be categorized into either of the above categories.
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Abstract
Introduction: High Von Willebrand Factor (VWF) and low ADAMTS13 levels are asso-
ciated with an increased risk of ischemic stroke and myocardial infarction. One of the 
candidate mechanisms underlying this association may be the increase of VWF levels 
by atherosclerosis. Therefore, we assessed the association between novel imaging 
biomarkers of the advanced atherosclerotic plaque and VWF levels and ADAMTS13 
activity.
Methods: In 180 patients of the PARISK-study with a recent TIA or ischemic stroke 
and a symptomatic mild-to-moderate carotid artery stenosis (Plaque-At-RISK; clini-
caltrials.gov NCT01208025), we measured VWF antigen (VWF:Ag) and ADAMTS13 
activity. Imaging biomarkers of carotid atherosclerosis were determined by MDCTA 
(n=158) and MRI (n=169). In this cross-sectional analysis, we used linear regression 
analysis to assess the association between imaging biomarkers and VWF:Ag levels 
and ADAMTS13 activity.
Results: Age and blood group were associated with VWF:Ag (ß=0.01 IU/ml, p=0.001; 
ß=0.22 IU/ml, p<0.001). Age and time between event and blood withdrawal were 
inversely associated with ADAMTS13 (ß=-0.60%, p=0.002; ß=-0.13%, p=0.008). 
None of the imaging biomarkers were associated with VWF:Ag or ADAMTS13.
Conclusion: In our study, we found no association between imaging biomarkers of 
advanced atherosclerosis and VWF and ADAMTS13 in patients. It remains unclear 
whether the blood biomarkers mark widespread atherosclerosis or have a more com-
plex role in atherosclerotic plaque development.
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Introduction
Atherosclerosis of the carotid arteries is an important risk factor for ischemic strokes. 
With improved imaging techniques like multidetector-row computed tomography 
(MDCTA) and magnetic resonance imaging (MRI), atherosclerotic burden can be 
quantified by for example degree of stenosis, maximum vessel wall area or calcifica-
tion volume; and characteristics of the vulnerable – rupture-prone – plaque can be 
visualized like plaque ulceration, intraplaque hemorrhage (IPH) and lipid core.1, 2 
Vulnerable plaque rupture is crucial in the pathophysiological cascade from athero-
sclerotic plaque development to thrombus formation and eventually ischemic stroke 
or TIA. 
Von Willebrand Factor (VWF) has an important function in primary hemostasis 
via its role in platelet adhesion and aggregation, and increases as a result of endothe-
lial damage. A Disintegrin And Metalloprotease with ThromboSpondin motif repeats 
13 (ADAMTS13) cleaves large VWF multimers into smaller and less prothrombotic 
forms. Levels of VWF are increased in ischemic stroke patients and the highest levels 
of VWF are found in large vessel disease and cardio-embolic strokes.3, 4 High VWF 
and low ADAMTS13 levels are associated with an increased risk of ischemic stroke 
and myocardial infarction.5-7 One of the candidate mechanisms underlying the as-
sociation between VWF and ischemic stroke may be atherosclerosis. Previous studies 
suggest that atherosclerosis (and not only thrombus formation) is a determinant of 
VWF levels.8 On the other hand, in vitro and in vivo studies suggest that VWF might 
contribute to the pathogenesis of atherosclerosis.9 In addition, studies on animals 
with a VWF deficiency suggest that VWF deficiency has a protective effect against 
atherosclerosis and VWF may be a determinant of atherosclerosis.9-11 When taking all 
these studies together, the data on this topic are inconclusive.9, 12, 13 We expect that, 
due to the role of ADAMTS13 in the metabolism of VWF, atherosclerosis might play a 
role in the association between ADAMTS13 and ischemic events as well. 
The aim of our study was to evaluate the association between novel imaging 
biomarkers of the atherosclerotic plaque and VWF and ADAMTS13 in patients with a 
recent TIA or ischemic stroke and a symptomatic mild-to-moderate carotid artery ste-
nosis to help clarify the association between atherosclerosis, VWF and ADAMTS13. 
Methods
Study population
Patients were derived from the PARISK-study (Plaque-At-RISK; clinical trials.gov 
NCT01208025); details of the study design have been previously described.14 The 
PARISK-study is a prospective multicenter cohort study using non-invasive plaque im-
aging to identify patients with an ipsilateral mild-to-moderate carotid artery stenosis 
(30-69%) with an increased risk of recurrent stroke. All included patients had a recent 
TIA, including amaurosis fugax, or minor stroke in the carotid artery territory prior 
to inclusion. Institutional Review Board approval was obtained and all patients gave 
written informed consent.
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Between September 2010 and December 2014, 240 patients were included in the 
PARISK-study; 180 patients had either a MDCTA (n=158) or MRI (n=169) of the 
carotid arteries, and had an available blood sample.
MDCTA and 3T MRI data acquisition and analysis
Standardized, previously described, contrast-enhanced MDCTA and multi-sequence 
contrast-enhanced MRI protocols were used.14 All imaging studies were evaluated by 
trained readers blinded for clinical data and other imaging tests.15
MDCTA images were reviewed using dedicated 3D analysis software (Leonardo 
and syngo.via; Siemens, Erlangen, Germany). First, image quality was rated on a 
3-point scale; poor (not eligible for analysis), moderate and good (eligible for analy-
sis).15 The most severe stenosis in the symptomatic carotid bifurcation and internal 
carotid artery was measured according to the ECST criteria, perpendicular to the 
central lumen line.16 Additionally, we defined plaque ulceration as an extension of 
FRQWUDVWPDWHULDORI!PPLQWRWKHDWKHURVFOHURWLFSODTXHRQDWOHDVWRUWKRJRQDO
planes.17, 18 Finally, a custom-made plug-in for the freely available Image J software 
(National Institutes of Health, Bethesda, Maryland) was used to quantify calcifica-
tions in the symptomatic carotid artery within 3 cm proximal and distal to the bifur-
cation. We used a threshold of 600 HU to differentiate calcifications from contrast 
material in the lumen; calcification volume was expressed in cubic millimeters. A 
detailed description of the measurements is provided elsewhere.19
MR images were evaluated with dedicated vessel wall analysis software (Ves-
selmass, Department of Radiology, Leiden University Medical Center, Netherlands). 
Image quality was rated on a 5-point scale; low SNR (not eligible for analysis) to 
marginal and high SNR (eligible for analysis).15, 20 MR images were automatically 
registered by delineating the lumen and outer vessel wall of the symptomatic carotid 
artery. Registration was manually corrected if needed. Plaque components of the 
symptomatic carotid artery (lipid, calcifications, IPH) were manually segmented. Fif-
teen transverse adjoining slices of 2 mm each covering the entire plaque were anno-
tated. Maximum vessel wall area and plaque component volumes of the symptomatic 
carotid artery were derived from these annotations.
DGG<K9EHDAF?./D=N=DK9F<%,+âä9;LANALQE=9KMJ=E=FLK
Citrated blood was centrifuged at 2000 g for 10 minutes; then the plasma was cen-
trifuged at 14000 g for 10 minutes and stored in aliquots at -80ºC. VWF:Antigen 
(VWF:Ag) levels were measured with an in-house ELISA, using polyclonal rabbit anti-
human VWF antibodies (Dakocytomation, Glostrup, Denmark) for catching and tag-
ging. ADAMTS13 activity was measured using the Fluorescence Resonance Energy 
Transfer Substrate VWF 73 (FRETS-VWF73).21 The inter- and intra-assay coefficient of 
variation for VWF:Ag levels and ADAMTS13 activity were 8.7% and 1.9% (VWF:Ag); 
13.1% and 2.9% (ADAMTS13), respectively. 
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Statistical analysis
In this cross-sectional analysis, linear regression models were used to investigate 
the association between imaging biomarkers of the symptomatic carotid artery and 
VWF:Ag levels or ADAMTS13 activity, respectively. VWF:Ag levels were not normally 
distributed and therefore log-transformed. All quantitative imaging biomarkers were 
divided into tertiles. Adjustments were made for age and gender (model 1), and 
additionally for cardiovascular risk factors (model 2; age, gender, current smoking, 
hypertension, hypercholesterolemia, diabetes mellitus, cardiovascular history, BMI). 
In the analyses with VWF:Ag, we also adjusted for blood group. The analyses were 
repeated after adding interval event-blood withdrawal to the covariates. Statistical 
analyses were performed using STATA software (version 13.1, StataCorp, College 
Station, Texas). P<0.05 was considered statistically significant.
Results
Baseline clinical characteristics, VWF:Ag levels, ADAMTS13 activity and imaging 
characteristics are shown in Table 1. Mean age was 68 years, 74% were male and 
prevalence of cardiovascular risk factors was high. We found a median VWF:Ag level 
of 1.45 IU/ml [1.10 - 1.81] and a mean ADAMTS13 activity of 98.6% (± 22.8%). 
There was no correlation between VWF:Ag levels and ADAMTS13 activity (R=0.06, 
P=0.42). Mean symptomatic carotid artery stenosis (ECST) was 55 ± 15 %. 
Clinical characteristic (n=180)
Age (years) 68 ± 9
Male 133 (74%)
Current smoking 39 (22%)
BMI 26.7 ± 4.4
Hypertension 127 (71%)
Hypercholesterolemia 139 (77%)
Diabetes Mellitus 44 (24%)
History of CVD and PAD 85 (47%)
Classification event
 TIA
 Stroke
 Amaurosis fugax
77 (43%)
80 (44%)
23 (13%)
Table 1. Clinical characteristics, blood measurements and imaging biomarkers*
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Increasing age was associated with higher VWF:Ag levels (ß= 0.01IU/ml/year, 
p=0.001) and individuals with blood group non-O had higher VWF:Ag levels com-
pared with individuals with blood group O (ß= 0.22 IU/ml, p<0.001). None of the 
other clinical characteristics were significantly associated with VWF:Ag levels. Age 
was inversely associated with ADAMTS13 activity (ß= -0.60%/year, p=0.002). We 
also found an inverse association between the time from event to blood withdrawal 
and ADAMTS13 activity (ß= -0.13%/day, p=0.008). None of the other clinical char-
acteristics were associated with ADAMTS13 activity. 
  None of the qualitative and quantitative measures of atherosclerosis were as-
sociated with VWF:Ag levels or ADAMTS13 activity in model 1 and 2 (Table 2). Ad-
ditional adjustment for interval event–blood withdrawal did not change the results.
Blood measurements (n=180)
Interval event-blood withdrawal (days) 47 [32-67]
VWF:Ag (IU/ml) 1.45 [1.10-1.81]
ADAMTS13 activity (%) 98.6 ± 22.8
Blood group non-O 106 (59%)
Imaging biomarkers (symptomatic artery)
Degree of stenosis (ECST) (%)† 55 ± 15
MDCTA (n=158)
 Interval event–MDCTA (days) 32 [12-54]
 Presence plaque ulceration 43 (27%)
 Presence calcifications 142 (90%)
 Calcification volume (mm3) 25.9 [5.1-80.7]
MRI (n=169)
 Interval event–MRI (days) 47 [30-67]
 Maximum vessel wall area (mm2) 72.7 [57.2-88.1]
 Presence IPH 66 (39%)
 IPH volume (mm3) 0.0 [0.0-39.7]
 Presence lipid 106 (63%)
 Lipid volume (mm3) 26.2 [0-146.0]
* Data are mean ± SD, absolute numbers of patients (%), or median [25th–75th percentile]; † If MDCTA 
was absent, degree of stenosis was assessed at MRI (n=22); CVD, cardiovascular disease; PAD, periph-
eral arterial disease; TIA, transient ischemic attack; ECST, European Carotid Surgery Trial; IPH, intra-
plaque hemorrhage
Continuation of Table 1.
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Discussion
This study does not show associations between novel imaging biomarkers of athero-
sclerosis and VWF:Ag levels or ADAMTS13 activity in patients with a recent TIA or 
ischemic stroke and a symptomatic mild-to-moderate carotid artery stenosis.
The strength of our study is that we characterized the carotid atherosclerotic 
plaque using two image modalities (MDCTA and MRI) and assessed atherosclerotic 
burden as well as vulnerable plaque characteristics. Furthermore, this is the first study 
investigating the relationship between novel imaging biomarkers with VWF:Ag levels 
and ADAMTS13 activity. A limitation of our study was the cross-sectional design, 
which precludes the unraveling of cause and effect. We had a median delay of 47 
days between clinical event and blood sampling/imaging, which might have influ-
enced the association via a change in plaque composition and VWF levels.22 VWF 
is known to be increased in the acute phase of an event.23 However, imaging and 
blood sampling were performed at the same moment and we found no significant 
correlation between the interval event-blood withdrawal and VWF:Ag. We found a 
slight correlation between the interval event-blood withdrawal and ADAMTS13 activ-
ity, however this might be a chance finding. Nonetheless, adjustment for the interval 
did not influence the association between imaging and blood biomarkers. 
In a previous study, we found a strong correlation between calcification volume 
in the aortic arch and carotid arteries and VWF levels in patients with an ischemic 
stroke or TIA. In accordance to literature we also found in this previous study sig-
nificantly higher VWF levels in patients with large artery atherosclerosis compared to 
other etiological subtypes of TIA or stroke.3, 4, 24 No previous studies are known investi-
gating the association between ADAMTS13 and atherosclerosis. In the current study, 
all patients had a carotid artery stenosis and we assessed plaque volume as well as 
vulnerable plaque characteristics; no associations were found between any of the 
novel imaging biomarkers and VWF and ADAMTS13. It might be that VWF levels are 
Table 2. Imaging characteristics and VWF:Ag levels  and ADAMTS13 activity
* Adjusted for age and gender; additionally for blood group non-O in case of VWF; † in tertiles; ECST, 
European Carotid Surgery Trial; IPH, intraplaque hemorrhage
Characteristic VWF (model 1)* ADAMTS13 (model 1)*
Beta [95% CI] P value Beta [95% CI] P value
Degree of stenosis (ECST)† -0.02 [-0.09;0.04] 0.53 -2.29 [-6.30;1.71] 0.26
Maximum vessel wall area† -0.03 [-0.11;0.05] 0.41 2.50 [-2.11;7.10] 0.29
Calcification volume† 0.00 [-0.07;0.08] 0.91 -1.87 [-6.44;2.71] 0.42
Lipid volume† -0.05 [-0.12;0.02] 0.14 1.43 [-2.76;5.62] 0.50
IPH volume† -0.04 [-0.10;0.02] 0.18 0.70 [-3.11;4.51] 0.72
Plaque ulceration -0.12 [-0.24;0.01] 0.08 0.56 [-7.40;8.52] 0.89
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differently associated with plaque volume measurements than with vulnerable plaque 
characteristics. For instance, in acute coronary syndrome patients, the presence of 
atherosclerosis measured by IVUS was associated with VWF:Ag levels, but VWF:Ag 
levels were not associated with high risk, prone-to-rupture atherosclerotic lesions.25 
However, due to the clear role of VWF in thrombus formation and the less clear role 
of VWF and ADAMTS13 in atherosclerotic plaque development, we expected to find 
the opposite. It seems that neither the local disturbance of blood flow nor the disrup-
tive plaque surface in the carotid bifurcation causes an increase in VWF or a decrease 
in ADAMTS13. It may be that the systemic alteration of the endothelial layer due 
to widespread atherosclerotic disease causes the change in VWF. If this is the case, 
blood coagulation markers are then a marker of a widespread atherosclerotic disease 
and not a modifiable risk marker for secondary prevention. However, a complex role 
of VWF and ADAMTS13 in atherosclerotic plaque development cannot be ruled out. 
Conclusions
Imaging biomarkers of atherosclerosis were not associated with VWF:Ag levels or AD-
AMTS13 activity in patients with a recent TIA or ischemic stroke and a symptomatic 
mild-to-moderate carotid artery stenosis. Whether the blood biomarkers are simply a 
marker of widespread atherosclerosis or have a more complex role in atherosclerotic 
plaque development, remains unclear. 
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Abstract
Background and Purpose: Atherosclerotic plaque development may result in a spe-
cific morphologic buildup of plaque components, the so-called vulnerable plaque, 
which is mechanically unstable and can lead to plaque rupture, ending in an ischemic 
stroke. Plaque ulceration is considered a result from plaque rupture. An increased 
plasma level of von Willebrand Factor (VWF) is a result of endothelial dysfunction 
and is associated with an increased risk of ischemic stroke. We investigated the re-
lationship between carotid artery plaque ulceration and VWF levels in patients with 
ischemic stroke.
Methods: We included 985 patients with TIA or ischemic stroke. Carotid imaging 
was performed with multidetector computed tomography angiography. Both carotid 
arteries were evaluated for volume of calcifications (mm3) and the presence of plaque 
XOFHUDWLRQGHILQHGDVH[WHQVLRQRIFRQWUDVWPDWHULDORI!PPLQWRWKHVXUURXQGLQJ
atherosclerotic plaque on at least two orthogonal planes. Linear regression analysis 
was used to analyze the relationship between ulceration and VWF:Antigen (VWF:Ag) 
levels. Adjustments were made for age and gender (model I) and additionally for 
blood group, calcification volume and cardiovascular risk factors (model II).
Results: A significant correlation was found between plaque ulceration and VWF 
levels, after correction for age and gender (ß=0.066 [0.003-0.129]; p=0.040). After 
additional adjustment for blood group, calcification volume and cardiovascular risk 
factors, plaque ulceration was not significantly associated with VWF levels (ß=0.027 
[-0.036-0.089]; p=0.403).
Conclusion: Atherosclerotic plaque ulceration in the carotid arteries is not, indepen-
dently of calcification volume, related to higher levels of VWF in patients with TIA or 
ischemic stroke.
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Introduction
Atherosclerotic plaque development starts with endothelial dysfunction, which leads 
to intimal thickening that finally ends in lipid accumulation beneath a fibrous cap, 
and formation of calcifications.1-3 Atherosclerotic plaques with a specific morphologic 
buildup of plaque components, the so-called vulnerable plaque, are mechanically 
unstable, which can lead to plaque rupture. Carotid plaque rupture can lead to plate-
let aggregation, thrombus formation and embolization of thrombus and/or plaque 
material into the distal intracranial arteries, which causes an ischemic stroke.4 Previ-
ous studies have shown a strong correlation between carotid artery plaque ulceration 
and histologic characteristics of plaque instability, such as intraplaque hemorrhage 
and plaque rupture.5 New accurate imaging techniques like Computed Tomography 
Angiography (CTA) and Magnetic Resonance Imaging (MRI) can identify atheroscle-
rotic plaque composition, such as lipid-rich necrotic core, intraplaque hemorrhage 
and calcifications with a high accuracy.6-8 In addition, plaque ulceration, which is an 
independent predictor of  ischemic stroke, can be detected with CTA and MRI as well. 
9, 10,11
Von Willebrand Factor (VWF) is a plasma glycoprotein, produced by endotheli-
um, megakaryocytes and sub-endothelial connective tissue. VWF is involved in plate-
let adhesion and aggregation,  leads to thrombus formation.12 An increased level of 
VWF is seen as a result of adverse changes to endothelium13 and is associated with an 
increased risk of ischemic stroke.14 It is yet unknown whether atherosclerotic plaque 
leads to changes in hemostasis with a subsequent increase in ischemic stroke risk 
or whether atherosclerotic plaque and hemostatic changes independently increase 
ischemic stroke risk. In a previous study we evaluated the association between degree 
of calcification volume and VWF levels, and concluded that extent of calcification 
volumes in the carotid arteries and aortic arch are strongly associated with VWF lev-
els. 15As plaque ulceration is considered as an important step in the pathophysiology 
of ischemic stroke, we investigated whether there is a relationship between plaque 
ulceration in the carotid artery and VWF levels in patients with ischemic stroke.
Methods
Study population
This study is embedded in the Erasmus Stroke Study, an ongoing registry of pa-
tients with acute transient ischemic attack (TIA) or ischemic stroke treated at a single 
university medical center, Erasmus MC Rotterdam. In the current study we included 
985 patients who were evaluated between July 2005 and November 2010 and had 
undergone blood sampling, genotyping and a CTA of the carotid bifurcation. All par-
ticipants provided written informed consent. The study was approved by the Medical 
Ethics Committee of the Erasmus MC. 
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Baseline characteristics
Hypertension, hypercholesterolemia and diabetes mellitus were defined as the use 
of drugs (respectively antihypertensive, anti-cholesterol drugs and oral and/or par-
enteral antidiabetic drugs) before inclusion to the study. Patients documented with a 
history of ischemic heart disease (such as myocardial infarction, angina pectoris or 
cardiac revascularization therapy), peripheral arterial diseases, atrial fibrillation, TIA 
or ischemic stroke and/or the use of platelet aggregation inhibitors were considered 
as patients with a history of ischemic cardiovascular diseases. Body mass index (BMI) 
was used as a measurement of body fat, based on height and weight, applied to adult 
men and women. Stroke severity was assessed using the National Institutes of Health 
Stroke Scale (NIHSS) and classified by subtypes by using the Trial of Org 10172 in 
Acute Stroke Treatment (TOAST) criteria, at admission at the stroke unit or at the 
outpatient clinic. More information can be found elsewhere. 16, 17 
CTA acquisition and analysis
Imaging was performed with a 16, 64 or 128 slice multidetector CT scanner (Sensa-
tion 16, Sensation 64, Definition, Definition AS+ or Definition flash, Siemens Medi-
cal Solutions, Erlangen, Germany), using a standardized and optimized contrast-en-
hanced protocol (120 kVp, 180-200 mAs, collimation 16 x 0.75 mm; 32 x 2 x 0.6 
mm; 64 x 2 x 0.6 mm, pitch <1), at a median of 5 days (interquartile range 2-14 
days) after onset of symptoms. All patient received 80 ml contrast material (320 mg/
mL iodixanol, Visipaque, Amersham Health, Little Chalfont, UK) , followed by 45 ml 
saline bolus chaser, both at an injection rate of 4 or 5 ml/s. Synchronization between 
data acquisition and the passage of contrast material was achieved by real-time bolus 
tracking at the level of the ascending aorta. The CTA scan reached from the ascend-
ing aorta to the intracranial vasculature. Parameters for image reconstructions were: 
field of view of 120 mm, matrix size 512 x 512, slice thickness 0.75 or 1.0 mm, incre-
ment 0.4-0.6 mm, with an intermediate reconstruction algorithm. 
Experienced observers blinded for clinical data analyzed the CTA images. Cal-
cification volume in the carotid arteries was quantified with dedicated commercially 
available software (Syngo CalciumScoring, Siemens) and expressed in cubic milli-
meters (mm³). The carotid arteries were measured at both sides within three cm 
proximal and distal of the bifurcation. Calcifications were differentiated from contrast 
material in the lumen by using a threshold of 600 Hounsfield Units. Second, MDC-
TA images were transferred to a workstation equipped with dedicated 3D analysis 
software (Leonardo and syngo.via; Siemens, Erlangen, Germany). The multiplanar 
reformatting application allowed analysis of both carotid arteries in oblique, coro-
nal, and sagittal planes. Both carotid arteries were evaluated for presence of plaque 
XOFHUDWLRQGHILQHGDVH[WHQVLRQRIFRQWUDVWPDWHULDORI!PPLQWKHVXUURXQGLQJ
atherosclerotic plaque on at least two orthogonal planes. 5, 18 
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Blood samples and VWF measurement
Patients were subjected to blood sampling approximately 6 days after onset of symp-
toms (interquartile range 3-14 days). The citrated blood samples were centrifuged 
at room temperature for 15 min at 1700xg and stored within 2 hours at -80 °C. 
MagNA Pure (Roche Diagnostics) was used to isolate DNA from blood and likewise 
stored at -80 °C. An in-house ELISA was used to determine VWF:Ag levels, using 
rabbit anti-human VWF antibodies (DakoCytomation, Glostrop, Denmark) for catch-
ing and tagging. No significant correlation was found between VWF levels and time 
from event till blood sampling (ß – 0.0001 IU/ml per day; p = 0.33). Reference stan-
dard plasma was calibrated against the international standard (Cryocheck Reference, 
Kordia, Leiden, the Netherlands). In most of the patients, blood group was assessed 
with a standard test of blood group antibodies. In the remaining patients, we geno-
typed rs687289, which can be used to discriminate blood group O from non-O status, 
using custom TaqMan Genotyping Assays (Applied Biosystems, Foster City, CA, USA)15.
Statistical Analysis
The distributions of VWF levels and calcification volumes in the carotid arteries were 
normalized by logarithmic transformation. For the analysis of calcification volume, 
we added 1.0 mm3 to the nontransformed values to deal with participants with a 
calcification volume of zero. The data are presented as geometric means and 95% 
confidence interval (CI). Linear regression analysis was used to analyze the rela-
tionship between ulceration, calcification volume and cardiovascular risk factors and 
VWF levels. Ulceration was scored as present if one of the carotid arteries showed 
a plaque ulceration. The average calcification volume of both carotid arteries was 
used. Model I was adjusted for age and gender. Model II was additionally adjusted for 
blood group, calcification volume, and for cardiovascular risk factors with a p value 
< 0.05 in model I. The linear regression analysis was repeated for patients with large 
artery atherosclerosis according to the TOAST criteria. All analyses were performed 
using SPSS version 21.0 (IBM, Somers, NY, USA). A P value <0.05 was considered 
to indicate statistical significance.
Results
21 of the 985 patients were excluded due to lack of information about the carotid 
bifurcation, as a result of missing CTA (n=12), major artifacts (n=7) or poor contrast 
enhancement (n=2). The baseline characteristics of our remaining 964 study partici-
pants are shown in Table 1. Mean age at baseline was 62 ± 14 year and 46% of the 
patients were female. Mean VWF:Ag levels were 1.6 ± 0.7 IU/ml. Table 2 shows the 
imaging characteristics of the 1928 carotid arteries and in 964 patients. Plaque ulcer-
ation was seen in 7% (136/1928) of the carotid arteries and in 128 patients. Plaque 
calcifications were present in 48% of the vessels with a volume of 1.68 ± 1.89 mm3. 
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The determinants of VWF levels are presented in Table 3. A significant correlation 
was seen between plaque ulceration and VWF levels, after correction for age and 
gender ß=0.066 [0.003 - 0.129]; p=0.040). After additional adjustment for blood 
group, calcification volume and all  cardiovascular risk factors with p value <0.05 
plaque ulceration was not significant associated with VWF levels (ß=0.027 [-0.036 
- 0.089]; p=0.403). Reanalysis in the patients with large artery atherosclerosis re-
vealed no association between plaque ulceration and VWF levels.
Table 1. Clinical characteristics. Total cohort: n = 964
Clinical characteristic
Age, years 62 ± 14
Female 462 (47%)
Body mass index (kg/m²) 27.3 ± 13.1
Hypertension 531 (54%)
Hypercholesterolemia 354 (36%)
Diabetes mellitus 140 (14%)
History of CVD 644 (65%)
Current smokers 299 (30%)
Blood group
 O
 Non-O
445 (45%)
534 (54%)
VWF (IU/ml) 1.6 ± 0.7
TOAST classification
 Large artery atherosclerosis
 Cardio-embolism
 Small vessel occlusion
 Other determined etiology
 Undetermined
163 (17%)
116 (12%)
191 (20%)
54 (6%)
440 (46%)
Data are presented as n (%), unless for age and body mass index, where mean ± SD are shown.
CVD indicates cardiovascular disease. VWF indicates Von Willebrand Factor. TOAST indicates stroke sub-
type according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria. Data were missing 
on Body Mass Index (n=377), hypertension (n=1), hypercholesterolemia (n=1), diabetes mellitus (n=1), 
history of CD (n=2), current smokers (n=45) and blood group (n=2)
Table 2. Imaging characteristics
Carotid arteries (n=1928) Patients (n=964)
Carotid plaque ulceration 136 (14%) 128 (13%)
Plaque calcification 920 (48%) 558 (58%)
Data are presented as n (%) 
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Discussion
In the current study we evaluated whether plaque ulceration was related to an in-
creased VWF level. Our findings showed no significant correlation between plaque 
ulceration and increased VWF levels after adjustment for age, gender, blood group 
and calcification volume. 
Previous studies have demonstrated a strong correlation between ischemic 
stroke and a higher VWF levels 4. Lip et al has shown that a high level of VWF has a 
prognostic value in patients with ischemic heart disease and inflammatory vascular 
disease. However, there is limited evidence that a higher level of VWF induces pro-
gression of vascular diseases13. Wieberdink et al. studied the correlation between the 
risk of stroke and VWF levels in the general population, and found a significant cor-
relation also after adjustment for additional confounders.19 Similar results were found 
in the study of Sonneveld et al., in which the association between the extent of ath-
erosclerosis in the aortic arch and the carotid arteries and VWF levels was showed in 
patients with TIA or ischemic stroke. Higher levels of VWF were also associated with 
Table 3. Determinants of Von Willebrand Factor.
Characteristics Model I a
Beta [95% CI] p value
Model II b
Beta [95% CI] p value
Age, years .008 [.007;.010] <0.001 .005 [.003;.007] .000
Female .048 [-.002;.098] .062 - -
Body mass index (kg/m²) .001 [-.001;.004] .329 - -
Hypertension .080 [.028;.133] .003 .044 [-.007;.095] .090
Hypercholesterolemia .049 [-.004;.103] .072 - -
Diabetes mellitus .074 [.002;.145] .044 .047 [-.021;.114] .175
History of CVD .010 [-.044;.064] .716 - -
Current smoking .010 [-.046;.066] .735 - -
Blood group O -.266 [-.313;-.218] .000 -.264 [-.311;-.217] .000
TOAST classification
 Large artery atherosclerosis
 Cardio-embolism
 Small vessel occlusion
 Undetermined
.133 [.066;.200]
.081 [.004;.159]
-.081 [-.143; -.018]
-.054[-.105;.004]
.000
.040
.012
.035
.079 [-.039;.197]
.057 [-.065;.178]
-.071 [-.184; .042]
-.014[-.119;.092]
.190
.361
.217
.798
Carotid plaque ulceration .066 [.003;.129] .040 .027 [-.036;.089] .403
Calcification volume (mm3) .067 [.041;.092] .000 .053 [.028;.079] .000
a Adjusted for age and gender; b Adjusted for age, gender, blood group, calcification volume and all car-
diovascular risk factors with p value <0.05 in model I.
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a poor outcome.15 This supports the hypothesis that VWF levels could be an index of 
endothelial damage in vascular disease. 20
As high VWF levels increases the risk of ischemic stroke, 19 the question arises 
whether atherosclerotic plaque leads to changes in hemostasis and a subsequent 
increased risk of ischemic stroke, or whether both atherosclerotic plaque and he-
mostatic changes independently increase risk of ischemic stroke. The absence of an 
association between plaque ulceration and VWF levels after adjustment for calcifica-
tions does not support the hypothesis that VWF levels are affected by the presence of 
plaque ulceration and that a higher level of VWF an intermediate risk factor is in the 
pathway between atherosclerotic disease and ischemic stroke. 
Strengths of our study are the large group of ischemic stroke patients, with avail-
ability of well-documented clinical information and plasma of almost all patients. The 
carotid arteries were analyzed with CTA, which gave us the opportunity to evaluate 
the vulnerable plaque characteristic plaque ulceration as well as a measure of athero-
sclerosis (calcification volume).  
A limitation of our study is that patients with significant comorbidity, very severe 
stroke or those who died within 24h, were not included in this study. This resulted in 
a relatively less severely affected cohort and as a result less patients with ulcerations 
are included in this study resulting in dilution of a possible association.
In conclusion, atherosclerotic plaque ulceration in the carotid arteries is not, 
independently of calcification volume, related to higher levels of VWF in patients with 
TIA or ischemic stroke.
Processed on: 2-12-2016
506902-L-sub01-bw-vanDijk
55
VWF and plaque ulceration
2.3
References
1.  Ross R. The pathogenesis of atherosclerosis a perspective for the 1990s. Nature. 
1993;362:801-809
2.  Fuster V. Mechanisms leading to myocardial infarction: Insights from studies of vascular 
biology. Circulation. 1994;90:2126-2146
3.  Finn AV, Kolodgie FD, Virmani R. Correlation between carotid intimal/medial thickness 
and atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30:177-181
4.  Lammie GA, Sandercock PA, Dennis MS. Recently occluded intracranial and extracranial 
carotid arteries. Relevance of the unstable atherosclerotic plaque. Stroke. 1999;30:1319-
1325
5.  Lovett JK, Gallagher PJ, Hands LJ, et al. Histological correlates of carotid plaque surface 
morphology on lumen contrast imaging. Circulation. 2004;110:2190-2197
6.  Saam T, Ferguson MS, Yarnykh VL, et al. Quantitative evaluation of carotid plaque com-
position by in vivo MRI. Arterioscler Thromb Vasc Biol. 2005;25:234-239
7.  Yuan C, Mitsumori LM, Ferguson MS, et al. In vivo accuracy of multispectral magnetic 
resonance imaging for identifying lipid-rich necrotic cores and intraplaque hemorrhage in 
advanced human carotid plaques. Circulation. 2001;104:2051-2056
8.  de Weert TT, Ouhlous M, Meijering E, et al. In vivo characterization and quantification of 
atherosclerotic carotid plaque components with multidetector computed tomography and 
histopathological correlation. Arterioscler Thromb Vasc Biol. 2006;26:2366-2372
9.  Eliasziw M, Streifler JY, Fox AJ, et al. Significance of plaque ulceration in symptomatic 
patients with high-grade carotid stenosis. North american symptomatic carotid endarter-
ectomy trial. Stroke. 1994;25:304-308
10.  Rothwell PM, Gibson R, Warlow CP. Interrelation between plaque surface morphology and 
degree of stenosis on carotid angiograms and the risk of ischemic stroke in patients with 
symptomatic carotid stenosis. On behalf of the european carotid surgery trialists’ collab-
orative group. Stroke. 2000;31:615-621
11.  Groen HC, Gijsen FJ, van der Lugt A, et al. Plaque rupture in the carotid artery is localized 
at the high shear stress region. Stroke. 2007;38:2379-2381
12.  Ruggeri ZM. The role of von willebrand factor in thrombus formation. Throm Res. 
2007;120:S5-9
13.  Lip GY, Blann A. Von willebrand factor: A marker of endothelial dysfunction in vascular 
disorders? Cardiovasc Res. 1997;34:255-265
14.  Cortellaro M, Boschetti C, Cofrancesco E, et al. The plat study: Hemostatic function in 
relation to atherothrombotic ischemic events in vascular disease patients. Principal re-
sults. Plat study group. Progetto lombardo atero-trombosi (PLAT) study group. Arterioscler 
Thromb. 1992;12:1063-1070
15.  Bongers TN, de Maat MP, van Goor ML, et al. High von willebrand factor levels increase 
the risk of first ischemic stroke: Influence of ADAMTS13, inflammation, and genetic vari-
ability. Stroke. 2006;37:2672-2677
16.  Catto AJ, Carter AM, Barrett JH, et al. Von Willebrand factor and factor VIII: C in acute 
cerebrovascular disease. Relationship to stroke subtype and mortality. Thromb Haemost. 
1997;77:1104-1108
17.  Sonneveld MA, van Dijk AC, van den Herik EG, et al. Relationship of von Willebrand factor 
with carotid artery and aortic arch calcification in ischemic stroke patients. Atherosclero-
sis. 2013;230:210-215
Processed on: 2-12-2016
506902-L-sub01-bw-vanDijk
5
Chapter 2.3
18.  Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic 
stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute 
Stroke Treatment. Stroke. 1993;24:35-41
19.  Adams HP Jr, Davis PH, Leira EC, et al. Baseline NIH stroke scale score strongly pre-
dicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment 
(TOAST). Neurology. 1999;53:126-131
20.  de Weert TT, Cretier S, Groen HC, et al. Atherosclerotic plaque surface morphology in 
the carotid bifurcation assessed with Multidetector Computed Tomography Angiography. 
Stroke. 2009;40:1334-1340
21.  Wieberdink RG, van Schie MC, Koudstaal PJ, et al. High von Willebrand factor levels in-
crease the risk of stroke: The Rotterdam Study. Stroke. 2010;41:2151-2156
22.  Boneu B, Abbal M, Plante J, et al. Factor VIII complex and endothelial damage. Lancet. 
1975;1:1430
Processed on: 2-12-2016
506902-L-sub01-bw-vanDijk
5
VWF and plaque ulceration
2.3
Processed on: 2-12-2016
506902-L-sub01-bw-vanDijk
Processed on: 2-12-2016
506902-L-sub01-bw-vanDijk
Chapter 3 
Comparison of non-invasive 
plaque imaging techniques
Processed on: 2-12-2016
506902-L-sub01-bw-vanDijk
Processed on: 2-12-2016
506902-L-sub01-bw-vanDijk
AJNR Am J Neuroradiol. 2015;36:2127-2133
A.C. van Dijk, M.T.B. Truijman, B. Hussain, T. Zadi, G. Saiedie, 
A.A.J. de Rotte, M.I. Liem, A.F.W. van der Steen, M.J.A.P. Daemen, 
P.J. Koudstaal, P.J. Nederkoorn, J. Hendrikse,
M.E. Kooi, A. van der Lugt
Intraplaque hemorrhage
and the plaque surface
in carotid atherosclerosis.
The Plaque At RISK study
(PARISK)
Chapter 3.1 
Processed on: 2-12-2016
506902-L-sub01-bw-vanDijk

Chapter 3.1
Abstract
Background and purpose: An important characteristic of vulnerable plaque, intra-
plaque hemorrhage, may predict plaque rupture. Plaque rupture can be visible on 
noninvasive imaging as a disruption of the plaque surface. We investigated the asso-
ciation between intraplaque hemorrhage and disruption of the plaque surface.
Materials and methods: We selected the first 100 patients of the Plaque At RISK 
study, an ongoing prospective noninvasive plaque imaging study in patients with mild-
to-moderate atherosclerotic lesions in the carotid artery. In carotid artery plaques, 
disruption of the plaque surface (defined as ulcerated plaques and/or fissured fibrous 
cap) and intraplaque hemorrhage were assessed by using MDCTA and 3T MR imag-
ing, respectively. We used a X2 test and multivariable logistic regression to assess the 
association between intraplaque hemorrhage and disrupted plaque surface.
Results: One hundred forty-nine carotid arteries in 78 patients could be used for the 
current analyses. Intraplaque hemorrhage and plaque ulcerations were more preva-
lent in symptomatic compared with contralateral vessels (hemorrhage, 38% versus 
11%; P < .001; and ulcerations, 27% versus 7%; P = .001). Fissured fibrous cap was 
more prevalent in symptomatic compared with contralateral vessels (13% versus 4%; 
P = .06). After adjustment for age, sex, diabetes mellitus, and degree of stenosis, 
intraplaque hemorrhage was associated with disrupted plaque surface (OR, 3.13; 
95% CI, 1.25–7.84) in all vessels.
Conclusions: Intraplaque hemorrhage is associated with disruption of the plaque 
surface in patients with a carotid artery stenosis of <70%. Serial studies are needed 
to investigate whether intraplaque hemorrhage indeed increases the risk of plaque 
rupture and subsequent ischemic stroke during follow-up.
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Introduction
The need to identify patients with mild-to-moderate carotid artery stenosis and an 
increased stroke risk who might benefit from surgical treatment has shifted research 
interest from assessment of the degree of carotid stenosis to assessment of vulner-
able plaque characteristics.1 Vulnerable plaques are atherosclerotic plaques more 
prone to rupture and are associated with a higher risk for thromboembolism and 
ischemic stroke.2,3 Intraplaque hemorrhage is an important characteristic of the vul-
nerable plaque.4 Prevalence of intraplaque hemorrhage has been shown to be higher 
in symptomatic than in asymptomatic lesions.5 Moreover, the presence of intraplaque 
hemorrhage in carotid artery disease is associated with an increased risk of cerebral 
ischemic events.6-8
The pathophysiologic mechanism leading to intraplaque hemorrhage is a topic 
of debate. However, a common viewpoint is that small leaky neovessels in the ath-
erosclerotic plaques are a likely source of intraplaque hemorrhage.5,9,10 The pres-
ence of intraplaque hemorrhage is thought to initiate several biologic processes like 
phagocytosis and local inflammation, leading to the release of proteolytic enzymes, 
deposition of free cholesterol and subsequently plaque growth, plaque destabiliza-
tion, and possible plaque rupture.5,9-12 Plaque rupture can be visible on imaging as a 
disruption of the atherosclerotic plaque surface (plaque ulceration and/or a fissured 
fibrous cap).13,14 
A previous study reported that plaque ulceration on CTA was useful for the pre-
diction of intraplaque hemorrhage on MR imaging in a broad group of symptomatic 
patients referred for carotid artery imaging.15 Ulcerated plaques themselves are inde-
pendently associated with an increased risk of ipsilateral ischemic events as well.16,17
The aim of the current study was to investigate the association between in-
traplaque hemorrhage, as assessed on MR imaging, and disruption of the plaque 
surface, assessed on MDCTA, in symptomatic patients with a carotid artery stenosis 
of <70%.
Materials and methods
Study population
Patients were derived from the Plaque At RISK (PARISK) study (clinical trials.gov, 
NCT01208025). Details of the PARISK study are previously described.18 The PARISK 
study is an ongoing prospective multicenter cohort study focusing on the identifica-
tion of patients with mild-to-moderate carotid artery stenosis with an increased risk 
of recurrent stroke by using noninvasive plaque imaging. Eligible for inclusion are pa-
tients with a TIA, including amaurosis fugax, or minor stroke in the carotid artery ter-
ritory and a mild-to-moderate stenosis (30%– 69%) of the ipsilateral internal carotid 
artery. “TIA” was defined as an episode of temporary and focal cerebral dysfunction 
of vascular origin, lasting for a maximum 24 hours, leaving no persistent neurologic 
deficits. “Minor stroke” was defined as an episode of temporary and focal cerebral 
G\VIXQFWLRQRIYDVFXODURULJLQODVWLQJIRU!KRXUVRUDQRQGLVDEOLQJVWURNHZLWKD
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PRGLILHG5DQNLQ6FDOHVFRUHRI $´PDXURVLVIXJD[µZDVGHILQHGDVDVXGGHQORVV
of vision of presumed vascular origin and confined to 1 eye. The degree of stenosis 
was determined with clinically obtained Doppler sonography or MDCTA. The upper 
cutoff value of 70% was based on the NASCET criteria. The lower cutoff value was 
an atherosclerotic plaque with a thickness of at least 2–3 mm, which corresponds to 
a European Carotid Surgery Trial (ECST) stenosis of 30%.19 Exclusion criteria were a 
probable cardiac source of embolism, a clotting disorder, severe comorbidity, stan-
dard contraindications for MR imaging, a documented allergy to MR imaging or CT 
contrast agents, or a renal clearance of <30 mL/min. Institutional review board ap-
proval was obtained in all university hospitals, and all patients gave written informed 
consent. For the current analyses, we selected the first 100 included patients.
9J<AGN9K;MD9JJAKC>9;LGJK
´+\SHUFKROHVWHUROHPLDµ ZDV GHILQHG DV IDVWLQJ WRWDO FKROHVWHURO RI!PPRO/ RU
the use of cholesterol-lowering medication at the time of the TIA or ischemic stroke. 
:HGHILQHG´K\SHUWHQVLRQµDVV\VWROLFEORRGSUHVVXUHRI!PP+JRUDGLDVWROLF
EORRG SUHVVXUH RI!PP+J GXULQJ  HSLVRGHV RI DW OHDVW PLQXWHV RI FRQ-
tinuous noninvasive blood pressure measurement or treatment with antihypertensive 
PHGLFDWLRQ´'LDEHWHVPHOOLWXVµZDVGHILQHGDVDIDVWLQJVHUXPJOXFRVHOHYHORI!
PPRO/KRXUSRVWORDGJOXFRVHOHYHORI!PPRO/RUWKHXVHRIDQWLGLDEHWLF
medication. We assessed smoking status at the time of the TIA or ischemic stroke and 
dichotomized it into current smoker or no current smoker. In addition, we recorded 
body mass index, the use of cardiovascular medications, and medical history.
MDCTA data acquisition and analysis
We performed image acquisition by using a standardized protocol, as discussed in the 
study design article.18 All MDCTA studies were evaluated by trained readers blinded 
to clinical data and other imaging tests. The MDCTA images were transferred to 
a workstation equipped with dedicated 3D analysis software (Leonardo and syngo.
via; Siemens, Erlangen, Germany). The multiplanar reformatting application allowed 
analysis of both carotid arteries in oblique, coronal, and sagittal planes. Image quality 
was rated on a 3-point scale: 1) poor, defined as low contrast and major artifacts and 
not eligible for analysis; 2) moderate, defined as moderate artifacts and eligible for 
analysis; and 3) good, defined as few or no artifacts and eligible for analysis.
First, we evaluated the presence of an atherosclerotic plaque in both carotid 
arteries, defined as the presence of calcifications and/or thickening of the vessel wall 
!§PP,ISUHVHQWGLVUXSWLRQRIWKHSODTXHVXUIDFHZDVDVVHVVHGLQERWKDUWHU-
ies at the same time. “Disruption of the plaque surface,” defined as the presence 
of plaque ulceration and/or a fissured fibrous cap, was assessed by 2 independent 
observers (B.H., 12 months, and A.C.v.D., 4 years of experience); discrepancies were 
solved by consensus and/or an experienced third observer (A.v.d.L, 10 years of experi-
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HQFH:HGHILQHG´SODTXHXOFHUDWLRQµDVDQH[WHQVLRQRIFRQWUDVWPDWHULDORI!PP
into the atherosclerotic plaque on at least 2 orthogonal planes (Fig 1).13,20 We defined 
“fissured fibrous cap” according to the criteria of Saba and Mallarini, extension of 
FRQWUDVWPDWHULDORIPPLQWRWKHDWKHURVFOHURWLFSODTXHDQGDQDQJOHRI!
with the lumen (Fig 2).21
Figure 1. Plaque ulceration on MDCTA. Transversal (left) and longitudinal (right) MDCTA images of the 
carotid bifurcation. A “plaque ulceration,” defined as the extension of contrast material in the atheroscle-
rotic plaque, is visible on both planes (arrows; arrowheads indicate the edges of the plaque ulceration). 
ECA indicates external carotid artery.
Figure 2. Fissured fibrous cap on MDCTA. Transversal (left) and longitudinal (right) MDCTA images of 
the carotid bifurcation. A “fissured fibrous cap,” defined as an extension of contrast material of <1 mm 
LQWRWKHDWKHURVFOHURWLFSODTXHDQGDQDQJOHRI!ZLWKWKHOXPHQLVYLVLEOHRQO\RQWKHWUDQVYHUVDO
plane (arrows).
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Interobserver variability for the initial review was moderate (K = 0.41) for the detec-
tion of disruption of the plaque surface (plaque ulceration and/or fissured fibrous 
cap), moderate (K = 0.46) for the detection of plaque ulceration, and fair (K = 
0.24) for the detection of fissured fibrous cap. Moreover, the most severe stenosis in 
the carotid bifurcations and internal carotid arteries was measured according to the 
ECST and NASCET criteria, perpendicular to the central lumen line.19,22 A custom-
made plug-in for the freely available ImageJ software (National Institutes of Health, 
Bethesda, Maryland) was used to quantify calcifications in both carotid arteries within 
3 cm proximal and distal to the bifurcation. We used a threshold of 600 HU to dif-
ferentiate calcifications from contrast material in the lumen; calcification volume was 
expressed in cubic millimeters. A detailed description of the measurements is pro-
vided elsewhere.23
MR imaging data acquisition and analysis
Image acquisition was performed on a 3T MR imaging system (Achieva; Philips 
Healthcare, Best, the Netherlands; or Discovery MR 750; GE Healthcare, Milwau-
kee, Wisconsin). A multi- sequence contrast-enhanced protocol was used; a detailed 
description of this protocol is provided in the study design article.18 For this study, we 
used the 3D-T1W fat suppressed spoiled gradient echo sequence (GE Healthcare) or 
the 2D-T1W inversion recovery turbo field echo sequence (Philips Healthcare). A 3D 
volume of the extracranial carotid artery (GE Healthcare) or 15 transverse adjoining 
sections of 2 mm each covering the entire plaque (Philips Healthcare) were imaged.
Figure 3. Intraplaque hemorrhage on MR imaging. Carotid bifurcations of 2 patients: left, the 3D-T1W 
fat suppressed spoiled gradient echo sequence (Discovery MR 750; GE Healthcare), and right, the 2D-
T1W inversion recovery turbo field echo sequence (Achieva; Philips Healthcare). In both patients, intra-
plaque hemorrhage is present (arrows; arrowheads indicate the edges of the intraplaque hemorrhage), 
defined as a hyperintense signal in the atherosclerotic plaque compared with the sternocleidomastoid 
muscle (asterisk).
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All MR imaging studies were evaluated by a trained reader (M.T.B.T., 4 years of ex-
perience) blinded to clinical data and other imaging tests. MR images were reviewed 
by using a standard DICOM viewer. Image quality was rated on a 5-point scale: 1) 
low SNR, limits use, arterial wall and vessel margins unidentifiable; 2) marginal SNR, 
arterial wall visible, with the substructure, lumen, and outer boundaries indistinct; 3) 
marginal SNR, wall structures identifiable with the lumen and outer boundaries par-
tially obscured; 4) high SNR with minimal artifacts; vessel wall, lumen, and adventitial 
margins well-defined; and 5) high SNR without artifacts, wall architecture depicted 
in detail, lumen and adventitial boundary clearly defined.24 Intraplaque hemorrhage 
was scored in both arteries at the same time and was defined as a hyperintense sig-
nal in the plaque compared with the adjacent sternocleidomastoid muscle (Fig 3).24 
In 47 vessels, the presence of intraplaque hemorrhage was assessed by a second 
independent observer (A.C.v.D, 4 years of experience; the minimum interval between 
MDCTA and MR imaging scores was 8 months) to assess interobserver variability, and 
an excellent agreement was found (K = 0.95; 95% CI, 0.86 –1.00).
Statistical analysis
Baseline characteristics are shown for all patients; vessel characteristics are shown 
for all vessels and for symptomatic and contralateral vessels separately. Data are 
presented as mean ± SD, median (25th–75th percentile), or number of patients (per-
centage). Differences between symptomatic and contralateral vessels were evaluated 
by using a X2 test for categorical data and a Student t test or Mann-Whitney U test 
for continuous data. For the analysis of calcification volume, we used natural log-
transformed values and added 1.0 mm3 to the nontransformed values to deal with 
participants with a calcification volume of zero. First, we used a X2 test to assess the 
association between intraplaque hemorrhage and disrupted plaque surface (ulcer-
ated plaques and/or a fissured fibrous cap) in all vessels. We used all vessels because 
we assumed that the underlying pathophysiologic mechanism would be similar in 
symptomatic and contralateral vessels. Additionally, a logistic regression was used 
to further investigate the association between intraplaque hemorrhage, other plaque 
characteristics, and cardiovascular risk factors on the one hand and disrupted plaque 
surface on the other. We used a generalized estimation equation approach with an 
unstructured correlation matrix to adjust for the correlation between both carotid 
arteries in each patient. Adjustments were made for age and sex (model 1) supple-
mented with all variables with a P value < .10 in model 1 (model 2, included the de-
gree of stenosis according to the ECST criteria to correct for differences in stenosis).
Analyses were repeated to assess the association between intraplaque hem-
orrhage and ulcerated plaques alone. In addition, analyses were repeated for the 
symptomatic artery. The location of intraplaque hemorrhage and disrupted plaque 
surface was visually correlated by 2 independent observers after manual alignment of 
the MR imaging and MDCTA scans based on vessel geometry and the location of the 
plaque. Statistical analyses were performed by using STATA software (Version 13.1; 
StataCorp, College Station, Texas). P < .05 was considered statistically significant.
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Results
Patient characteristics
In 20 of the 100 patients, MDCTA (n = 18) or MR imaging (n = 2) of the carotid ar-
teries had not been performed due to contra-indications. Two patients were excluded 
due to inferior image quality of the MDCTA. Of the remaining 78 patients, 149 ves-
sels could be used for the current analyses. Seven contralateral vessels were excluded 
from analysis due to the absence of plaque (n = 5) or occlusion of the carotid artery 
(n = 2). Baseline characteristics are shown in Table 1. Forty-one of the 78 patients 
(53%) had an ischemic stroke; 37 (47%) patients had a TIA, including 7 with amau-
rosis fugax.
Table 1. Clinical characteristics of patients (n=78) a
Clinical characteristic
Age (years) 67 ± 9
Male sex 57 (73%)
Classification event
 TIA
 Stroke
 Amaurosis fugax
30 (38%)
41 (53%)
7 (9%)
Hypercholesterolemia 43 (55%)
Hypertension 56 (72%)
Diabetes Mellitus 19 (24%)
Current smoking
 No
 Yes
58 (74%)
20 (26%)
Body mass index 25.2 [24.3-28.4]
Current use 
 Antiplatelet therapy
 Oral anticoagulants
 Statins
 Antihypertensive medication
 Antidiabetic medication
36 (46%)
0 (0%)
36 (46%)
50 (64%)
13 (17%)
History 
 Ischemic stroke or TIA
 Ischemic heart disease
 Peripheral arterial disease
13 (17%)
16 (21%)
15 (19%)
a Data are mean ± SD, absolute numbers of patients (%) or median [25th-75th percentile]
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Vessel characteristics
The median interval between the neurologic event and MDCTA was 32 days (25th 
to 75th percentile, 14 –56 days); the median interval between the event and MR 
imaging was 44 days (25th to 75th percentile, 27– 62 days). Characteristics of all 
vessels and symptomatic and contralateral vessels separately are shown in Table 2. 
The mean severity of stenosis was 51% ± 17% (ECST). The prevalence of intraplaque 
hemorrhage in the symptomatic and contralateral vessels was 38% and 11%, respec-
tively. Twenty-six of the 149 vessels (17%) showed plaque ulceration; the prevalence 
in the symptomatic vessels and the contralateral vessels was 27% and 7%, respective-
ly. In 13 of the 149 vessels (9%), a fissured fibrous cap was present; most were found 
in the symptomatic vessels (n = 10), but the difference was not significant (P = .06).
 
Intraplaque hemorrhage and disrupted plaque surface
In Table 3, the association between the presence of intraplaque hemorrhage and dis-
rupted plaque surface (ulcerated plaque and/or fissured fibrous cap) is shown. In ves-
sels with intraplaque hemorrhage, a disrupted plaque surface was significantly more 
prevalent compared with vessels without intraplaque hemorrhage (45% versus 15%; 
P < .001). Table 4 shows the results of the multivariable logistic regression. After 
correction for age and sex, the presence of intraplaque hemorrhage was associated 
with a disrupted plaque surface (OR, 3.98; 95% CI, 1.73–9.16; P = .001). Addition-
ally, we found an association between the degree of stenosis and disrupted plaque 
surface (OR per 10% increase 1.42; 95% CI, 1.09 –1.84; P = .009). After correction 
for age, sex, and all variables with P < .10, intraplaque hemorrhage was still signifi-
Table 2. Vessel characteristicsa
Vessel characteristic All vessels Symptomatic 
vessels
Contralateral 
vessels
P value, symptomatic vs 
contralateral vessels
No. 149 78 71
Plaque ulceration 26 (17%) 21 (27%) 5 (7%) .001b
Fissured fibrous cap 13 (9%) 10 (13%) 3 (4%) .06
Calcium volume (mm3) 21.0  
[3.6-56.2]
24.2  
[6.2-71.8]
17.2  
[1.9-53.1]
.09
Degree of stenosis 
(ECST) (%)
51 ± 17 55 ± 17 47 ± 16 .004b
Degree of stenosis 
(NASCET) (%)
8 [0-32] 14 [0-35] 2 [0-26] .03b
Intraplaque hemorrhage 38 (26%) 30 (38%) 8 (11%) <.001b
a Data are absolute numbers of vessels (%), median [25th-75th percentile] or mean ± SD; b p<.05
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cantly associated with disrupted plaque surface (OR, 3.13; 95% CI, 1.25–7.84; P = 
.02). Diabetes mellitus was inversely associated with disrupted plaque surface (OR, 
0.31; 95% CI, 0.11– 0.94; P = .04). Similar results were found when the analyses 
were repeated to assess the association between intraplaque hemorrhage and ulcer-
ated plaque alone. The association between intraplaque hemorrhage and disrupted 
plaque surface was attenuated when the analyses were repeated in only the symp-
tomatic arteries (Supplementary Tables 1–3). The location of the plaque ulceration 
and/or fissured fibrous cap was the same as that of the intraplaque hemorrhage in 16 
of the 21 lesions (76%); an example is shown in Fig 4.
Table 3. Association of intraplaque hemorrhage and disrupted plaque surface in all vesselsa
Disrupted plaqueb Intact plaque surface Total
Intraplaque hemorrhage present (n=38) 17 (45%) 21 (55%) 38
Intraplaque hemorrhage absent (n=111) 17 (15%) 94 (85%) 111
Total 34 115 149
a p<0.001; b defined as ulcerated plaques and/or fissured fibrous cap
Table 4. Multivariable OR for association among clinical characteristics, vessel characteristics and  
disrupted plaque surface in all vessels
Multivariable
(Age, sex)
Multivariablea
(Age, sex, factors p<.10)
Characteristic OR [95% CI] P value OR [95% CI] P value
Age 1.05 [1.00-1.10] .07 1.05 [1.00-1.10] .07
Sex 0.42 [0.15-1.12] .08 0.50 [0.17-1.42] .19
Hypertension 1.98 [0.73-5.35] .18
Diabetes Mellitus 0.40 [0.14-1.10] .08 0.31 [0.11-0.94] .04b
Hypercholesterolemia 1.41 [0.63-3.15] .40
Current smoking 0.48 [0.16-1.46] .20
Intraplaque hemorrhage 3.98 [1.73-9.16] .001b 3.13 [1.25-7.84] .02b
Degree of stenosis 
(ECST, per 10%)
1.42 [1.09-1.84] .009b 1.30 [1.00-1.69] .07
Calcification volume 0.86 [0.69-1.08] .21
a We corrected for age, sex, diabetes mellitus and degree of stenosis (ECST); b P < .05
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Discussion
This study shows that intraplaque hemorrhage is associated with a disrupted plaque 
surface (plaque ulceration and/or fissured fibrous cap) and plaque ulceration alone. 
In 76% of the vessels with both intraplaque hemorrhage and a disrupted plaque sur-
face, intraplaque hemorrhage and plaque ulceration or fissured fibrous cap shared 
the same location. The association between these 2 vulnerable plaque characteristics 
may support the notion that intraplaque hemorrhage increases the risk of plaque rup-
ture. However, because of the cross-sectional study design, serial studies are needed 
to further investigate the role of intraplaque hemorrhage in plaque rupture.
Some methodologic issues need to be discussed first. A strength of our prospec-
tive study is that most vessels showed a mild stenosis. Most previous studies focused 
on patients with a moderate or severe carotid artery stenosis. However, plaque imag-
ing in this patient group is less relevant for clinical decision making because patients 
with a moderate (male patients) or severe (all patients) symptomatic carotid artery 
stenosis are already eligible for carotid endarterectomy.16 Moreover, the amount of 
calcification will probably be higher in patients with a moderate or severe carotid 
artery stenosis, complicating the detection of plaque surface morphology. Second, 
we reviewed MDCTA and MR images of all patients with a disrupted plaque surface 
and intraplaque hemorrhage to investigate whether the intraplaque hemorrhage and 
plaque disruption were at the same location. The finding that the location was indeed 
similar in 76% strengthens the association between the 2 vulnerable plaque charac-
teristics.
A limitation of our multicenter study is that we used different MDCTA and MR 
imaging scanners. MDCTA scanning protocols, however, were similar. We used the 
3D-T1W fat suppresssed spoiled gradient echo or the 2D-T1W inversion recovery 
turbo field echo MR imaging sequence to detect intraplaque hemorrhage. Bitar et al. 
and Cappendijk et al. used sequences like ours and found a good sensitivity, specific-
Figure 4. Correlated intraplaque hemorrhage on MR imaging and plaque ulceration on MDCTA. An ex-
ample of MR imaging and MDCTA images of the left carotid bifurcation. On the 3D-T1W fat suppressed 
echo-spoiled gradient echo MR imaging sequence, intraplaque hemorrhage is visible in the atheroscle-
rotic plaque (A, arrow). MDCTA images show a small ulceration on both the transversal and longitudinal 
plane at the site of the intraplaque hemorrhage (B and C, arrows; arrowheads indicate the edges of the 
plaque ulceration).
Processed on: 2-12-2016
506902-L-sub01-bw-vanDijk

Chapter 3.1
ity, and interobserver agreement for the detection of intraplaque hemorrhage in both 
sequences.25,26 They also found good agreement between MR imaging– depicted in-
traplaque hemorrhage and histologic sections. In addition, our overall prevalence of 
intraplaque hemorrhage of 26% is in accordance with that in the literature.4,5,15 Cor-
rection for MR imaging protocol used in the multivariate model did not change our 
results. A second limitation is the lack of histology. We used MDCTA instead of MR 
imaging for the evaluation of the plaque surface, because MDCTA has been shown 
to have a high sensitivity and specificity for the detection of plaque ulceration and has 
fewer limitations such as partial volume effects and flow artifacts that mimic plaques. 
27,28 In addition, when we reviewed the MR images and MDCTA images side by side, 
plaque ulcerations were hardly visible on the MR images. Saba et al. showed a good 
sensitivity and specificity for the detection of plaque ulceration by using MDCTA and 
multiplanar reconstruction (sensitivity, 75.8%; specificity, 90.8%).27 We found an over-
all prevalence of plaque ulceration of 17%. Similar prevalence of plaque ulceration 
was found in other studies, ranging from 13% to 22%.15,20,29,30 Detection of the pres-
ence of a fissured fibrous cap has been studied less intensively. We found an overall 
prevalence of the presence of a fissured fibrous cap of 9%, in agreement with the 
11% found by Saba and Mallarini.20 Rupture of the fissured fibrous cap was signifi-
cantly associated with cerebrovascular symptoms (P = .003).20 Based on the good 
sensitivity and specificity of MDCTA for plaque ulcerations and the good agreement 
between MR imaging–depicted intraplaque hemorrhage and histology, we therefore 
conclude that it is legitimate to use imaging techniques such as MDCTA and MR im-
aging to study the relationship between intraplaque hemorrhage and the disruption 
of the plaque surface.25,26 Moreover, the use of MDCTA and MR imaging provides the 
opportunity to investigate the relationship in a specific category of patients—that is, 
those with a mild-to-moderate carotid artery stenosis, patients who are treated medi-
cally and thus have no available histology. The final limitation of our study is that it is 
cross-sectional. Our results should therefore be confirmed in a serial study.
Rupture of an atherosclerotic carotid artery plaque is an important cause of 
ischemic stroke. Therefore, understanding the pathophysiology of plaque rupture is 
very important. Infiltration of macrophages in pathologic intima thickening plays a 
key role in the development of atherosclerotic plaques. The combination of mac-
rophage infiltration, apoptosis, and hypoxia-induced necrosis leads to the develop-
ment of more advanced atherosclerotic plaques with a lipid-rich necrotic core. Previ-
ous studies already showed an association between lipid-rich necrotic core volumes 
and plaque ulceration.29-31 In these larger plaques, hypoxia and the inflammatory 
response are assumed to promote neovascularization. As stated previously, the com-
mon viewpoint is that these small leaky neovessels are responsible for the occur-
rence of intraplaque hemorrhage and subsequently the development of an unstable 
rupture-prone plaque.5,9-12,32 Our results—if confirmed in serial studies— can support 
the pathophysiologic relation between intraplaque hemorrhage and disrupted plaque 
surface. An alternative viewpoint to explain this relationship is that repeated fissuring 
of the plaque and associated formation of nonocclusive luminal thrombus incorpo-
rated in the plaque could be the cause of intraplaque hemorrhage.5 Nevertheless, 
observations that intraplaque hemorrhage is related to high attenuation of plaque 
neovessels, in the absence of plaque fissuring, supports the more common view of 
small leaky neovessels as the cause of intraplaque hemorrhage.5,10
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Conclusions
We showed that intraplaque hemorrhage is associated with a disrupted plaque sur-
face (plaque ulceration and/or fissured fibrous cap) in patients with a <70% carotid 
artery stenosis. Our findings suggest a strong association between these 2 vulnerable 
plaque characteristics. Nevertheless, because of the cross-sectional study design, ad-
ditional serial studies are needed to evaluate whether intraplaque hemorrhage indeed 
increases the risk for plaque rupture and subsequent TIA or ischemic stroke.
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Supplementary information
Supplementary Table I. Association intraplaque hemorrhage and disrupted plaque surface/plaque  
ulceration in symptomatic vessels
1defined as ulcerated plaques and/or fissured fibrous cap
Disrupted plaque1 Ulceration present
Intraplaque hemorrhage present (n=30) 15 (50%) 11 (37%)
Intraplaque hemorrhage absent (n=48) 12 (25%) 10 (21%)
p value p=0.02 p=0.13
Supplementary Table II. Multivariable OR for association between clinical characteristics, vessel  
characteristics and disrupted plaque surface in symptomatic vessels
Multivariable
(Age, gender)
Characteristic OR [95% CI] P value
Age 1.04 [0.98-1.10] 0.24
Gender 0.52 [0.16-1.63] 0.26
Hypertension 1.87 [0.58-5.98] 0.29
Diabetes Mellitus 0.35 [0.10-1.24] 0.11
Hypercholesterolemia 1.21 [0.45-3.27] 0.71
Current smoking 0.31 [0.08-1.23] 0.10
Intraplaque hemorrhage 2.63 [0.97-7.09] 0.06
Degree of stenosis (ECST, per 10%) 1.30 [0.91-1.69] 0.12
Calcification volume (per mm3) 0.76 [0.56-1.04] 0.09
ECST, European Carotid Surgery Trial
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Supplementary Table III. Multivariable OR for association between clinical characteristics, vessel  
characteristics and plaque ulceration in symptomatic vessels
Multivariable
(Age, gender)
Characteristic OR [95% CI] P value
Age 1.02 [0.96-1.09] 0.52
Gender 0.57 [0.17-1.95] 0.37
Hypertension 1.19 [0.36-3.92] 0.77
Diabetes Mellitus 0.08 [0.01-0.70] 0.02*
Hypercholesterolemia 0.62 [0.21-1.78] 0.37
Current smoking 0.25 [0.05-1.28] 0.10
Intraplaque hemorrhage 1.99 [0.70-5.65] 0.20
Degree of stenosis (ECST, per 10%) 1.09 [0.83-1.42] 0.53
Calcification volume (per mm3) 0.66 [0.47-0.93] 0.02*
ECST, European Carotid Surgery Trial; * p<0.05
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Abstract
Introduction: MRI is increasingly used for atherosclerotic plaque characterization. 
Previous studies suggest that MRI is less suitable than MDCTA for the detection of 
plaque calcifications. We investigated the agreement between MRI and MDCTA in 
the detection of calcifications in patients with carotid artery stenosis.
Methods: We assessed calcification volume (mm3) in the symptomatic carotid artery 
in 185 patients of the PARISK-study with both MDCTA and multi-sequence contrast-
enhanced MRI. Sensitivity and specificity of MRI to detect calcifications were es-
timated, using MDCTA as reference. We evaluated correlation and differences in 
calcification volume between MRI and MDCTA.
Results: Prevalence of calcifications on MRI and MDCTA was 90%. Sensitivity and 
specificity of MRI to detect calcifications were 93% (95%CI: 89-97%) and 39% 
(95%CI: 17-64%). Mean calcification volume on MRI was 58.7±71.0 mm3 and simi-
lar to MDCTA (58.1±87.7mm3; p=0.88). However, absolute individual differences 
could be large (mean difference -0.6 mm3 (range -154.6 to +279.4mm3)).
Conclusions: MRI has good sensitivity to detect plaque calcifications. Overall agree-
ment in calcification volume assessed with MRI and MDCTA was good, but individual 
differences were substantial. MRI presently cannot be recommended to estimate 
plaque calcification volume in individual patients with carotid artery stenosis.
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Introduction
Currently, degree of carotid artery stenosis is the main imaging characteristic to se-
lect patients with an ischemic stroke for an invasive carotid endarterectomy (CEA). 
In the last two decades, evidence has accumulated that focusing on the composition 
and morphology of the atherosclerotic plaque may help to expand knowledge of the 
pathophysiology of ischemic stroke caused by large artery atherosclerosis and may 
aid in risk stratification.1, 2 Extensive imaging research has been performed to char-
acterize the atherosclerotic carotid plaque beyond degree of stenosis. Atheroscle-
rosis is a chronic inflammatory disease of the large arteries with different stages of 
plaque development. In the more advanced atherosclerotic plaques, calcifications are 
formed.3, 4 Carotid calcifications are associated with degree of carotid artery stenosis 
and are increasingly used as a marker of atherosclerosis.5-7 (Macro)calcifications are 
considered to be plaque stabilizers, as shown by a decrease in cardiovascular risk with 
an increase in coronary calcification density.8, 9 In addition, the proportion of plaque 
calcification is inversely associated with the occurrence of symptoms in patients with 
D FDURWLG DUWHU\ VWHQRVLV DFFRUGLQJ WR WKH 1$6&(7 FULWHULD10, 11 Therefore, 
plaque calcifications are an important characteristic of the atherosclerotic plaque and 
may become one of the imaging biomarkers to estimate stroke risk in patients with 
carotid stenosis.
Two non-invasive image modalities used for plaque imaging are Multi-Detector 
Computed Tomography Angiography (MDCTA) and Magnetic Resonance Imaging 
(MRI). MDCTA is already extensively used for the assessment of carotid artery ste-
nosis. In addition, it is an excellent tool for the detection of atherosclerotic plaque 
ulceration and the detection and quantification of plaque calcifications.6, 12-15 The 
Agatston score (measure of calcification burden assessed at CT) is already used ex-
tensively in clinical and research practice.13, 16 Studies have shown that calcification 
volume measurements assessed on CT are even more reproducible than Agatston 
score.13, 16-18 Nevertheless, histological validation studies of plaque calcifications in 
the carotid artery assessed at CT are sparse and it is known that CT probably overes-
timates calcification volume due blooming effects.15, 19-21 MRI of the carotid athero-
sclerotic plaque is not yet performed in clinical practice, but due to the excellent soft 
tissue contrast, it is a very promising image modality to assess plaque composition 
(lipid-rich necrotic core, intraplaque hemorrhage, calcifications, fibrous tissue).22 Al-
though atherosclerotic calcifications can be assessed both with MDCTA and MRI, to 
date MRI showed lower diagnostic accuracy in detecting and quantifying atheroscle-
rotic calcifications.22-25 MRI plaque imaging techniques are, however, rapidly improv-
ing. In the current study, we aimed to assess the current diagnostic accuracy of MRI 
plaque imaging compared to MDCTA in detecting calcifications, in patients with a 
recently symptomatic carotid artery stenosis. In addition, we investigated the correla-
tion between calcification volumes assessed at MRI and MDCTA.
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Methods
Study population
Patients were derived from the PARISK-study (Plaque-At-RISK; clinical trials.gov 
NCT01208025). Details of the study design have been previously described.26 The 
PARISK-study is a prospective multicenter diagnostic cohort study using non-invasive 
plaque imaging to identify patients with an ipsilateral carotid plaque of at least 2-3 
mm and a mild-to-moderate carotid artery stenosis (<70%) with an increased risk of 
recurrent stroke. All included patients had a recent TIA, including amaurosis fugax, 
or minor stroke in the carotid artery territory prior to inclusion. Institutional Review 
Board approval was obtained and all patients gave written informed consent.
MDCTA data acquisition and analysis
We performed image acquisition using a standardized protocol, as discussed in the 
study design paper.26 All MDCTA studies were evaluated by trained readers blinded 
for clinical data and other imaging tests. Image quality was rated on a three point 
scale; poor (1) defined as low contrast and major artefacts and not eligible for analy-
sis, moderate (2) defined as moderate artefacts and eligible for analysis and good 
(3) defined as little or no artefacts and eligible for analysis. The most severe stenosis 
in the carotid bifurcation and internal carotid artery was measured according to the 
ECST criteria as well as the NASCET criteria, perpendicular to the central lumen 
line.11, 27 A custom-made plug-in for the freely available software ImageJ (Rasband, 
National Institute of Mental Health, Bethesda, MD) was used to semi-automatically 
quantify calcifications in the symptomatic carotid artery within 3 cm proximal and 
distal of the bifurcation to ensure the complete scan range of MRI (variable segments 
of common and internal carotid artery) was covered. We used a threshold of 600 
Hounsfield units to differentiate calcifications from contrast material in the lumen. 
Calcification volume was expressed in millimeter cubed. A detailed description of the 
measurements is provided elsewhere.28 
MRI data acquisition and analysis
Image acquisition was performed on a 3T MRI system (General Electric (GE) Health-
care, Milwaukee, MI, United States of America or Philips Healthcare, Best, Nether-
lands). A multi-sequence contrast-enhanced protocol was used. A detailed descrip-
tion of this protocol is provided in the study design paper.26 All MRI carotid artery 
studies were evaluated by trained readers blinded for clinical data and other imaging 
tests using dedicated vessel wall analysis software (Vesselmass, Department of Radi-
ology, Leiden University Medical Center, Netherlands). 
Information of all five MRI carotid artery sequences was used (GE; 3D-FSPGR, 
3D-T1w-FS-SPGR, 2D-T2w-DIR-FSE, 2D-T1w-DIR-FSE pre- and postcontrast; Philips; 
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3D-TOF-FFE, 3D-T1w-IR-TFE, 2D-T2w TSE, 2D-T1w-QIR-TSE pre- and postcontrast). 
MR images were automatically registered by delineating the lumen and outer vessel 
wall. Registration was manually corrected if needed. Plaque components (lipid-rich 
necrotic core, calcifications, intraplaque hemorrhage) were manually segmented. 
Calcifications were defined as areas with hypointense signal relative to the signal of 
the adjacent sternocleidomastoid muscle in at least two different weightings. Fifteen 
transverse adjoining slices of 2 mm each (total carotid artery coverage of 3 cm) cover-
ing the entire plaque (various segments of common and internal carotid artery) were 
annotated. Calcification volumes (expressed in millimeter cubed) could be derived 
from these annotations.
Statistical analysis
Baseline clinical characteristics are listed for all patients. Imaging characteristics are 
shown for the symptomatic carotid artery. Data are presented as mean ± SD, median 
[25th-75th percentile] or number of patients (%). A 2x2 table was used to calculate 
sensitivity and specificity including 95% confidence intervals (95% CIs) for MRI to 
detect calcifications with MDCTA as the reference standard. Correlation between 
calcification volume on MRI and calcification volume on MDCTA was analyzed us-
ing a Pearson correlation coefficient. Difference in calcification volumes on MRI and 
MDCTA were evaluated with paired t-test and a Bland-Altman plot. Analyses were 
repeated for the two different MRI protocols acquired on two different scanners (GE 
versus Philips), because one of the sequences used for the detection of plaque cal-
cifications differed between both protocols (3D-FSPGR vs 3D-TOF-FFE). Thereafter, 
individual MRI and MDCTA scans of patients with absence of calcifications on one 
modality and presence of calcifications on the other modality (mismatch in detection 
of calcifications) and patients with a difference of more than 50 mm3 between calci-
fication volumes of both image modalities were visually compared by an experienced 
observer (AD; 3 years) to assess possible reasons for these discrepancies. Statistical 
analyses were performed using STATA software (version 14.1, STATA). P<0.05 was 
considered statistically significant.
Results
Patient characteristics
Between September 2010 and December 2014, 240 patients were included in the 
PARISK-study. In 193 patients both an MDCTA and MRI of the carotid arteries was 
performed. Two patients did not undergo MDCTA and MRI of the carotid arteries 
due to contra-indications for both modalities (n=1) or a sudden neurological deficit 
during the MRI of the brain (n=1). One patients refused to further participate in the 
study after signing the informed consent; in 8 patients MRI was not performed and 36 
patients lacked MDCTA due to contra-indications for the image modality. Of the 193 
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available MDCTA and MRI scans, MDCTA or MRI calcification scores were missing 
in 8 patients due to bad image quality (n=2 and n=5, respectively) and a technical 
problem with measuring the amount of calcification on MDCTA (n=1). Finally, 185 
patients could be used for the current analyses. Baseline clinical and imaging char-
acteristics are shown in Table 1. 
+=FKALANALQ9F<KH=;AÍ;ALQG>%*!>GJ<=L=;LAGFG>;9D;AÍ;9LAGFK
Prevalence of calcifications on MRI as well as MDCTA was 90% (Table 1). In 156 of 
the 185 (84%) patients, calcifications were present on both MRI as well as MDCTA; 
in 7 (4%) patients calcifications were absent in both modalities (Table 2). Sensitivity of 
MRI to detect calcifications compared to MDCTA was 93% (95% CI: 89-97%); speci-
ficity of MRI to detect calcifications compared to MDCTA was 39% (95% CI: 17-64%). 
Repeating the analyses for the two different MRI protocols showed similar results.
Characteristic
Age (year) 68 ± 8
Male 131 (71%)
Classification event
 TIA
 Stroke
 Amaurosis fugax
78 (42%)
89 (48%)
18 (10%)
MRI protocol
 GE (3D-FSPGR)
 Philips (3D-TOF-FFE)
46 (25%)
139 (75%)
Degree of stenosis, ECST (%) 55 [47;66]
Degree of stenosis, NASCET (%) 12 [0;30]
Interval event – MDCTA (days) 33 [16;55]
Interval event – MRI (days) 47 [30;66]
Interval MDCTA – MRI (days) 1 [0;15]
Presence calcifications MDCTA 167 (90%)
Calcification volume MDCTA (mm3) 58.1 ± 87.7
Presence calcifications MRI 167 (90%)
Calcification volume MRI (mm3) 58.7 ± 71.0
Table 1. Baseline characteristics (n=185)
Data are mean ± SD, absolute numbers of patients (%), or median [25th;75th percentile] 
TIA Transient Ischemic Attack, GE General Electric, ECST European Carotid Surgery Trial, NASCET North 
American Symptomatic Carotid Endarterectomy Trial
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A good correlation between calcification volume on MRI and MDCTA was found 
(l=0.81; p<0.0001). Mean calcification volume on MRI was 58.7 ± 71.0 mm3 and 
similar to mean calcification volume on MDCTA 58.1 ± 87.7 mm3 (p=0.88). Howev-
er, individual absolute differences between calcification volume on MRI and MDCTA 
were substantial (mean difference -0.6 ± 51.3 mm3, range -154.6 to +279.4 mm3; 
Figure 1). Repeating these analyses for the two different MRI protocols showed simi-
lar results. 
Table 2. Comparison presence calcifications MDCTA and MRI (n=185)
MDCTA calcifications 
present
MDCTA calcifications 
absent
Total
MRI calcifications present 156 11 167
MRI calcifications absent 11 7 18
Total 167 18 185
Figure 1. Bland-Altman plot of difference of MDCTA and MRI measurements of calcifications (n=185)
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In 51 patients (28%) a mismatch regarding the detection of calcifications (n=22) or 
a difference in calcification volume between MRI and MDCTA of more than 50 mm3 
(n=29) was found. In 29 of these patients, two possible reasons for the mismatch or 
difference were identified, and in one patient three reasons. A total of 82 possible 
reasons for the mismatch or large difference (in the 51 patients) are identified and 
presented in Table 3 and 4. MDCTA and MR images to illustrate these explanations 
for a mismatch in presence of calcifications or difference of more than 50 mm3 are 
shown in Figure 2-5.
Table 3. Explanation of possible reasons of mismatch in presence or large difference in volume of  
calcifications
Reason Explanation
1. Methodological
600 HU threshold MDCTA A threshold of 600 HU to differentiate calcifications from contrast 
material in the lumen leads to underestimation of MDCTA 
calcifications by missing or excluding low dense calcifications on 
MDCTA.
Extended scan range MDCTA The assessment of calcifications on MDCTA within 3 cm proximal 
and distal of the bifurcation (6 cm in total) to make sure the 
complete scan range of MRI was covered (3 cm in total, including 
the entire atherosclerotic plaque but variable segments of 
common and internal carotid artery) leads to overestimation of 
calcifications on MDCTA.
2. Technical or interpretation
Wrong interpretation MRI Misinterpretation of MR images (for example perivascular tissue 
is incorrectly interpreted as calcifications or calcifications are 
erroneously interpreted as lumen) leads to overestimation or 
underestimation of calcifications on MRI.
Inferior image quality MRI Inferior image quality and artefacts of MR images obscures 
calcifications on MRI and leads to underestimation of 
calcifications on MRI.
Wrong manual segmentation 
MRI
Misinterpretation leads to the drawing of (too) small or (too) 
broad calcification contours on MRI and as a result under- or 
overestimation of calcifications on MRI compared to MDCTA.
Blooming effect MDCTA The blooming effect of calcifications on MDCTA leads to 
overestimation of calcifications on MDCTA.
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Missed calcifications MRI Due to very small volume of calcifications or slight differences 
in slice position of the different MRI sequences, calcifications 
are missed on MRI and therefore leads to underestimation of 
calcifications on MRI.
Shadowing by IPH on MRI Bright signal of the intraplaque hemorrhage on MRI obscures 
small calcifications and therefore leads to underestimation of 
calcifications on MRI.
Including ECA calcifications  
on MDCTA
Inclusion of calcifications of the external carotid artery on MDCTA 
(partly due to limited soft tissue contrast) leads to overestimation 
of calcifications on MDCTA.
Figure 2. Example of how the use of a 600 HU threshold on MDCTA have led to underestimation of 
calcifications on MDCTA compared to MRI. Corresponding MDCTA and MR images of a patient in which 
the mismatch between MDCTA and MRI (MDCTA calcifications absent; MRI calcifications present) can 
be explained by the use of the 600 HU threshold on MDCTA: large calcification (arrow) is missed on 
MDCTA. C common carotid artery; arrow calcification.
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Total Mismatch 
presence 
calcifications
Difference 
of >50 
mm3
Consequence
Methodological reasons
600 HU threshold MDCTA (Fig. 2) 15 9 6 MDCTA 
underestimates
Extended scan range MDCTA 6 1 5 MDCTA overestimates
Technical or interpretation reasons
Hypointensity on MRI incorrectly 
interpreted as calcification, 
probable component1:
 Fibrous tissue
 Perivascular tissue
 Lipid-rich necrotic core
 Ulceration (Fig. 3)
 Lumen
 
12
5
3
2
1
7
4
2
2
0
5
1
1
0
1
MRI overestimates
Total 16 9 7
Inferior image quality MRI 9 8 1 MRI underestimates
Wrong manual segmentation MRI 
– contours too small (Fig. 4)
7 0 7 MRI underestimates
Blooming effect MDCTA 6 0 6 MDCTA overestimates
Calcifications MRI incorrectly 
interpreted as2:
 Fibrous tissue
 Perivascular tissue
 Lumen
3
2
2
0
1
0
3
1
2
MRI underestimates
Total 6 1 5
Missed calcifications MRI 6 2 4 MRI underestimates
Wrong manual segmentation MRI 
– contours too broad
6 0 6 MRI overestimates
Shadowing by IPH on MRI (Fig. 5) 3 1 2 MRI underestimates
Including ECA calcifications on 
MDCTA
2 0 2 MDCTA overestimates
1 In 5 patients hypointensity on MRI was misinterpreted as two different probable components; in 1  
patient hypointensity on MRI was misinterpreted as three different probable components 
2 In 1 patient hypointensity on MRI was scored as two different components instead of calcification
Table 4. Overview of possible causes of mismatch in the detection of calcifications or large difference in 
calcification volume measurements. (n=82)
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3.2Figure 3. Example of how misinterpretation of the MRI have led to overestimation of calcifications on 
MRI compared to MDCTA. Corresponding MDCTA and MR images of a patient in which the mismatch 
between MDCTA and MRI (MDCTA calcification absent; MRI calcification present) can be explained by 
misinterpretation of the hypointensity on MRI: hypointensity is scored as calcification on MRI, whereas 
a plaque ulceration was identified on MDCTA (arrow head). E external carotid artery; I internal carotid 
artery; arrow calcification.
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Figure 4. Example of how misinterpretation of the MRI have led to underestimation of calcifications on 
MRI compared to MDCTA. Corresponding MDCTA and MR images of a patient in which the difference 
EHWZHHQ0'&7$DQG05,0'&7$FDOFLILFDWLRQYROXPH!PP3 larger than MRI volume) can be ex-
plained by the drawing of calcification contours on MRI which seems to be too small. E external carotid 
artery; I internal carotid artery; arrow calcification.
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Discussion
This study shows that MRI has a good sensitivity, but a low specificity for the detection 
of plaque calcifications compared with MDCTA as a reference standard. A good cor-
relation was found between MRI and MDCTA calcification volumes and no significant 
difference was found between MRI and MDCTA estimates of calcification volumes. 
However, individual absolute differences could be substantial. Therefore, current MRI 
plaque imaging techniques cannot be recommended to estimate volume of plaque 
calcifications in individual patients with symptomatic carotid artery stenosis.
Some methodological issues need to be discussed first. A strength of our study 
is that we compared calcifications assessed on MRI and MDCTA in a large group of 
patients (n=185). In addition, we used patients of a multicenter study which made it 
possible to compare different MRI protocols, mirrors clinical practice and increases 
external validity. Finally, we explored reasons for the mismatch or large difference 
between MRI and MDCTA by reviewing individual cases retrospectively in order to 
identify possible future targets for improvement of the correlation between MRI and 
MDCTA derived calcifications. A limitation of our study is that MRI and MDCTA ex-
amination were performed mostly on different days due to the use of a contrast agent 
in both examinations. This led to a slight time interval between MRI and MDCTA in 
Figure 5. Example of how overshadowing of intraplaque hemorrhage on MRI have led to underestima-
tion of calcifications on MRI compared to MDCTA. Corresponding MDCTA and MR images of a patient 
in which the mismatch between MDCTA and MRI (MDCTA calcifications present; MRI calcifications 
absent) can be explained by missing the calcification on MRI because overshadowing of the intraplaque 
hemorrhage (blue contour). C common carotid artery; arrow calcification.
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some patients. However, calcium growth in the atherosclerotic plaque is a slow pro-
cess.3,29 Therefore, the effect of this delay between the two scans will be minimal. 
Another limitation is that we had to apply a threshold of 600 HU to automatically 
distinguish calcifications from the dense contrast material in the lumen on MDCTA. 
In non-contrast enhanced CT scans or studies which are able to exclude the high 
density lumen from the measurements, a threshold of 130 HU is applied.13, 23 The 
use of a 600 HU threshold will have led to lower calcification size and missing small 
calcifications and therefore a subsequent underestimation of the calcification volume 
on MDCTA in comparison to a threshold of 130 HU and to MRI. At visual inspec-
tion, we found that in 15 patients (29%) the use of a 600 HU threshold was probably 
one of the reasons for the mismatch in detection of calcifications or a difference of 
more than 50 mm3 between MRI and MDCTA. Finally, the evaluated longitudinal 
range differed between MRI and MDCTA (3 vs. 6 cm, respectively). The scan range 
on MRI was placed in such a way that the entire atherosclerotic plaque was covered. 
In practice this meant that variable ranges of the common and internal carotid ar-
tery were scanned. We evaluated MDCTA images within 3 cm proximal and distal 
of the bifurcation in order to ensure we included the complete scan range of MRI. 
However, in only 6 of the 51 patients with a mismatch in detecting calcifications or a 
large difference in calcification volume between MRI and MDCTA, MDCTA revealed 
calcifications outside the MRI scan range. Ababneh et al. showed that although cal-
cified plaque is heterogeneously distributed in carotid endarterectomy tissue, most 
calcifications are found in the carotid bulb and adjacent internal and external carotid 
segments.30 Automated registration of MDCTA and MR images would be optimal for 
head to head comparison, but is not trivial.31 
Histological studies have shown that calcifications can be assessed with MRI 
with an overall sensitivity ranging from 76% to 92% and specificity ranging from 86% 
to 95%.22 Kwee et al. compared calcification volumes assessed on CT with volumes 
on MRI and also found a moderate correlation between CT and MRI assessed cal-
cification volume and also a considerable variation in absolute differences between 
CT and MRI measurements.32 In contrast to our study, they found that calcifica-
tion volume was significantly higher on CT than on MRI (246.3 mm3 vs. 65.8 mm3; 
p<0.001, respectively).32 They were able to apply a threshold of 130 HU on MDCTA, 
leading to a consistent increase in the volume of calcifications on MDCTA compared 
to our MDCTA derived calcification volume (246.3 mm3 vs. 58.1 mm3, respectively). 
Their calcification volume on MRI was in the same range as our MRI derived calcifica-
tion volume (65.8 mm3 vs. 58.7 mm3, respectively).
Besides the previous mentioned methodology related causes, we found other 
causes for a decreased MRI sensitivity or MRI misinterpretation. Low signal intensity 
regions on MRI were interpreted as calcification, but after comparison with MDCTA 
were found likely to be other tissue components like  fibrous tissue, perivascular tis-
sue, lipid-rich necrotic core, ulceration or lumen. In contrast, some hypointense re-
gions on MRI were considered to be non-calcified but were retrospectively more likely 
to be a calcifications. Both situations have affected the detection and quantification 
of individual calcified spots. In addition, the image quality of MRI and wrong manual 
segmentation of calcifications (contours were likely drawn too small or too broad), or 
simply missing some calcifications on MRI, were all prevalent reasons for a mismatch 
in detection or a large difference in calcification volume between MRI and MDCTA. 
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We also found that the bright signal of intraplaque hemorrhage could obscure small 
calcifications. In most cases, we could retrospectively identify a small calcification 
on MRI when we compared it to MDCTA. However, some studies have shown that 
calcifications can have high signal intensity in some T1-weighted sequences.25, 33, 34
Although MRI shows an overall agreement with histology and MDCTA in the 
detection and quantification of plaque calcifications, the results for MRI assessed 
calcifications on individual patient level are disappointing. The findings in the present 
study may be used to identify complicated cases that could be used during training 
of MRI observers. We expect that agreement between MRI and MDCTA calcifica-
tions can be improved by an increase in image quality of MRI. In addition, the use of 
dedicated (automated) annotation tools can further improve agreement.35 Otherwise, 
combining information from different image modalities for segmentation of the ath-
erosclerotic plaque can be a future scenario.31
Summary
MRI has a good sensitivity for the detection of plaque calcifications with MDCTA as 
reference standard. An overall agreement was found in calcification volume assessed 
with MRI and MDCTA; however individual absolute differences could be substantial. 
Therefore, current MRI plaque imaging techniques cannot be recommended to esti-
mate volume of plaque calcifications in individual patients with symptomatic carotid 
artery stenosis.
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Abstract
Previous data have indicated that carotid plaque ulceration is a strong predictor of 
cerebrovascular events. Standard ultrasound and color Doppler ultrasound (CDUS) 
scans have poor diagnostic accuracy for the detection of carotid plaque ulceration. 
The aim of the present prospective study was to assess the value of contrast-en-
hanced ultrasound (CEUS) scans for the detection of carotid plaque ulceration. The 
Institutional Ethics Committee approved the study protocol, and all patients provid-
ed informed consent. The patients had symptomatic stenosis of the internal carotid 
artery and underwent carotid computed tomographic angiography as part of their 
clinical evaluation. All patients underwent a CDUS examination in conjunction with 
&(86&DURWLGSODTXHXOFHUDWLRQZDVGHILQHGDVWKHSUHVHQFHRIGLVUXSWLRQVLQWKH
SODTXHOXPHQERUGHU[PP&DURWLGFRPSXWHGWRPRJUDSKLFDQJLRJUDSK\ZDV
used as reference technique. The study population consisted of 20 patients (mean 
age 64 ± 9 years, 80% men), and 39 carotid arteries were included in the present 
analysis. Computed tomographic angiography demonstrated that the plaque surface 
was smooth in 15 (38%), irregular in 7 (18%) and ulcerated in 17 (44%) carotid arter-
ies. The sensitivity, specificity, accuracy, positive predictive value, and negative pre-
dictive value of CDUS for the detection of ulceration was 29%, 73%, 54%, 46%, and 
57%, respectively. The sensitivity, specificity, accuracy, positive predictive value, and 
negative predictive value of CEUS for the detection of ulceration was 88%, 59%, 72%, 
63%, and 87%, respectively. CEUS had superior sensitivity and diagnostic accuracy for 
the assessment of carotid plaque ulceration compared with CDUS. CEUS improved 
the intrareader and inter-reader variability for the assessment of carotid plaque ulcer-
ation compared with CDUS. In conclusion, CEUS could be an additional method for 
the detection of carotid plaque ulceration. The role of CDUS for the assessment of 
carotid plaque ulceration seems limited.
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Introduction
Previous studies have demonstrated that carotid plaque ulceration is a strong predic-
tor of cerebrovascular events.1,2 Ultrasound is the most frequently used imaging tech-
nique for the assessment of carotid atherosclerosis. It is readily available, of low cost, 
safe, and accurately identifies the presence of flow-limiting stenosis.3-5 Nevertheless, 
ultrasound, including color Doppler ultrasound (CDUS), fails to accurately identify 
carotid plaque ulceration.4-9 Contrast- enhanced ultrasound (CEUS) is an advanced 
form of ultrasound imaging using a microbubble contrast agent. CEUS provides a 
better delineation of the carotid lumen than does CDUS.10-14 The use of CEUS for 
the detection of carotid plaque ulceration has not yet been studied. The aim of the 
present prospective study was to assess the value of CEUS for the detection of carotid 
plaque ulceration in patients with symptomatic carotid atherosclerosis. Carotid com-
puted tomographic angiography (CTA) was used as the reference technique.
Methods
The Institutional Ethics Committee approved the study protocol. All patients provided 
informed consent. A total of 20 consecutive patients were included in the present 
study. All patients had symptomatic stenosis of the internal carotid artery and under-
went carotid CTA as part of their clinical evaluation. All patients also underwent a 
carotid CDUS examination in conjunction with CEUS. The exclusion criteria included 
contraindications for the use of an ultra- sound contrast agent, such as unstable 
angina, acute cardiac failure, acute endocarditis, known right-to-left shunts, and a 
known allergy to microbubble contrast agents.
CDUS and CEUS were performed using a Philips iU-22 ultrasound system (Phil-
ips Medical Systems, Bothell, Washington), equipped with an L9-3 transducer. CDUS 
consisted of standard B-mode and color Doppler imaging and was performed using 
a standard scanning protocol.15 In brief, both left and right carotid arteries were ex-
amined with the patient in the supine position with the head supported at a 45° angle 
turned to the contralateral side. The common carotid artery, carotid bulb, internal ca-
rotid artery, and external carotid artery were evaluated using CDUS and pulsed wave 
Doppler imaging. All anatomic sites were examined from different angles of view, and 
each site was scanned in the cross-sectional view and longitudinal view.
After the CDUS examination, CEUS was performed using intravenous adminis-
tration of SonoVue contrast agent (Bracco SpA, Milan, Italy). The contrast mode of 
the ultrasound system, using amplitude modulation and a mechanical index of 0.06, 
was used to optimize the CEUS examination. The ultrasound contrast agent was 
injected in 0.5-ml boluses. Each contrast agent bolus was followed by a saline flush 
using 2.0 ml NaCl 0.9% solution. After administration of the contrast agent, high-
quality contrast images could be obtained for approximately 1 minute. The bolus 
injection of the contrast agent was repeated when necessary. Both carotid arteries 
were examined using a standard acquisition protocol, and still frames and cine clips 
were digitally stored for offline analysis.
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All studies were analyzed by 2 readers who were unaware of the clinical and CTA data. 
Discrepancies in their readings were resolved by consensus; if a consensus could not 
be reached, a third experienced reader was consulted. The CDUS and CEUS studies 
were analyzed separately. The image quality of the region of interest was scored using 
a 3-point scale as good, moderate, or poor image quality. The plaque border was vi-
sually scored as smooth, irregular (Figure 1), or ulcerated (Figures 2 and 3).16 Carotid 
SODTXHXOFHUDWLRQZDVGHILQHGDVWKHSUHVHQFHRIGLVUXSWLRQVRIWKHSODTXHOXPHQ
ERUGHU[PP7KHSUHVHQFHRIFDOFLILFDWLRQZDVVFRUHGXVLQJDVHPLTXDQWLWDWLYH
grading system: 0, no calcification; 1, limited calcification; 2, moderate calcification; 
and 3, severe calcification. For each study, the readers indicated whether the pres-
ence of calcification hindered the evaluation of the plaque surface morphology.
CTA was performed using a 128-slice, multidetector CT system (Definition AS+ 
or Definition flash [1 patient], Siemens Medical Solutions, Forchheim, Germany) using 
a contrast-enhanced CTA protocol (120 kVp, 180 mA, collimation 64x2x0.6 mm, pitch 
<1). The scan range extended from the ascending aorta to the intracranial circulation 
(3 cm above the sella turcica). Of the 20 patients, 19 received 80 ml of contrast agent 
(320 mg/ml iodixanol, Visipaque, Amersham Health, Little Chalfont, United Kingdom), 
followed by 45-ml saline bolus chaser, both at an injection rate of 5 ml/s. One patient 
received 60 ml of contrast agent, followed by a 45-ml saline bolus chaser, both at an 
injection rate of 4 ml/s. Real-time bolus tracking at the level of the ascending aorta 
was used to synchronize the passage of the contrast agent and data acquisition. Image 
reconstructions were made with a field of view of 120 to 170 mm, matrix size
Figure 1. Longitudinal B-
mode ultrasound (A), CDUS 
(B), CTA (C), and CEUS (D) 
images of carotid plaque 
classified as irregular using 
both CEUS and CTA. Cal-
cification of carotid artery 
(C, arrow) caused acoustic 
shadow that hindered accu-
rate color Doppler evaluation 
(B, arrow). A clear evaluation 
is possible with CEUS (D), 
providing information similar 
to that obtained with CTA 
(C). The enhancement under-
neath the vessel (D, arrows) 
is a pseudoenhancement 
artifact.
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512 x 512, slice thickness 1.0 mm, increment 0.6 mm, and an intermediate recon-
struction algorithm.
All CTA studies were evaluated with the reviewers unaware of the clinical and 
ultrasound data. A 2-dimensional axial image viewer was used to assess the image 
quality and degree of stenosis of both carotid arteries. The image quality of the region 
of interest was scored using a 3-point scale as good, moderate, or poor image qual-
ity. The degree of stenosis was calculated using the North American Symptomatic 
Carotid Endarterectomy Trial (NASCET) criteria perpendicular to the central lumen 
line.17 Dedicated 3-dimensional analysis software with multiplanar reformatting was 
used to evaluate the plaque surface in the oblique, coronal, and sagittal plane. The 
plaque surface of all carotid arteries was independently evaluated by 2 readers. Dis-
crepancies in their evaluation were solved by consensus; if consensus could not be 
reached, a third experienced reader was consulted. The CTA and ultrasound studies 
were analyzed by different readers. The surface of the plaque was scored as smooth, 
irregular, or ulcerated. Carotid plaque ulceration was defined as the presence of con-
WUDVWH[WHQGLQJEH\RQGWKHYDVFXODUOXPHQPPLQSODQHV7KHFDOFLXPYROXPH
was measured from 3 cm proximal to 3 cm distal of the flow divider using semiau-
tomated quantification software. A threshold of 600 Hounsfield units was used to 
differentiate calcium from contrast.
Statistical analyses were performed using the Statistical Package for Social Sci-
ences for Windows, version 17.0 (SPSS, Chicago, Illinois). Continuous variables are 
reported as the mean ± SD or median and interquartile range. Categorical variables 
are expressed as numbers and percentages. The CDUS and CEUS studies of the right 
Figure 2. Longitudinal im-
ages of carotid plaque clas-
sified as ulcerated using 
CDUS, CEUS, and CTA. Lon-
gitudinal B-mode ultrasound 
(A), CDUS (B), CTA (C), and 
CEUS (D). A hypoechoic 
plaque with ulceration is pres-
ent in carotid bulb (arrows). 
A small calcification causes 
shadowing that hindered 
visualization of a small part 
of the plaque surface (D, ar-
rowhead).
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and left carotid artery were analyzed independently, with the corresponding CTA study 
as the reference technique. The measurements of accuracy (sensitivity, specificity, ac-
curacy, positive predictive value, and negative predictive value) were calculated. Dif-
ferences in diagnostic accuracy were compared using McNemar’s test. The CTA de-
termined calcium volume and ultrasound calcium scores were compared using Spear-
man’s rank correlation. The inter- reader and intrareader reproducibility was assessed 
using weighted k statistics. p Values <0.05 were considered statistically significant.
Results
The clinical characteristics of the study population (mean age 64 ± 9 years, 80% 
men) are listed in Table 1. All CDUS, CEUS, and CTA studies were performed without 
adverse reactions. One patient had previously undergone right-sided endarterectomy; 
this carotid artery was excluded from the analysis, resulting in 39 carotid arteries for 
the present analysis.
The image quality of the CDUS studies was good in 31 (79%), moderate in 6 
(15%), and poor in 2 (5%) carotid arteries. CEUS resulted in improved image quality, 
with 37 (95%) studies of good, 2 (5%) of moderate, and 0 of poor quality. None of 
the ultrasound studies were judged to be uninterpretable. The CTA image quality was 
good in 37 (95%) and moderate in 2 (5%) arteries. No CTA scan was judged to be 
uninterpretable.
Figure 3. Longitudinal im-
ages of carotid plaque classi-
fied as ulcerated with CEUS 
and smooth with CTA. Lon-
gitudinal B-mode ultrasound 
(A), CDUS (B), CTA (C), and 
CEUS (D). A hypoechoic 
plaque was present in the 
near wall of the carotid ar-
tery, the full extent of which 
was not visible on B-mode 
ultrasound (A). CDUS (B) pro-
vided improved visualization 
of the plaque size but did not 
identify an ulcer. (D) CEUS 
GHPRQVWUDWHGDVPDOO§[
mm) ulcer (arrow) not visible 
using CDUS or CTA (C).
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CTA demonstrated that the plaque surface was smooth in 15 (38%), irregular in 7 
(18%), and ulcerated in 17 (44%) carotid arteries (Table 2). The performance char-
acteristics of CDUS for the evaluation of the carotid plaque surface are listed in Table 
3. CDUS revealed 5 of 17 ulcerations (29%) identified at CTA, with 6 additional 
ulcerations detected that could not be confirmed. This resulted in a poor agreement 
between CDUS and CTA (k = 0.19, 95% confidence interval [CI] 0.00 to 0.42).
Table 1. Patient characteristics (n = 20)
Variable Value
Men 16 (80)
Age (yrs) 64 ± 9
Body mass index (kg/m2) 29 ± 6
Hypertension 10 (50)
Diabetes mellitus 5 (25)
Smoker 9 (45)
Quit smoking 6 (30)
Dyslipidemia 7 (35)
Coronary artery bypass grafting 2 (10)
Myocardial infarction 1 (5)
Amaurosis fugax 5 (25)
Transient ischemic attack 8 (40)
Ischemic stroke 5 (25)
Retinal infarction 1 (5)
Pulsatile tinnitus 1 (5)
Platelet aggregation inhibitor use 19 (95)
ß-Blocker therapy 12 (60)
Statin therapy 19 (95)
Data are presented as mean ± SD or n (%). 
'\VOLSLGHPLDZDVGHILQHGDVWRWDOFKROHVWHUROPPRO/PJGO
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Variable Value
Mean stenosis (NASCET [%])
 <50% NASCET stenosis
 50-69% NASCET stenosis
 1$6&(7VWHQRVLV
43 ± 24
18 (46)
17 (44)
4 (10)
Plaque surface morphology
 Ulcerated
 Irregular
 Smooth
17 (44)
7 (18)
15 (38)
Presence of calcium 35 (90)
Calcium volume (mm3)
 Median
 Interquartile range
35.2
7.1-127.4
Data are presented as mean ± SD or n (%), unless otherwise noted.
NASCET = North American Symptomatic Carotid Endarterectomy Trial.
Table 2. Computed tomographic angiographic results (n = 39 carotid arteries)
Table 3. Standard ultrasound, including color Doppler evaluation of carotid plaque surface compared 
with computed tomographic angiography (CTA)
CDUS CTA Total
Smooth Irregular Ulcerated
Smooth 7 (19) 1 (3) 2 (5) 10
Irregular 6 (15) 2 (5) 10 (26) 18
Ulcerated 2 (5) 4 (10) 5 (13) 11
Total 15 7 17 39
Data are presented as n (%).
Table 4. Contrast-enhanced ultrasound (CEUS) of carotid plaque surface compared with computed  
tomographic angiography (CTA)
CEUS CTA Total
Smooth Irregular Ulcerated
Smooth 5 (13) 0 0 5
Irregular 7 (19) 1 (3) 2 (5) 10
Ulcerated 3 (8) 6 (15) 15 (38) 24
Total 15 7 17 39
Data are presented as n (%).
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Carotid CEUS detected 15 of 17 ulcerations (88%) identified at CTA and identified 
9 additional ulcerations that were not confirmed at CTA (Table 4). The addition of 
CEUS to the CDUS study provided a substantial improvement in agreement between 
ultrasound and CTA (k = 0.42, 95% CI 0.26 to 0.62). CEUS significantly improved 
the sensitivity for identifying ulcerations (sensitivity 29% for CDUS vs 88% for CEUS, 
p <0.01), without significantly decreasing the specificity (specificity 73% for CDUS vs 
59% for CEUS, p = 0.45). The diagnostic accuracy of CDUS and CEUS for the detec-
tion of carotid plaque ulceration is summarized in Table 5.
CTA demonstrated the presence of calcification in 35 carotid arteries (90%), 
with a median calcium volume of 35.2 mm3 (interquartile range 7.1 to 127.4). CDUS 
demonstrated no calcification (grade 0) in 3 (8%), limited calcification (grade 1) in 15 
(38%), moderate calcification (grade 2) in 11 (28%), and severe calcification (grade 
3) in 10 (26%) carotid arteries. CEUS demonstrated no calcification (grade 0) in 5 
(13%), limited calcification (grade 1) in 11 (28%), moderate calcifications (grade 
Table 5. Comparison of color Doppler ultrasound (CDUS) and contrast-enhanced ultrasound (CEUS) for 
detection of carotid plaque ulceration
Variable  Method
CDUS CEUS
Sensitivity (%) 29 88
Specificity (%) 73 59
Accuracy (%) 54 72
PPV (%) 46 63
NPV (%) 57 87
NPV = negative predictive value; PPV = positive predictive value
Figure 4. Box plot of semi-
quantitative calcium grading 
obtained with CEUS com-
pared with CTA determined 
calcium volume (logarithmic).
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2) in 19 (49%), and severe calcification (grade 3) in 4 (10%) carotid arteries. Both 
the CDUS and CEUS semiquantitative calcium grading showed a strong correlation 
with the CTA deter- mined calcium volume (Spearman’s r = 0.69, p <0.001, and r 
= 0.72, p <0.001, respectively; Figure 4). In none of the patients, did the observers 
judge the calcification to obscure the plaque such that an evaluation with ultrasound 
was not possible. The exclusion of studies with heavy calcification did not change the 
accuracy of ulceration detection.
The inter-reader and intrareader reproducibility of CDUS for the detection of plaque 
ulceration was moderate (intrareader variability, k = 0.38, 95% CI 0.15 to 0.61; in-
trareader variability, k = 0.61, 95% CI 0.40 to 0.81). CEUS improved the inter-reader 
and intrareader variability for the assessment of carotid plaque ulceration compared 
with CDUS (inter-reader variability, k = 0.65, 95% CI 0.42 to 0.88; intrareader vari-
ability, k = 0.69, 95% CI 0.52 to 0.85).
Discussion
The main finding of the present study was that CEUS could be an additional method 
for the detection of carotid plaque ulceration in patients with symptomatic carotid 
atherosclerosis. CEUS had a significantly greater sensitivity and diagnostic accuracy 
for the assessment of carotid plaque ulceration compared with CDUS. CEUS improved 
the intrareader and inter-reader variability for the assessment of carotid plaque ul-
ceration compared with CDUS. These findings suggest that the role of CDUS for the 
assessment of carotid plaque ulceration is limited. The results of the present study 
could have implications for the use of CEUS in the evaluation of patients with carotid 
plaques.
These results have confirmed the findings from previous studies using CDUS for 
the detection of carotid plaque ulceration. Previous studies have shown that CDUS 
has a limited accuracy for the detection of carotid plaque ulceration.6-11 Saba et al7 
studied 103 carotid arteries with CDUS using the histologic examination as the refer-
ence method and demonstrated a sensitivity similar to our study (sensitivity 37.5%, 
specificity 91.5%). The poor sensitivity led the investigators to conclude that CDUS 
has no place in the evaluation of carotid plaque morphology.7 They consequently 
recommended the use of CTA for this purpose.7 The present results are in line with 
those from previous experimental studies. Sirlin et al10 demonstrated that CEUS pro-
vides a more accurate delineation of the vascular lumen than CDUS. In that initial 
study, CEUS was performed without a contrast-specific image acquisition setting, but 
CEUS improved the depiction of the luminal and wall abnormalities in an in vivo rab-
bit model of atherosclerosis and in replicas of diseased human carotid arteries. Kono 
et al11 showed that phase-inversion harmonic imaging further increased the sensitivity 
of ultrasound to a contrast agent, leading to improved visualization of the vascular 
lumen and tissues.
The present study is the first to evaluate the value of CEUS for the detection 
of carotid plaque ulceration. CEUS was relatively easily incorporated into the stan-
dard carotid ultra- sound acquisition protocol and significantly improved the accuracy 
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for the assessment of plaque ulceration. However, the agreement between CEUS 
and CTA in our study was not perfect. This could have been caused by several fac-
tors. First, the ultrasound acquisition might have been hindered because of calcified 
plaques owing to acoustic shadowing. CDUS and CEUS demonstrated severe calcium 
in 26% and 10% of the carotid arteries, respectively. The semiquantitative calcium 
scales obtained by ultrasound were in line with the semiautomated quantification 
of calcium using CTA. None of the ultrasound studies was judged to be uninterpre-
table, and the exclusion of severely calcified plaques did not change the diagnostic 
accuracy. However, we could not exclude that ulcerations could have been missed 
as a result of acoustic shadowing. Second, both CDUS and CEUS were performed 
using 2-dimensional acquisition, but CTA is a 3-dimensional imaging technique. The 
2-dimensional acquisition might have decreased the accuracy of CEUS for the as-
sessment of plaque ulceration. Third, in the present study, carotid CEUS identified 9 
additional ulcerations that were not detected using CTA. This fact raises the question 
of whether CTA is a reliable reference standard for detecting plaque ulcerations. Be-
cause of the lower local and temporal resolution of CTA compared with ultrasound 
imaging, CEUS might even exceed the diagnostic performance for detecting plaque 
ulcerations compared with CTA. Finally, the present study was limited by the relatively 
small number of patients (n = 20) and carotid lesions (n = 39).
The results of our study should be viewed in the context of risk assessment of 
patients with atherosclerosis of the carotid artery. The presence of ulceration is 1 
of the specific risk features of the unstable atherosclerotic plaque.18 Carotid plaque 
ulceration can lead to embolism and occlusion, and previous studies have indicated 
that ulceration is an important risk marker for neurologic symptoms and acute isch-
emic stroke.1,2 These studies have focused on plaque ulceration in patients with symp-
tomatic carotid atherosclerosis. Additional studies are needed to assess the predictive 
value of carotid plaque ulceration in asymptomatic patients. The detection of plaque 
ulceration using CEUS could be implemented in clinical practice for the identification 
of plaques at high risk of causing thromboembolic events. The assessment of these 
unstable or vulnerable plaques could help to further improve the identification of 
patients who might benefit from aggressive medical therapy or carotid surgery. The 
challenge for the future is to develop accurate risk stratification models.
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Abstract
Background and Purpose: Nonlacunar cerebral infarcts are presumed to be caused 
by thromboembolism from the heart or extracranial arteries, whereas lacunar infarcts 
are thought to be caused by small vessel disease. We investigated to what extent arte-
rial calcifications differ between nonlacunar and lacunar ischemic strokes.
Methods: We studied 820 consecutive patients with transient ischemic attack or 
ischemic stroke in the anterior circulation who underwent multidetector computed 
tomography angiography and had no rare cause of stroke. The presence of likely 
cardioembolic pathogenesis was determined according to the Trial of Org 10172 
in Acute Stroke Treatment criteria. The remaining 708 patients were categorized as 
nonlacunar or lacunar strokes, either transient ischemic attacks or strokes, based on 
clinical symptoms corrected by brain imaging results. We measured volume of calcifi-
cations in the aortic arch, symptomatic extracranial and intracranial carotid artery us-
ing multidetector computed tomography angiography. The difference in calcifications 
between nonlacunar and lacunar strokes was assessed with a multivariable logistic 
regression analysis. We adjusted for degree of symptomatic carotid artery stenosis 
and cardiovascular risk factors.
Results: We found an independent association between volume of aortic arch cal-
cifications and nonlacunar ischemic strokes (adjusted odds ratio [95% confidence 
interval], 1.11 [1.02–1.21]). No independent associations between extracranial and 
intracranial carotid artery calcifications and nonlacunar strokes were present.
Conclusions: The only difference we found between nonlacunar and lacunar strokes 
was a higher calcification volume in the aortic arch in nonlacunar strokes. Our find-
ings only partially confirm the notion of distinct etiologies and suggest that the poten-
tial role of other plaque components, plaque morphology, and aortic arch calcifica-
tions in ischemic stroke subtypes awaits further evaluation.
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Introduction
Nonlacunar infarcts are presumed to be caused by thromboembolism from the heart 
or large extracranial arteries, whereas lacunar infarcts are considered to be caused 
by the occlusion of small perforating arteries. Jackson et al1,2 found that cardiovas-
cular risk factors, such as hypertension and diabetes mellitus, are equally common 
in nonlacunar and lacunar infarcts, but atrial fibrillation or cardiac valve disease and 
significant carotid artery stenosis were more frequent in non- lacunar infarcts com-
pared with lacunar infarcts, supporting the notion of separate etiologies. Others have 
found a lower risk of early stroke recurrence and myocardial infarction in patients with 
lacunar versus nonlacunar infarcts.3,4 Imaging of the extracranial and intracranial 
arteries allows assessment of not only the presence of atherosclerosis, but also the 
atherosclerotic plaque surface and plaque composition. Homburg et al5 showed that 
plaque ulceration is associated with nonlacunar ischemic stroke, suggesting indeed 
that nonlacunar and lacunar infarcts have different types of atherosclerotic disease 
and supporting the notion of different underlying pathophysiology.
Calcifications are present in the more severe atherosclerotic plaques and are 
easily detectable on multidetector computed tomography angiography (MDCTA) and 
can therefore be used as a marker of atherosclerosis.6 We investigated whether and 
to what extent calcifications in the aortic arch, symptomatic extracranial and intracra-
nial carotid artery differ between nonlacunar and lacunar ischemic strokes.
Methods
Study population
Patients were derived from an ongoing prospective registry of all patients with neu-
rovascular diseases admitted to our hospital (Erasmus Stroke Study [ESS]). MDCT of 
the brain and MDCTA are part of the clinical work-up. Detailed clinical information, 
imaging, blood samples, and DNA are collected from all participants. Written in-
formed consent was obtained from all patients, as approved by the Institutional Ethics 
Committee. All patients with an ischemic event, either transient ischemic attack (TIA) 
or stroke, in the anterior circulation were included in this study. Patients with a rare 
cause of stroke, carotid artery dissection, absent MDCTA, or amaurosis fugax were 
excluded.
+LJGC=;D9KKAÍ;9LAGF
First, the presence of a likely cardioembolic pathogenesis according to the Trial of 
Org 10172 in Acute Stroke Treatment criteria was determined.7 We categorized all 
remaining ischemic events, either TIAs or strokes, as nonlacunar or lacunar strokes 
based on the clinical Oxfordshire Community Stroke Project criteria and corrected for 
relevant infarcts on MDCT scan of the brain.8 Lacunar ischemic strokes were defined 
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as pure motor strokes, pure sensory strokes, sensory-motor strokes, or ataxic hemi-
paresis.8,9 Patients who were not categorized as lacunar strokes were categorized as 
nonlacunar strokes. In both the nonlacunar and the lacunar stroke groups, TIAs and 
ischemic strokes were represented.
9J<AGN9K;MD9JJAKC>9;LGJK
+\SHUFKROHVWHUROHPLDZDVGHILQHGDVIDVWLQJWRWDOFKROHVWHURO!PPRO/RUWKHXVH
of cholesterol-lowering medication at the time of the TIA or ischemic stroke. Hyper-
WHQVLRQZDV GHILQHG DV V\VWROLF EORRG SUHVVXUH!PP+JRU D GLDVWROLF EORRG
SUHVVXUH!PP+JGXULQJHSLVRGHVRIPLQXWHVRIFRQWLQXRXVQRQLQYDVLYH
blood pressure measurement or treatment with antihypertensive medication. Diabe-
WHVPHOOLWXVZDVGHILQHGDV IDVWLQJSODVPDJOXFRVH OHYHO!PPRO/RUDKRXU
SRVWORDGJOXFRVHOHYHO!PPRO/RUWKHXVHRIDQWLGLDEHWLFPHGLFDWLRQ6PRNLQJ
status was assessed at the time of the ischemic event and dichotomized into current 
smoker or no current smoker.
MDCT and MDCTA data acquisition
Image acquisition was performed using a 16-slice, 64-slice, or 128-slice MDCT sys-
tem (Sensation 16, Sensation 64, Definition, Definition AS+ or Definition Flash, Sie-
mens Medical Solutions, Erlangen, Germany) using a standardized optimized con-
trast-enhanced proto- col (120 kVp; 180–200 reference mAs; collimation 16×0.75 
mm, 32×2×0.6 mm, or 64×2×0.6 mm; pitch <1).
 The MDCTA scan ranged from the ascending aorta to the intracranial circu-
lation (3 cm above the sella turcica). All patients received 80 mL of contrast agent 
(320 mg/mL iodixanol, Visipaque, Amersham Health, Little Chalfont, United King-
dom), followed by 45-mL saline bolus chaser, both at an injection rate of 4 to 5 mL/s. 
Real-time bolus tracking at the level of the ascending aorta was used to synchronize 
passage of contrast agent and data acquisition. Image reconstructions were made 
with field of view of 120 mm, matrix size 512×512, slice thickness 1.0 or 0.75 mm, 
increment 0.6 to 0.4 mm, and an intermediate reconstruction algorithm.
The MDCT brain scan ranged from the foramen magnum to the vertex. Image 
reconstructions were made with a 200 to 250 mm field of view, matrix size 512×512, 
slice thickness 3 to 5 mm, and an inter- mediate reconstruction algorithm.
MDCT and MDCTA data analysis
All MDCT and MDCTA studies were evaluated by trained readers blinded for clinical 
data. Relevant cerebral infarctions on MDCT of the brain were classified as small 
deep, large deep, end zone, border- line, or multiple infarcts and dichotomized into 
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nonlacunar strokes (large deep, end zone, borderline, and multiple infarcts) or lacu-
nar strokes (small deep infarcts).10
The most severe stenosis in the symptomatic carotid bifurcation and internal 
carotid artery was measured on MDCTA according to the North American Symptom-
atic Carotid Endarterectomy Trial criteria.11 The aortic arch was defined as the origin 
of the aortic arch to the first 1 cm of its branches. The extracranial carotid artery was 
defined as the carotid artery within 3 cm proximal and distal of the bifurcation. The 
intracranial internal carotid artery was defined as the horizontal segment of the pe-
trous internal carotid artery to the top of the internal carotid artery. Calcifications in 
the aortic arch and symptomatic extracranial carotid artery were quantified semiau-
tomatically using dedicated commercially available software (Syngo CalciumScoring, 
Siemens). A custom-made plug-in for the freely available software ImageJ (Rasband, 
National Institute of Mental Health, Bethesda, MD) was used to quantify calcifications 
in the symptomatic intracranial carotid artery, because of the close relationship of the 
intracranial carotid artery and the skull, automatic quantification was not possible. A 
threshold of 600 Hounsfield units was used to differentiate calcifications from con-
trast material in the lumen; calcification volume was expressed in millimeter cubed. A 
detailed description of the measurements is provided elsewhere.12-15
An intraclass correlation coefficient and coefficient of variation for the aortic 
arch, extracranial and intracranial carotid artery scoring method was assessed in 29 
MDCTA examinations based on the ratings of 2 observers. The intraclass correlation 
coefficient was 1.00 and the coefficient of variation 10% to 11% for all 3 vessel beds.
Statistics
We compared cardiovascular risk factors, degree of symptomatic carotid artery ste-
nosis, and extent of calcifications between patients with nonlacunar strokes, lacunar 
strokes, and cardioembolic strokes. Data are presented as mean ± SD, medians with 
interquartile range, or number of patients with percentages (%). Differences between 
categorical data were analyzed with a X2 test; differences between continuous data 
were analyzed using a Student t test or Mann–Whitney U test. In the analyses with 
calcification as continuous measure, we used natural log-transformed values and 
added 1.0 mm3 to the non-transformed values to deal with participants with a calcifi-
cation volume of zero. We estimated the extent of misclassification of ischemic stroke 
subtype according to the criteria of Jackson et al.2
For the purpose of this study we focused on the comparison between nonlacunar 
and lacunar ischemic strokes. Cardiovascular risk factors, degree of symptomatic ca-
rotid artery stenosis (per 10%), presence and volume of calcifications (per mm3) among 
nonlacunar versus lacunar ischemic strokes were analyzed with a univariable logistic 
regression model. Thereafter, a multivariable logistic regression analysis was performed 
to assess the difference in calcifications between nonlacunar and lacunar ischemic 
strokes. Adjustments were made for age, sex, and degree of symptomatic carotid artery 
stenosis (model 1) supplemented with cardiovascular risk factors (model 2).
Statistical analyses were performed with STATA software (version 12.0, STATA). 
P<0.05 was considered statistically significant.
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Results
Patient characteristics
Between December 2005 and September 2010, 1597 patients with a TIA or ischemic 
stroke were registered in the ESS. Reasons for exclusion in the present study are 
shown in the Figure. Subsequently, the aortic arch, the symptomatic extracranial and 
intracranial carotid artery could be analyzed in 813, 794, and 788 patients, respec-
tively.
Figure. Overview study cohort and ex-
clusion criteria.
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Excluded patients without a MDCTA (n=134) were significantly older than pa-
tients with a MDCTA (mean age, 73 versus 63 years; P<0.001), had a stroke more 
frequently instead of a TIA (prevalence stroke 77% versus 68%; P=0.04), and had 
a higher total National Institute of Health Stroke Scale score on admission (median 
score, 5 versus 2; P<0.001).
Cardioembolic stroke was present in 112 patients. Of the remaining 708 pa-
tients, 365 (52%) had a nonlacunar and 343 (48%) a lacunar ischemic stroke. Char-
acteristics of the study population are shown in Table 1. In 199 of the 708 patients 
(28%), a relevant infarct was visible on the MDCT of the brain; in 132 (36%) of the 
nonlacunar stroke patients and in 67 (20%) of the lacunar stroke patients, respec-
tively. A total of 35 patients were reclassified using their brain imaging. Extrapolating 
this percentage to the patients without an infarct on brain imaging, 90 of the 708 
patients were estimated to be misclassified (13%), with a slightly higher proportion in 
the lacunar strokes compared with the nonlacunar strokes (21% versus 8%). Patients 
with a nonlacunar stroke were significantly older than patients with a lacunar stroke, 
were less frequent men, and were less often a current smoker. About the other car-
diovascular risk factors no significant differences were found between the 2 groups.
Table 1. Baseline characteristics in patients with nonlacunar and lacunar ischemic strokes (n=708)
Characteristics Nonlacunar ischemic strokes Lacunar ischemic strokes P value
n 365 (52%) 343 (48%)
Age, y 64 ± 14 61 ± 13 <0.001
Men 164 (45%) 187 (55%) 0.01
Hypercholesterolemia 261 (72%) 257 (75%) 0.33
Hypertension 254 (70%) 248 (72%) 0.46
Diabetes mellitus 121 (33%) 126 (37%) 0.32
Current smoking 114 (31%) 133 (39%) 0.04
Use of statins 122 (33%) 116 (34%) 0.62
History of stroke 95 (26%) 76 (22%) 0.30
Type of event
 TIA
 Stroke
 Unknown
103 (28%)
260 (71%)
2 (0.5%)
119 (35%)
223 (65%)
1 (0.3%)
0.07
TIA indicates transient ischemic attack.
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Presence and volume of aortic arch calcifications were significantly higher in patients 
with a nonlacunar stroke compared with patients with a lacunar stroke (prevalence 
73% versus 62%; P<0.01 and median volume 62.2 versus 10.5 mm3; P<0.001; 
Table 2). In patients with a nonlacunar stroke, prevalence of calcifications was 56% 
and 59% in the symptomatic extracranial and intracranial carotid artery, respectively. 
Similar prevalences of calcifications were found in patients with a lacunar stroke. 
There was no significant difference in calcification volume in the symptomatic ex-
tracranial and intracranial carotid artery between patients with a nonlacunar and a 
lacunar stroke.
A significant difference in severity of symptomatic carotid artery stenosis was 
found between patients with a nonlacunar and a lacunar stroke. In patients with a 
nonlacunar ischemic stroke, more occlusions were found compared with patients with 
a lacunar ischemic stroke (10% versus 1%; Table 2).
Calcifications in cardioembolic strokes seemed in between (aortic arch) or lower 
(extracranial and intracranial carotid artery) than that of nonlacunar and lacunar 
strokes (Supplementary Table I).
Characteristics Nonlacunar ischemic 
strokes
Lacunar ischemic 
strokes
P value
n 365 (52%) 343 (48%)
Presence of calcifications* †
 Aortic arch 
 Symptomatic extracranial carotid
 Symptomatic intracranial carotid 
261 (73%)
198 (56%)
210 (59%)
211 (62%)
169 (50%)
178 (54%)
<0.01
0.11
0.13
Calcification volume (median)†
 Aortic arch 
 Symptomatic extracranial carotid
 Symptomatic intracranial carotid 
62.2 [0-408.8]
1.1 [0-27]
2.2 [0-20.7]
10.5 [0-148.6]
0.2 [0-16.7]
0.7 [0-16.5]
<0.001
0.06
0.06
Maximum stenosis symptomatic carotid
 0%
 1-49%
 50-69%
 70-99%
 100%
 unknown
206 (56%)
69 (19%)
18 (5%)
26 (7%)
36 (10%)
10 (3%)
244 (71%)
54 (16%)
19 (6%)
21 (6%)
3 (1%)
2 (1%)
<0.001
Table 2. Vessel characteristics in patients with nonlacunar and lacunar ischemic strokes (n=708)
3UHVHQFHRIFDOFLILFDWLRQVLVGHILQHGDVDFDOFLILFDWLRQYROXPH!PP3. 
† Of the nonlacunar ischemic strokes, calcifications were assessed in the aortic arch of 360 patients, the 
symptomatic extracranial and intracranial carotid artery of 351 and 353 patients, respectively. Of the 
lacunar ischemic strokes, calcifications were assessed in the aortic arch of 341 patients, the symptomatic 
extracranial and intracranial carotid artery of 336 and 331 patients, respectively. 
Processed on: 2-12-2016
506902-L-sub01-bw-vanDijk

Calcifications in nonlacunar and lacunar strokes
4.1
Ta
bl
e 
3.
 D
et
er
m
in
an
ts
 o
f n
on
la
cu
na
r 
ve
rs
us
 la
cu
na
r 
is
ch
em
ic
 s
tr
ok
es
 (
n=
70
8)
C
ha
ra
ct
er
is
ti
cs
U
ni
va
ri
ab
le
M
ul
ti
va
ri
ab
le
 M
od
el
 1
 
(a
ge
, s
ex
, s
ym
pt
om
at
ic
 c
ar
ot
id
 
st
en
os
is
)
M
ul
ti
va
ri
ab
le
 m
od
el
 2
  
(a
ge
, s
ex
, s
ym
pt
om
at
ic
 c
ar
ot
id
 
st
en
os
is
, c
ar
di
ov
as
cu
la
r 
ris
k 
fa
ct
or
s)
O
R
 (
95
%
 C
I)
P 
va
lu
e
O
R
 (
95
%
 C
I)
P 
va
lu
e
O
R
 (
95
%
 C
I)
P 
va
lu
e
A
ge
, y
 
1.
02
 (
1.
01
-1
.0
3)
<
0.
01
1.
01
 (
1.
00
-1
.0
2)
0.
02
1.
02
 (
1.
00
-1
.0
3)
0.
01
M
en
0.
68
 (
0.
51
-0
.9
2)
0.
01
0.
57
 (
0.
42
-0
.7
8)
<
0.
00
1
0.
55
 (
0.
40
-0
.7
5)
<
0.
00
1
H
yp
er
ch
ol
es
te
ro
le
m
ia
 
0.
85
 (
0.
61
-1
.1
8)
0.
33
0.
66
 (
0.
46
-0
.9
4)
0.
02
0.
71
 (
0.
50
-1
.0
3)
0.
07
H
yp
er
te
ns
io
n
0.
88
 (
0.
64
-1
.2
2)
0.
46
0.
66
 (
0.
47
-0
.9
4)
0.
02
0.
67
 (
0.
46
-0
.9
6)
0.
03
D
ia
be
te
s 
m
el
lit
us
0.
85
 (
0.
63
-1
.1
6)
0.
32
0.
75
 (
0.
54
-1
.0
4)
0.
08
0.
76
 (
0.
55
-1
.0
6)
0.
11
C
ur
re
nt
 s
m
ok
in
g
0.
72
 (
0.
53
-0
.9
8)
0.
04
0.
80
 (
0.
57
-1
.1
1)
0.
18
0.
74
 (
0.
53
-1
.0
4)
0.
09
H
is
to
ry
 o
f s
tr
ok
e
1.
28
 (
0.
93
-1
.7
5)
0.
13
1.
24
 (
0.
91
-1
.6
9)
0.
17
1.
26
 (
0.
87
-1
.8
4)
0.
22
Pr
es
en
ce
 o
f c
al
ci
fic
at
io
ns
*
 
A
or
tic
 a
rc
h 
 
Sy
m
pt
om
at
ic
 e
xt
ra
cr
an
ia
l c
ar
ot
id
 
Sy
m
pt
om
at
ic
 in
tr
ac
ra
ni
al
 c
ar
ot
id
1.
62
 (
1.
18
-2
.2
3)
1.
28
 (
0.
95
-1
.7
3)
1.
26
 (
0.
93
-1
.7
1)
<
0.
01
0.
11
0.
13
1.
19
 (
0.
78
-1
.8
2)
0.
88
 (
0.
61
-1
.2
7)
0.
97
 (
0.
68
-1
.3
9)
0.
43
0.
50
0.
87
1.
30
 (
0.
84
-2
.0
2)
0.
93
 (
0.
64
-1
.3
4)
1.
04
 (
0.
72
-1
.5
0)
0.
24
0.
69
0.
82
C
al
ci
fic
at
io
n 
vo
lu
m
e 
(p
er
 m
m
3 )
 
A
or
tic
 a
rc
h 
 
Sy
m
pt
om
at
ic
 e
xt
ra
cr
an
ia
l c
ar
ot
id
 
Sy
m
pt
om
at
ic
 in
tr
ac
ra
ni
al
 c
ar
ot
id
1.
14
 (
1.
08
-1
.2
1)
1.
08
 (
1.
00
-1
.1
7)
1.
09
 (
1.
00
-1
.1
9)
<
0.
00
1
0.
06
0.
06
1.
09
 (
1.
01
-1
.1
9)
0.
98
 (
0.
88
-1
.0
8)
1.
00
 (
0.
90
-1
.1
1)
0.
03
0.
62
0.
95
1.
11
 (
1.
02
-1
.2
1)
0.
90
 (
0.
89
-1
.1
0)
1.
02
 (
0.
92
-1
.1
4)
0.
02
0.
85
0.
69
M
ax
im
um
 s
te
no
si
s 
(p
er
 1
0%
)
 
Sy
m
pt
om
at
ic
 c
ar
ot
id
1.
12
 (
1.
07
-1
.1
7)
<
0.
00
1
1.
11
 (
1.
06
-1
.1
7)
<
0.
00
1
1.
13
 (
1.
08
-1
.1
9)
<
0.
00
1
9D
OXH
VU
HS
UHV
HQ
WR
GG
VU
DWL
R


FR
QIL
GH
QF
HL
QWH
UYD
O
3
UHV
HQ
FH
RI
FD
OFL
ILF
DWL
RQ
VL
VG
HIL
QH
GD
VD
FD
OFL
ILF
DWL
RQ
YR
OXP
H!
P
P3
Processed on: 2-12-2016
506902-L-sub01-bw-vanDijk

Chapter 4.1
Risk factors for nonlacunar ischemic strokes
A comparison of risk factors between nonlacunar and lacunar ischemic strokes is 
shown in Table 3. After adjusting for age, sex, symptomatic carotid artery stenosis, 
and cardiovascular risk factors, age, symp-tomatic carotid artery stenosis, and vol-
ume of the aortic arch calcifications (adjusted odds ratio, 1.11; 95% CI, 1.02–1.21) 
were independently associated with nonlacunar strokes. Male sex and hypertension 
were independently associated with lacunar strokes. Volumes of extracranial and in-
tracranial carotid artery calcifications were not independently associated with nonla-
cunar ischemic strokes.
Discussion
This study shows a high overall prevalence of vascular calcifications in both nonlacu-
nar and lacunar ischemic strokes. We found no significant difference in symptomatic 
extracranial and intracranial carotid artery calcification volume between nonlacunar 
and lacunar ischemic strokes, but only a significantly higher calcification volume in 
the aortic arch in nonlacunar strokes compared with lacunar strokes.
Previous studies have investigated the association between arterial calcifications 
and cerebral ischemic strokes on brain imaging.12,16 Bos et al12 found in a population 
study an independent association between calcification volume in the aortic arch, 
extracranial and intracranial carotid artery, and the presence of cerebral infarcts on 
MRI of the brain. In contrast, Babiarz et al16 found no difference in cavernous cal-
cifications between patients with a MRI-confirmed acute stroke and age-matched 
healthy controls without a stroke. This could partially be explained by the qualitative 
calcification scoring system used in that study with the inherent risk of misclassifica-
tion. Few studies have investigated the association between arterial calcifications and 
ischemic stroke subtypes or the difference in arterial calcifications between ischemic 
stroke subtypes. Bos et al12 found an association between extracranial and intracra-
nial carotid artery calcifications and the presence of lacunar infarcts and an associa-
tion between aortic arch calcifications and the presence of cortical infarcts. Our find-
ing of an independent association between aortic arch calcifications and nonlacunar 
strokes combined with the common notion that severe atheroma in the aortic arch is 
an important risk factor for ischemic stroke, indicates that the potential role of aortic 
arch calcifications in ischemic stroke should be further explored.17 
The role of carotid artery atherosclerosis in ischemic stroke is established but 
the exact pathophysiologic pathway is unclear. In the past decade, research focus has 
shifted from luminal stenosis to the composition and morphology of the atherosclerot-
ic plaque. The so-called vulnerable plaque with a large lipid-rich necrotic core, a thin 
fibrous cap, inflammation, intraplaque hemorrhage, and plaque ulceration is more 
prone to rupture and can cause an ischemic cerebral event after embolization of 
atherosclerotic debris and thrombus.18 Symptomatic carotid artery plaques are sug-
gested to have a lower degree of calcification than asymptomatic plaques, implying 
that calcifications may play a stabilizing role.19 Others have shown that size, number, 
and location of calcifications may influence plaque vulnerability.20 As embolization 
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after rupture of a vulnerable plaque will predominantly lead to cortical infarcts, one 
hypothesis might be that patients with nonlacunar ischemic strokes are more likely to 
have vulnerable plaques than patients with lacunar strokes. Our study shows that ca-
rotid artery stenosis is more prevalent in nonlacunar ischemic strokes, but the similar 
extent of extracranial carotid artery calcification in nonlacunar and lacunar ischemic 
strokes as well as in cardioembolic strokes implies that other plaque components or 
plaque morphology may play a more important role. For instance, Homburg et al5 
showed that plaque ulceration, a characteristic of the vulnerable plaque, is associated 
with nonlacunar stroke. 
Strengths of our study are that we studied calcifications as a marker of the ath-
erosclerosis in a relatively large group of consecutive patients and that we assessed 
calcifications in multiple vessel beds. Coronary artery calcifications are generally ac-
cepted as a sensitive marker for atherosclerosis of the coronary arteries. The guide-
lines of the American heart Association and American College of Cardiology uses the 
coronary artery calcium score as a diagnostic tool for clinical decision making.21 In 
contrast, calcifications of the aortic arch, extracranial and intracranial carotid arteries 
have been studied less extensively. Extracranial and intracranial carotid artery calcifi-
cations are associated with cardiovascular risk factors and history of stroke.13,22,23 Fur-
thermore, extracranial carotid artery calcifications are associated with carotid artery 
stenosis in asymptomatic patients, but in symptomatic patients this association is less 
clear.24-26 Moreover, calcifications can be assessed easily and quantified at MDCTA, 
an imaging modality increasingly used in daily clinical work-up of patients with stroke, 
making them a suitable and robust marker of atherosclerosis.
Our study has also some limitations. First, stroke subtype was assessed similarly 
to Jackson et al2,4 using clinical criteria and correcting for brain imaging results. Al-
though this is probably the least biased method, we found a potential misclassifica-
tion of 13% compared with 7% found by Jackson et al.2 We found a slightly higher 
misclassification proportion in the lacunar strokes compared with the nonlacunar 
strokes, which may led to an overestimation of the prevalence of lacunar strokes and 
a possible underestimation of the true association between calcifications and non-
lacunar stroke. A second limitation of our study is the absence of a MDCTA in 134 
patients. Reasons for not performing a MDCTA in our hospital were severe ischemic 
stroke, which were probably nonlacunar strokes, and kidney failure. Moreover, pa-
tients without a MDCTA were significantly older than patients with a MDCTA where it 
is known that the prevalence of calcifications increases with age.14 This may have led 
to an underestimation of the true association between calcifications and nonlacunar 
strokes. 
In summary, we found no difference in extracranial and intracranial carotid ar-
tery calcifications between nonlacunar and lacunar ischemic strokes. However, we 
did find that a higher calcification volume in the aortic arch is independently as-
sociated with nonlacunar ischemic strokes. These findings only partially confirm the 
notion of distinct etiologies for nonlacunar and lacunar ischemic strokes and suggest 
that the potential role of other plaque components, plaque morphology, and aortic 
arch calcifications in ischemic stroke subtypes needs further evaluation.
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Abstract
Background: Patients with symptomatic carotid artery stenosis are at high risk for 
recurrent stroke. To date, the decision to perform carotid endarterectomy in patients 
with a recent cerebrovascular event is mainly based on degree of stenosis of the 
ipsilateral carotid artery. However, additional atherosclerotic plaque characteristics 
might be better predictors of stroke, allowing for more precise selection of patients 
for carotid endarterectomy.
Aims and hypothesis: We investigate the hypothesis that the assessment of carotid 
plaque characteristics with magnetic resonance imaging, multidetector-row comput-
ed tomography angiography, ultrasonography, and transcranial Doppler, either alone 
or in combination, may improve identification of a subgroup of patients with < 70% 
carotid artery stenosis with an increased risk of recurrent stroke.
Methods: The Plaque At RISK (PARISK) study is a prospective multicenter cohort 
study of patients with recent (<3 months) neurological symptoms due to ischemia in 
the territory of the carotid artery and < 70% ipsilateral carotid artery stenosis who 
are not scheduled for carotid endarterectomy or stenting. At baseline, 300 patients 
will undergo magnetic resonance imaging, multidetector-row computed tomography 
angiography, and ultrasonography examination of the carotid arteries. In addition, 
magnetic resonance imaging of the brain, ambulatory transcranial Doppler record-
ing of the middle cerebral artery and blood withdrawal will be performed. After two 
years, imaging will be repeated in 150 patients. All patients undergo a follow-up brain 
magnetic resonance imaging, and there will be regular clinical follow-up until the end 
of the study. 
Study outcomes: The combined primary end-point contains ipsilateral recurrent isch-
emic stroke or transient ischemic attack or new ipsilateral ischemic brain lesions on 
follow-up brain magnetic resonance imaging.
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Introduction and rationale
Ischemic stroke is the second most common cause of death in Europe, accounting for 
almost 1.1 million deaths each year.1 Atherosclerosis is an important cause of clinical 
cerebrovascular events. The pathophysiology can be ascribed to cerebral embolism 
from an atherosclerotic carotid plaque or hypoperfusion due to carotid luminal ste-
nosis.
Currently, the decision to perform carotid endarterectomy (CEA) in patients with 
a recent cerebrovascular event is based on the degree of luminal stenosis. CEA is 
highly beneficial for symptomatic patients with an ipsilateral carotid artery stenosis 
of 70–99%.2–4 However, the beneficial effect of surgery for symptomatic patients with 
an ipsilateral stenosis between 30% and 69% is only marginal. Several studies show 
that vulnerable plaque features are related to cerebral embolization.5–7 Features of a 
vulnerable atherosclerotic plaque are a large lipid-rich necrotic core (LRNC), a thin 
or ruptured fibrous cap (FC), the presence of inflammatory cells, ulcerations, and in-
traplaque haemorrhage (IPH). Recent studies in symptomatic patients did show that 
IPH, LRNC, and a thin or ruptured FC as assessed with magnetic resonance imaging 
(MRI) are associated with cerebrovascular events.8-10 For multidetector-row computed 
tomography (MDCT), it is known that ulcerations and large calcifications and LRNC 
are significantly more present in symptomatic patients with an atherosclerotic cause 
of ischemic stroke.11 Prospective studies for MDCT have not been conducted yet. 
Several prospective studies have investigated the predictive value of ultrasonogra-
phy (US) in the occurrence of recurrent ischemic stroke, with conflicting results.12–14 
Microemboli detected with transcranial Doppler (TCD) predict short-term ipsilateral 
ischemic stroke.15 However, all these studies were single modality studies or had a 
relative small population size.8-11,15 Therefore, we hypothesize that the assessment of 
markers of plaque vulnerability with MRI, MDCT angiography (MDCTA), US, TCD, ei-
ther alone or in combination, improves the identification of a subgroup of patients in 
the < 70% carotid artery stenosis group with an increased risk of recurrent ischemic 
stroke. 
Methods
Study design
The Plaque At RISK (PARISK) study (clinical trials.gov NCT01208025) is a prospec-
tive multicenter cohort study (Table 1), which investigates whether (a combination 
of) non- or minimally invasive imaging techniques enable us to identify patients with 
symptomatic carotid artery stenosis < 70%, who have an increased risk of recurrent 
stroke. All patients undergo multi-sequence 3·0 Tesla (T) MRI, MDCTA and US imag-
ing of the carotid arteries, MRI of the brain and TCD recordings of the middle cerebral 
artery (MCA). Also blood will be drawn for the determination of different biomarkers. 
Imaging will be repeated two-years after inclusion.
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The primary objective of the PARISK study is to identify whether high-resolution MRI, 
MDCTA, US, and/or TCD enable us to predict future ischemic events in recent symp-
tomatic patients with < 70% carotid stenosis. The secondary objectives are to study 
(1) determinants for plaque progression; (2) the relationship between plaque char-
acteristics, microemboli, and vascular damage on brain MRI; and (3) the association 
between blood biomarkers and plaque parameters.
No. of center Name Abbreviation
1. Academic Medical Center Amsterdam 
(PJ Nederkoorn, MD, PhD)
Flevoziekenhuis, Almere (M Limburg, MD, PhD)
Kennemer Gasthuis, Haarlem (M Weisfelt, MD, PhD)
Slotervaartziekenhuis, Amsterdam (ND Kruyt, MD, PhD)
AMC
2. Erasmus Medical Center Rotterdam 
(A van der Lugt, MD, PhD; PJ Koudstaal, MD, PhD)
Maasstad Hospital, Rotterdam (R Saxena, MD, PhD)
Sint Franciscus Gasthuis, Rotterdam (SLM Bakker, MD, PhD)
Vlietland Hospital, Schiedam (JCB Verhey, MD)
IJsselland Hospital, Capelle a/day IJsel (AD Wijnhoud, MD, PhD)
EMC
3. Maastricht University Medical Center
(ME Kooi, PhD; WH Mess, MD, PhD; RJ van Oostenbrugge, MD, 
PhD)
Atrium Medical Center, Heerlen (T Schreuder, MD)
Laurentius, Roermond (AG Korten, MD, PhD)
Orbis Medical Center, Sittard (NP van Orshoven, MD, PhD)
Viecuri Medical Center, Venlo (BJ Meems, MD, PhD)
MUMC
4. University Medical Center Utrecht 
(J Hendrikse, MD, PhD; LJ Kappelle, MD, PhD)
Diakonessenhuis, Utrecht (R Donders, MD, PhD)
Sint Antonius ziekenhuis, Nieuwegein (S Tromp, MD, PhD)
Ter Gooi ziekenhuizen, Hilversum Blaricum (J de Kruijk, MD, PhD)
UMCU
Table 1. Participating centers in the Netherlands. In bold, the academic hospitals.
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Patient population
Eligible for the study are patients with a transient ischemic attack (TIA), amaurosis fu-
JD[RUPLQRUVWURNHPRGLILHG5DQNLQVFDOHRIWKHFDURWLGDUWHU\WHUULWRU\DQGDQ
atherosclerotic plaque with a < 70% stenosis of the ipsilateral internal carotid artery 
(ICA) who are not scheduled for a revascularization procedure. Patients need to be 
eligible for imaging and blood withdrawal within three-months after initial ischemic 
event. Exclusion criteria are a probable cardiac source of embolism, a clotting dis-
order, severe comorbidity, standard contraindications for MRI, a documented allergy 
for MRI or CT contrast agent or a renal clearance of <30 ml/min. Written informed 
consent will be obtained from all patients before enrolment.
Figure 1. Flowchart of study protocol.
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Study protocol
Degree of stenosis will be determined with clinically obtained Doppler US or CT an-
giography (CTA). The upper cutoff value of 70% is based on the North American 
Symptomatic Carotid Endarterectomy Trial criteria.16 The lower cutoff value is an ath-
erosclerotic plaque with a thickness of at least 2–3 mm, which corresponds to an Eu-
ropean Carotid Surgery Trial stenosis of 30%.3 A total of 300 patients will be included.
At baseline, clinical data such as age, sex, occurrence of last symptoms, medica-
tion use and cardiovascular risk factors are collected. Blood samples will be drawn. All 
noninvasive imaging examinations will be performed within a five-day time window. 
Follow-up by telephone will be done after three-months, one year, and yearly 
until the end of the study in December 2014 (Fig. 1). During follow-up, clinical data 
such as daily functioning (modified Rankin scale), changes in medication use, car-
diovascular risk factors, cardiovascular and cerebrovascular events and hospital ad-
missions are collected. Two-years after inclusion, noninvasive imaging of the carotid 
artery will be repeated in the first 150 patients. Follow-up brain MRI will be performed 
in all patients after two-years.
MRI
Magnetic resonance imaging will be performed on 3·0-T whole body scanners. A 
dedicated eight-channel phased-array coil (Shanghai Chenguang Medical Technolo-
gies Co., Shanghai, China) is used for imaging of the carotid artery in three centers; 
a dedicated four-channel carotid phased-array coil with an angulated setup (Machnet 
B.V., Roden, the Netherlands) is used in one center. For brain imaging, dedicated 
head coils are used. First, brain MR images will be acquired using the sequences as 
listed in Table 2. Second, the carotid bifurcation will be identified by means of MR an-
giography without contrast enhancement. The atherosclerotic plaque will be imaged 
with a multi-sequence MR protocol as listed in Table 3. Fifteen transverse adjoining 
Figure 2 Co-registered pre- 
(A) and postcontrast (B) 
T1-w TSE, T1-w TFE (C), 
T2-w TSE (D) TOF (E) and 
MDCTA (F) of the internal 
carotid artery from a 66 
year old male patient with 
transient dysarthria. 
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slices of 2 mm each, covering the entire plaque or a 3D volume of the extracranial 
carotid artery is used. Six-minutes after injection of 0·1 mmol/kg body weight of a 
gadolinium-based contrast agent the T1w DIR FSE (center 2) or T1w QIR TSE (center 
1, 3, 4) are repeated to obtain postcontrast images (Fig. 2).
MDCTA
Image acquisition will be performed using a 16, 64, or 128 slice multi-detector 
row CT system using a standardized optimized contrast-enhanced MDCTA proto-
col (120 kVp, 150–180 mAs, collimation 16 × 0·75 mm or 64 × 2 × 0·6 mm, 
 pitch <1). One center reconstructs 120 kVp images from the 100 kVp and 140 kVp 
images obtained with dual-energy MDCTA. The scan range extends from the ascend-
ing aorta to the intracranial circulation (3 cm above the sella turcica). All patients 
receive 80–85 ml of an iodinated contrast agent (300–320 mg/ml) followed by a 45 
ml saline bolus chaser, both at an injection rate of 4 or 5 ml/s. Real-time bolus track-
ing at the level of the ascending aorta is used. Image reconstructions are made with 
a FOV of 120–160 mm, matrix size 512 × 512, slice thickness 1·0 mm, increment 
0·6–0·7 mm and with intermediate reconstruction algorithms.
Figure 3 Transverse (A, B) en longitu-
dinal (C, D) ultrasound images of the 
internal carotid artery in B-mode (A, 
C) and colour-coded (B, D). Images 
are from the same patient as figure 2. 
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Ultrasound
After 10 min of rest in supine position, duplex ultrasound examination (Fig. 3) will be 
performed by a well-trained US technician. The extracranial arteries are visualized 
with a 17-5 MHz linear array transducer. If the artery is located too deep, a 12-5 or a 
9-3 MHz transducer will be used. The protocol consists of (1) longitudinal images of 
the common carotid artery (CCA), the carotid bulb, and the ICA in B-mode and color 
Doppler mode, (2) pulsed Doppler recordings of the CCA and the ICA with a sample 
volume of 1 mm, and (3) transversal recording from the CCA to the ICA in B-mode 
and color Doppler covering a total length of 8 cm. All images will be recorded from 
DQWHURODWHUDODQGSRVWHURODWHUDOYLHZVDWDIUDPHUDWH!+]DQGZLWKDFLQHORRS
of five seconds.
TCD
Transcranial Doppler measurements will be performed on the symptomatic side only. 
With conventional Doppler, the transtemporal window is investigated, as well as the 
depth of the main stem of the MCA. In case of a sufficient window, an ambulatory 
TCD system (TCD-X, Hemodynamics AG, Bern, Switzerland) is positioned at the lo-
cation of the transtemporal bone window. When the signal of the MCA is detected, 
settings such as sample volume, gain, power, and depth are optimized by means of 
dedicated software on a laptop connected to the TCD-X. Afterward, the device is 
disconnected from the laptop and the four-hour recording will start. 
Biomarkers
Nine milliliters (ml) of citrated plasma for platelet-rich plasma, 9 ml citrated plasma 
for platelet-poor plasma, 8·5 ml of serum, 10 ml of ethylenediaminetetraacetic acid 
plasma, and 4·5 ml acidified citrated plasma (Stabilyte) will be taken for the deter-
mination of different biomarkers. All samples will be processed within one-hour and 
VWRUHG LQÃPO WXEHV DWï &XQWLO DQDO\VLV0DUNHUV IRU WKURPEXVJHQHUDWLRQ
and formation, fibrinolysis, endothelial function, and vascular inflammation will be 
assessed. Blood samples will be stored for 15 years. The informed consent form 
includes an additional question on the use of blood samples for extra testing (e.g. 
genetic testing) for research related to the main hypothesis.
Image data analysis
All data will be evaluated by trained readers blinded to the results of other image 
modalities, clinical data, and baseline/follow-up data. Each reader performs training 
on test sets and interobserver reproducibility will be assessed beforehand.
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MRI evaluation of the carotid artery will be done using dedicated vessel wall 
analysis software (VesselMass, department of Radiology, Leiden University Medical 
Center, the Netherlands) as described previously.17 MR images will be assessed for 
vessel wall and luminal area, LRNC area, calcification area, presence of IPH and 
FC status using previously published criteria.18–20 MRI of the brain will be scored for 
cortical and lacunar infarcts, microbleeds, and the severity of white matter lesions 
according to Fazekas et al.21
All MDCTA data will be evaluated for the most severe stenosis in the carotid 
bifurcations and internal carotid arteries. Calcifications at extracranial carotid arter-
ies within 3 cm proximal and distal of the bifurcation will be measures and expressed 
as calcification volume in mm3. A threshold of 600 Hounsfield units will be used to 
differentiate calcifications from contrast material in the lumen. Plaque ulceration is 
GHILQHGDVH[WHQVLRQRIFRQWUDVWPDWHULDORI!PPLQWRWKHDWKHURVFOHURWLFSODTXHRQ
at least two orthogonal planes. Plaque volumes will be assessed with custom-made 
software.22 Plaques will be subdivided into fatty plaques, mixed or calcified plaques 
based on attenuation values.23
Ultrasound data will be analyzed on software developed in-house, based on 
previously published algorithms.24–26 The anatomical course of the carotid artery, the 
presence of plaques, and the degree of stenosis will be scored. Second, images will be 
quantified on appearance by using dedicated gray scale analysis software. The mor-
phology of the plaque will be determined by manually contouring plaques to quantify 
its area, thickness, length, and echogenicity. In addition, the morphology of the artery 
will be characterized by end diastolic diameter and vessel wall thickness, and their 
inhomogeneities along the artery section. Finally, dynamic vessel wall characteristics 
will be quantified by distension, i.e. the change in diameter over a cardiac cycle, and 
its spatial inhomogeneity.
The four-hour transcranial Doppler recordings will be analyzed using semiauto-
matic software (Hemodynamics AG, Bern, Switzerland). All high-intensity transient 
signals will be verified by a trained reader. Based upon predefined criteria they will be 
identified as either microembolic signals (Fig. 4) or artifacts.27 
Figure 4 The red box indicates a typical example of a microembolic signal, both in the frequency (a) and 
time (b) domain.
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Outcome measures
The primary end-point is an ipsilateral recurrent ischemic stroke, or TIA and/or new 
ipsilateral ischemic brain lesions on follow-up brain MRI. Clinical events are verified 
by a neurologist. Secondary end-point is new ipsilateral ischemic brain lesions on 
MRI. 
Statistical analysis
Cox proportional hazard models will be used to compute hazard ratios with 95% confi-
dence intervals for the association of plaque parameters with the primary and second-
ary end-points. In the primary analysis we will focus on four plaque parameters: (1) 
presence of IPH as assessed on ipsilateral MRI of carotid plaque, (2) ipsilateral carotid 
plaque ulceration as assessed on MDCTA, (3) ipsilateral carotid plaque volume as as-
sessed on MRI, and (4) the proportion of calcifications with respect to the ipsilateral 
carotid plaque volume as assessed with MDCTA. First, we will analyze the data uni-
variately, then we will adjust for age, sex, and major cardiovascular risk factors. Subse-
quently, we will adjust for the other plaque parameters. Additionally, we will investigate 
the association between number of microemboli, ultrasound gray scale values and ves-
sel wall motion, volume of plaque components on MRI (calcifications, LRNC, fibrous 
tissue), FC status on MRI, plaque volume on MDCTA, and the end-points.
Sample size 
The expected incidence of ischemic stroke is 2·5% per year based on the standard 
medical treatment of antiplatelet therapy, a statin and antihypertensive agents to 
obtain strict blood pressure control. This means in a group of 300 patients, with a 
follow-up of two-years, we expect an incidence rate of 15 ischemic strokes. In a re-
cent study in one of our participating centers 14/72 (19%) symptomatic patients with 
30–69% carotid stenosis had a new silent infarct on brain MRI after one-year. Assum-
ing that this number will not increase with a follow-up of two-years, we expect that 57 
of the 300 patients will demonstrate a new infarct on brain MRI. Based on this num-
ber we will be able to evaluate 6–11 imaging parameters for the primary analysis.
Data storage
All clinical information from the different centers will be stored in a sophisticated web-
based database system (OpenClinica version 3·1.2, Community Edition, Boston, MA, 
USA). All image data from different centers are anonymized and centrally stored on 
a DICOM server (based on open source DCM4CHEE software) hosted by one of the 
participating centers. Image data are accessible for all partners.
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Ethical and regulatory considerations
The PARISK study will be performed in the Netherlands and has been approved by 
the Medical Ethical Committees of the participating academic centers. All partici-
pants will provide written informed consent.
Discussion
We present the protocol of a prospective multicenter cohort study, PARISK, to identify 
imaging parameters that can improve risk prediction for stroke recurrence in recently 
symptomatic patients with < 70% carotid artery stenosis and help in the selection of 
patients for CEA. These imaging parameters will be determined using detailed imag-
ing of the carotid arteries using 3T MRI, MDCTA, and US as well as TCD of the MCA. 
Atherosclerotic plaques in carotid arteries have been studied intensively over the 
last decades. However, the PARISK study has a different approach, as compared with 
previously published studies. To our knowledge, it is the first prospective multicenter 
cohort study with multimodality imaging of the carotid artery. Patients referred to aca-
demic hospitals as well as to regional hospitals will be included and centrally imaged 
in the academic centers. This setting enables us to include a large number of patients 
in a relative short period of time. In the various academic hospitals different MRI and 
MDCT scanners are used, which reflects variation in clinical practice.
The multimodality approach allows us not only to study morphological param-
eters, such as the size of LRNC or FC status, but also biological and biomechanical 
parameters such as blood biomarkers and vessel wall motion. The ability to define 
which (combination of) parameters predicts a recurrent stroke makes this a highly 
clinical relevant prognostic cohort study. The event rate of stroke has significantly 
decreased in the last decade. Based on studies from Rothwell et al.2 we originally 
expected 30 clinical end-points in 36 months of follow-up in our study population. 
However, this number will probably be much lower due to widespread use of statins, 
antiplatelet therapy, and blood pressure optimization.28 For this reason, the PARISK 
trial uses a primary composite end-point that combines clinical events and silent brain 
infarcts on MRI.
Imaging studies have revealed that 30–50% of the TIAs are accompanied by 
ischemic lesions on diffusion weighted imaging MRI in the acute phase and that 
most of these lesions lead to permanent brain damage.29,30 Vernooij et al.31 showed 
in healthy participants that silent brain infarcts are much more prevalent than previ-
ously expected. These silent infarcts have the same risk factors as infarcts with neu-
rological deficits as result and are considered to have the same pathophysiological 
mechanism.
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Conclusion
The PARISK study represents a prospective multicenter study of symptomatic patients 
with recent (<3 months) neurological symptoms due to ischemia in the territory of 
the carotid artery and a < 70% ipsilateral carotid artery stenosis who are not sched-
uled for CEA or stenting. The primary objective of this study is to identify whether 
MRI, MDCTA, US, or TCD or a combination of these techniques enable us to identify 
patients with an increased stroke risk. This would highly influence clinical decision 
making.
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General discussion
Rupture is one of the major hazards of an atherosclerotic plaque and can lead to an 
ischemic stroke or TIA. Ischemic stroke is an important cause of disability and cardio-
vascular death. Imaging techniques like contrast-enhanced ultrasound (CEUS), multi-
detector-row computed tomography angiography (MDCTA) and magnetic resonance 
imaging (MRI) have made it possible to quantify atherosclerotic burden by degree of 
stenosis, maximum vessel wall area or calcification volume. In addition, character-
istics of the vulnerable, i.e.rupture-prone, plaque can be visualized as plaque ulcer-
ation, intraplaque hemorrhage (IPH) and lipid core. In this thesis, I focus on extracted 
imaging biomarkers of the atherosclerotic plaque in the carotid artery acquired using 
CEUS, MDCTA and MRI for a better understanding of plaque pathophysiology and 
the role of blood coagulation. In addition, I evaluate which image modalities and 
which imaging biomarkers can be valuable in the clinical setting. 
Atherosclerosis and coagulation
Von Willebrand factor (VWF) plasma levels increase as a result of endothelial damage 
and VWF plays an important role in the initial steps of thrombus formation.1 Levels of 
VWF are increased in ischemic stroke patients and the highest levels of VWF are found 
in patients with large vessel disease and cardio-embolic strokes.2, 3 In addition, high 
levels of VWF are associated with an increased risk of ischemic stroke.4 It has been 
suggested that because endothelial activation is related to atherosclerosis and an 
association has been found between the intima-media thickness and increased VWF 
levels in healthy individuals,  atherosclerosis itself (and not only thrombus formation) 
may be a determinant of VWF levels.5 In contrast, several in vitro and in vivo studies 
that for example evaluated interactions between VWF/Weibel-Palade bodies (which 
secret VWF) and low-density lipoproteins (LDL), smooth muscle cells (SMCs) and 
inflammation, suggest VWF might contribute to the pathogenesis of atherosclerosis.6 
In addition, animal studies have shown that absence of VWF may have a protective 
effect against the development of atherosclerosis which indicate that VWF could be 
a determinant of atherosclerosis.6-8 However, results of patients studies are inconclu-
sive. On the one hand, Bilora et al. found that patients with hemophilia A and von 
Willebrand disease had fewer carotid plaques and a smaller degree of carotid stenosis 
than normal subjects of the same sex and age.6, 9 On the other hand, Sramek et al 
found no substantial differences in intima-media thickness between Von Willebrand 
disease patients and healthy controls.6, 10 To conclude, the exact mechanism of the 
interaction between VWF and atherosclerosis seems complex and remains unclear.
A Disintegrin And Metalloprotease with Thrombo Spondin motif repeats 13 (AD-
AMTS13) has been studies less intensively than VWF. ADAMTS13 cleaves large VWF 
multimers into smaller and lower prothrombotic forms, and low ADAMTS13 activity is 
associated with an increased ischemic stroke risk.11, 12 The underlying mechanism of 
the association between ADAMTS13 and ischemic stroke risk, and the potential role 
of atherosclerosis, is also still unclear.
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Novel imaging biomarkers of atherosclerosis assessed by MDCTA and MRI do 
not only quantify atherosclerotic burden, but can also indicate that characteristics of a 
vulnerable, i.e. rupture-prone, plaque are present. We hypothesized that this detailed 
atherosclerotic plaque information could help identify an association between athero-
sclerosis and blood biomarkers VWF and ADAMTS13. We found a strong correlation 
between calcification volume in the aortic arch and carotid arteries and VWF levels 
in patients with an ischemic stroke or TIA suggesting a positive association between 
atherosclerosis and VWF (Chapter 2.1). In accordance with current literature2, 3, high-
est VWF levels were found in patients with large vessel disease compared with the 
other etiological subtypes (Chapter 2.1). However, if we look specifically in a group 
of patients with carotid artery atherosclerosis and a moderate carotid artery stenosis 
or if we look at vulnerable plaque characteristics like plaque ulceration, intraplaque 
hemorrhage and lipid, no associations were found between imaging biomarkers and 
the coagulation factors VWF and ADAMTS13 (Chapter 2.2 and 2.3). A previous 
study in acute coronary syndrome patients also showed that presence of atheroscle-
rosis (measured with IVUS) was associated with VWF levels, but no associations were 
found between VWF levels and high risk, prone-to-rupture atherosclerotic lesions.13 
Vulnerable plaque rupture is crucial in the pathophysiological cascade from ath-
erosclerotic plaque development to ischemic stroke or TIA. Due to the role of VWF and 
ADAMTS13 in thrombus formation and the less clear role of VWF and ADAMTS13 in 
atherosclerotic plaque development, we expected that the association between plaque 
ulcerations (and other vulnerable plaque characteristics) and the blood biomarkers is 
more clear than the association between plaque volume and VWF and ADAMTS13. 
However, the opposite was found and our results do, unfortunately, not clarify the as-
sociation between VWF and ADAMTS13 and atherosclerosis; more – probably basic 
or animal – studies are needed. It seems that not the local disturbance of blood flow 
or the disruptive plaque surface in the carotid bifurcation causes an increase in VWF 
or a decrease in ADAMTS13. The alteration of the endothelial layer due to widespread 
atherosclerotic disease may cause the change in coagulation markers. If this is true, 
blood coagulation markers are then a marker of a wide spread atherosclerotic disease 
and not a modifiable risk marker for secondary prevention. However, a complex role of 
VWF and ADAMTS13 in atherosclerotic plaque development can’t be ruled out. Our 
results show that quantifying atherosclerotic burden and assessing vulnerable plaque 
characteristics indeed provides different information about the atherosclerotic plaque 
and that a clear distinction should be made in future studies between plaque volume 
measurements and (vulnerable) plaque characteristics.
GEH9JAKGFG>FGFAFN9KAN=HD9IM=AE9?AF?L=;@FAIM=K
US, MDCTA and MRI are all used in current clinical practice to assess degree of 
carotid stenosis, and to some extent plaque irregularity, and help identifying stroke 
patients who benefit most from a carotid-endarterectomy (CEA). The last decades 
have witnessed increased interest in imaging of the atherosclerotic plaque to charac-
terize the plaque in other ways than only degree of stenosis and to gain knowledge 
on plaque pathophysiology. Plaque area, luminal border regularity, echolucency and 
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heterogeneity are all imaging biomarkers which can be assessed by US and can give 
information about plaque ulceration and plaque composition like lipid core, intra-
plaque hemorrhage and calcifications.14, 15 However, sensitivity and specificity vary 
and are limited.15 Fortunately, MDCTA is well capable to assess carotid plaque bur-
den, plaque component volumes (especially calcifications) and plaque ulceration.16-18 
Nevertheless, radiation exposure is a drawback of MDCTA, especially in a screening 
setting, and soft tissue contrast is limited.15, 19 MRI with excellent soft-tissue contrast 
and without ionizing radiation is, therefore, of great interest in plaque imaging re-
search; and MRI can correctly evaluate carotid plaque burden, plaque component 
volumes (especially intraplaque hemorrhage) and fibrous cap status.15, 19-22 However, 
MRI is less available, expensive and has relative long scan times.20-22 Although advan-
tages and limitations of the different non-invasive image modalities have been well 
studied individually, less is known about how the different image modalities relate to 
each other. In the clinical setting, it is impossible to perform all imaging techniques 
in one patient; it is time consuming, expensive and burdensome for the patients. We 
therefore do not know which imaging modality is best for application in the clinical 
setting. Many (prospective) studies on the clinical significance of plaque characteris-
tics will be needed to answer this question. In my thesis, I performed three cross-sec-
tional studies to investigate how US, MDCTA and MRI interrelate regarding plaque 
ulceration, intraplaque hemorrhage and calcifications.
 Plaque irregularity (plaque ulceration and/or fissured fibrous cap; a sign of 
plaque rupture) is associated with an increased risk of ipsilateral ischemic stroke. 
Plaque irregularity and ulceration can – as mentioned before – be well assessed using 
MDCTA.23, 24 However, some patients cannot undergo MDCTA due to contrast allergy 
and in addition, radiation exposure in MDCTA is a drawback in a screening setting. 
Perhaps US and MRI can be an alternative to visualize plaque ulceration. Assessment 
of plaque ulceration or fibrous cap status on MRI seems adequate, but multisequence, 
contrast-enhanced MRI protocols are necessary.25-27 Sensitivity of regular US to show 
plaque ulceration is low, only 37,5%.28 In contrast-enhanced ultrasound (CEUS) a mi-
crobubble contrast agent is administered and better delineation of the carotid lumen 
is achieved; CEUS might be a safe, cheaper and widely available alternative for MDC-
TA and MRI (Chapter 3.3).29 I found, in accordance with the literature, indeed limited 
use for regular ultrasound in the detection of plaque ulcerations, but also that the use 
of microbubbles improves the accuracy of ultrasound with an increased agreement 
between ultrasound and MDCTA (в=0.19 (US) to в=0.42 (CEUS); sensitivity 29% 
(US) to 88% (CEUS); specificity 73% (US) to 59% (CEUS); Chapter 3.3). Nevertheless, 
acoustic shadowing of calcifications remains a limitation of CEUS and can potentially 
obscure plaque ulcerations. In addition, the 2-dimensional image data in CEUS can 
be a disadvantage compared to the 3-dimensional volumetric data in MDCTA.
A second important characteristic of the vulnerable plaque is intraplaque hem-
orrhage. Presence of intraplaque hemorrhage in the carotid artery is associated with 
an increased risk of ischemic stroke.30-33 Common notion is that small leaky neoves-
sels in the atherosclerotic plaque are the likely source of intraplaque hemorrhage.34-36 
Intraplaque hemorrhage can lead to plaque destabilization which can subsequently 
result in plaque rupture.34-36 MDCTA is not capable to visualize intraplaque hemor-
rhage, but MRI can. In contrast, MRI is less suitable to detect plaque ulceration than 
MDCTA. By comparing MDCTA and MR images of the carotid artery in the same 
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patients, I found a strong association between intraplaque hemorrhage on MRI and 
disruption of the plaque surface (plaque ulceration and/or fissured fibrous cap) as-
sessed at MDCTA (Chapter 3.1). This finding supports the notion that intraplaque 
hemorrhage increases the risk of plaque rupture. However, due to the cross-sectional 
design of our study, serial studies are needed to evaluate whether intraplaque hemor-
rhage indeed increases the risk for plaque rupture and subsequent symptoms. 
Interobserver agreement for intraplaque hemorrhage was high (в=0.95, Chap-
ter 3.1), which makes assessment of presence of intraplaque hemorrhage on MRI a 
reliable prognostic marker in the clinical setting; probably more sound than the as-
sessment of disruption of the plaque surface with MDCTA (interobserver agreement 
в=0.41, Chapter 3.1).
Finally, a third interesting plaque characteristic is plaque calcification. Recently, 
interest in plaque calcification has renewed by arising evidence that plaque calcifica-
tion is not just a passive process.37 Carotid artery calcifications are associated with de-
gree of carotid artery stenosis and are increasingly used as a marker of atherosclero-
sis.38-40 (Macro)calcifications are considered to be plaque stabilizers; increased calcium 
density is associated with lower cardiovascular risk and the proportion of calcification 
in the atherosclerotic plaque is inversely associated with symptomatic plaques.41, 42 Al-
though MRI is increasingly used in plaque imaging studies, detection of calcifications 
with MRI is however a challenge.37, 43 I found a good sensitivity, but a low specificity of 
MRI for the detection of plaque calcifications in comparison to MDCTA (Chapter 3.2). 
In addition, an overall agreement was found in calcification volume assessed with 
MDCTA and MRI; however, absolute individual differences were substantial. Meth-
odological reasons like the use of a 600 HU threshold and an extended scan range 
(MDCTA), technical reason like  insufficient image quality of MRI as well as wrong 
interpretation and delineation of low signal intensities on MRI were found as the most 
prevalent reasons for a mismatch in the detection of calcifications or a large difference 
in calcification volume measurements. Although the results for MRI are disappointing 
for now, we expect that, agreement between MRI and MDCTA calcifications can be 
improved by training in MRI interpretation and also by an increase in image quality.
In conclusion, (CE)US, MDCTA and MRI have their own potentials and limita-
tions and are not interchangeable. No clear choice of one preferred or superior image 
modality can be made at this point. Additional cross-sectional and future prospective 
studies focusing on the evaluation of vulnerable plaque characteristics that increase 
the risk of ischemic stroke and TIA, should help clarify this question. However, the use 
of one or two short MRI series focusing on specific plaque characteristics, like intra-
plaque hemorrhage, in addition to a MDCTA to detect plaque ulcerations or calcifica-
tions, seems a likely possible scenario. Caution should be applied when interpreting 
calcifications on MRI.
Clinical studies
Numerous studies have investigated the opportunities and limitations of US, MDCTA 
and MRI to assess plaque characteristics and how these plaque characteristics relate 
with clinical characteristics or outcome. However, the question whether plaque imag-
Processed on: 2-12-2016
506902-L-sub01-bw-vanDijk
5
General discussion
5
ing can help clinical decision making is still unanswered.44, 45 The multicenter Plaque 
At RISK (PARISK), a large multicenter cohort study investigates if plaque imaging 
enables us to better identify patients in the 30-69% carotid stenosis group with an 
increased stroke risk, may help to answer this question (Chapter 4.2). 
Study design of the PARISK-study is described in Chapter 4.2. Cross-sectional 
analyses of the data collected in the PARISK-study are used in several chapters of my 
thesis (Chapter 2.2, 3.1 and 3.2). Therefore, I will discuss some methodological con-
siderations regarding the PARISK-study. The original goal of the PARISK-study was 
the inclusion of 300 patients in two years. However, a total of 240 patients was in-
cluded in 3,5 years. After a slight delay in the start of the inclusion due to Institutional 
Review Board formalities, inclusion rate was lower than expected due to strict inclu-
sion criteria and a higher refusal rate of patients than expected due to the intense 
study protocol (approximately 60% of eligible patients were willing to participate). By 
adding a fourth academic research center and addressing local peripheral hospitals, 
inclusion rate was increased. In addition, inclusion criteria were adapted. Amount of 
carotid atherosclerosis was a main inclusion criterion; the lower limit of amount of 
DWKHURVFOHURVLVZDVDGMXVWHGIURP1$6&(7!WR(&67!46, 47 We observed 
considerable amounts of carotid atherosclerosis but without a 30% NASCET stenosis. 
Because of the interest in plaque characteristics rather than the degree of stenosis, 
adjusting the inclusion criteria was – in our opinion – valid. 
The lower number of included patients and the new insights concerning the 
lower stroke recurrence rate due to improved secondary prevention have affected the 
statistical power of the PARISK-study. However, recent studies showed that 30-50% of 
the TIAs are accompanied by ischemic lesions on DWI-MRI in the acute phase and 
most of these lesions lead to permanent brain damage.48, 49 In addition, silent brain 
infarcts are much more frequent than previously expected and have the same risk 
factors, pathophysiological mechanisms and prognostic value as symptomatic brain 
infarcts.50 As a result, the primary endpoint of the study was changed into the com-
posite of ischemic stroke, or TIA, or new ischemic brain lesions on the follow-up brain 
MRI (compared to baseline brain MRI).
The PARISK-study is among the first studies in which several different imaging 
techniques are compared where most previous studies have focused on only one 
image modality. As a result, a large set of possible imaging and blood biomarkers 
can be investigated. Based on the literature and cross-sectional studies, like the ones 
performed in my thesis, the most promising biomarkers will be selected for hypothe-
sis-driven analysis. After the main analysis, other parameters can be investigated in 
hypothesis generating studies. Because of the multicenter design of the PARISK-study, 
different scanners are used and small differences in imaging protocols are inevitable. 
However, this reflects the normal clinical situation and increases the generalizability 
of the findings. Due to the amount of data, especially in the case of the MRI carotid 
artery data, the imaging data were scored by different observers. To ensure the qual-
ity of our data, all observers received training and were only allowed to analyze scans 
if an acceptable interobserver agreement was reached.
 In addition to the potential role of plaque imaging in risk stratification, im-
aging biomarkers may help expand our knowledge on plaque pathophysiology and 
ischemic stroke subtypes. A frequently used division of ischemic strokes are the la-
cunar versus the nonlacunar infarcts. Approximately 25% of all ischemic strokes are 
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supposed to be lacunar infarcts; caused by occlusion of small perforating arteries of 
the brain (small vessel disease).51 Whereas nonlacunar infarcts are supposed to be 
caused by thromboembolism from the heart or large extracranial arteries (large vessel 
disease), Jackson et al. already found a higher prevalence of significant carotid artery 
stenosis in nonlacunar infarcts compared to lacunar infarcts.51, 52 In addition, Hom-
burg et al. showed that plaque ulceration on MDCTA is associated with nonlacunar 
ischemic stroke as compared to lacunar strokes; supporting the notion that nonlacu-
nar and lacunar infarcts have different types of atherosclerotic disease.53 However, I 
found no difference in extracranial and intracranial carotid artery calcifications be-
tween nonlacunar and lacunar ischemic strokes, but I did find that a higher calcifica-
tion volume in the aortic arch was associated with nonlacunar strokes (Chapter 4.1). 
These findings only partially confirm the notion of distinct etiologies for nonlacunar 
and lacunar ischemic strokes and suggest that the potential role of other plaque 
components, plaque morphology, and aortic arch calcifications in ischemic stroke 
subtypes needs further evaluation; a research question which we can also address in 
the PARISK-study or other future prospective plaque imaging studies.
The PARISK consortium consists of several technical and clinical partners. The multi-
modality approach and addition of blood biomarkers and clinical follow-up makes it 
a multi-disciplinary effort as well. Reaching beyond the borders of one owns expertise 
will become more and more important to achieve scientific and clinical progress. 
From the perspective of personalized medicine, characterization of the atherosclerotic 
plaque by CEUS, MDCTA and MRI is an important feature to identify plaque charac-
teristics in an individual patient and to assess patient specific risks. The PARISK study 
will assess which imaging biomarkers increase the risk of recurrent stroke and this 
could mean a considerable step forward in personalized medicine in ischemic stroke 
and TIA patients. However, the translation of plaque imaging from research setting to 
the clinical setting still has to be effectuated. CEUS is better equipped to detect plaque 
ulcerations compared to regular US and has the potential to detect neovasculariza-
tion, however it is still very operator dependable and currently only 2-dimensional data 
is acquired. MDCTA is already used on a large scale in the clinical setting to assess 
degree of stenosis and can detect plaque ulceration and calcifications. However, ion-
izing radiation and the use of contrast material makes it less suitable for a screening 
setting. Plaque characterization with MRI is promising due to its excellent soft tissue 
contrast and reliable assessment of vulnerable plaque characteristics like intraplaque 
hemorrhage, but it is not a straightforward process. Duration of MRI sequences is 
long, plaque analysis needs elaborate training, is difficult and time consuming. How-
ever, the use of a few short MRI sequences focused on a specific plaque features, 
automated analysis and integration of different image modalities will be supportive in 
the transfer of plaque imaging from the research setting to the clinical setting.
Finally, performing a clinical multicenter study comes with a lot of challenges. 
Acquisition protocols need to be synchronized as much as possible, which is ham-
pered by different equipment and expertise. Observers need to be well trained. Inclu-
sion of patients for a study with an elaborate study protocol soon after an ischemic 
stroke or TIA with often significant implications for the patient, can be an arduous 
task. Fortunately, many patients are eager to help expanding knowledge on their 
disease.
Processed on: 2-12-2016
506902-L-sub01-bw-vanDijk
55
General discussion
5
Conclusions and future perspectives
Characterization of the atherosclerotic plaque by advanced imaging techniques gives 
unique and valuable insights in the association between atherosclerotic plaque com-
position and blood coagulation; between plaque composition and plaque pathophysi-
ology; and between plaque composition and ischemic stroke subtypes. The associa-
tion between VWF and ADAMTS13 and atherosclerosis remains unclear. In addition, 
CEUS, MDCTA and MRI each have their own advantages and limitations and do not 
allow an evidence based preference for one particular image modality at this point. 
The multicenter Plaque At RISK (PARISK) study will hopefully help answer the ques-
tion whether plaque imaging indeed can help clinical decision making. The PARISK 
study is an example for future studies; cooperation between different academic and 
technical partners and reaching beyond the borders of your own expertise to achieve 
scientific and clinical progress. 
Current plaque imaging techniques and analyses are elaborate and complicat-
ed. Future studies should focus on simplifying and standardization of plaque imaging 
protocols and analyses to enable the transition to the clinical situation. In addition, 
automated plaque analysis tools need to be further improved and simplified. A future 
prospective multicenter study is needed to compare (1) the elaborate plaque imag-
ing protocols and analyses currently used in the research setting (a multisequence 
contrast-enhanced MRI combined with a MDCTA and/or US and complete plaque 
delineation and assessment of the plaque surface), with (2) a more clinical feasible 
plaque imaging protocol (a few short MRI sequences, focusing on for example total 
plaque volume, presence (and volume) of intraplaque hemorrhage/(lipid), in com-
bination with MDCTA, to detect degree of stenosis, plaque ulceration and calcifica-
tions), and with (3) current clinical practice (assessment of degree of carotid artery 
stenosis). This may provide further insight into optimal plaque imaging that is feasible 
in the normal clinical setting.
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Summary
Cardiovascular disease is the second-leading cause of death in the Netherlands with 
approximately 38.000 deaths a year.1 In addition, stroke is the leading cause of dis-
ability. The majority of strokes is of ischemic origin (87%)2 in which a blood clot 
occludes one of the arteries of the brain. In a transient ischemic attack (TIA), this 
interruption and the subsequent neurological symptoms are only temporary, mostly 
hours, and do not lead to a permanent deficit.3 Ischemic stroke and TIA have similar 
causes and their clinical management is identical as atherosclerosis plays an impor-
tant causal role in both.2 
Atherosclerosis is a chronic inflammatory disease of especially large arteries 
with thickening of the arterial vessel wall which progresses into plaque development 
and stenosis of the vessel lumen. One of the major hazards of the atherosclerotic 
plaque is that it can rupture. Thrombogenic components of the plaque then come 
into contact with blood and a thrombus develops. This thrombus may generate distal 
emboli that occlude an artery of the brain, leading to an ischemic stroke. However, 
not all plaque ruptures lead to a clinical event (Chapter 1).4-6 
Imaging techniques like contrast-enhanced ultrasound (CEUS), multidetector-
row computed tomography angiography (MDCTA) and magnetic resonance imaging 
(MRI) have made it possible to quantify atherosclerotic burden by degree of stenosis, 
maximum vessel wall area or calcification volume. In addition, characteristics of the 
vulnerable, i.e.rupture-prone, plaque can be visualized as plaque ulceration, intra-
plaque hemorrhage (IPH) and lipid core. In this thesis, I focused on extracted imaging 
biomarkers of the atherosclerotic plaque in the carotid artery acquired using CEUS, 
MDCTA and MRI for a better understanding of plaque pathophysiology and the role 
of blood coagulation. In addition, I evaluated which image modalities and which im-
aging biomarkers can be valuable in the clinical setting. 
Blood coagulation plays a role in atherosclerosis and the development of ischemic 
events. We found a strong correlation between calcification volume in the aortic arch 
and carotid arteries and VWF levels in patients with an ischemic stroke or TIA suggest-
ing a positive association between atherosclerosis and VWF (Chapter 2.1). In accor-
dance with current literature7, 8, highest VWF levels were found in patients with large 
vessel disease compared with the other etiological subtypes (Chapter 2.1). However, 
if we look specifically in a group of patients with carotid artery atherosclerosis and a 
moderate carotid artery stenosis or if we look at vulnerable plaque characteristics like 
plaque ulceration, intraplaque hemorrhage and lipid, no associations were found be-
tween imaging biomarkers and the coagulation factors VWF and ADAMTS13 (Chap-
ter 2.2 and 2.3). The precise mechanism of the association between coagulation 
factors VWF and ADAMTS13 and cardiovascular disease risk remains unclear; blood 
biomarkers could mark widespread atherosclerosis or have a more complex role in 
atherosclerotic plaque development. 
US, MDCTA and MRI are all used in current clinical practice to assess degree of 
carotid stenosis, and to some extent plaque irregularity, and help identifying stroke 
patients who benefit most from a carotid-endarterectomy (CEA). The last decades 
have witnessed increased interest in imaging of the atherosclerotic plaque to charac-
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terize the plaque in other ways than only degree of stenosis and to gain knowledge on 
plaque pathophysiology. We found that intraplaque hemorrhage on MRI is associated 
with disruption of the plaque surface (plaque ulceration and/or fissured fibrous cap), 
a manifestation of plaque rupture, on MDCTA (Chapter 3.1). Because the cross-sec-
tional design of our study, serial studies are needed to confirm a causal relationship 
between intraplaque hemorrhage, plaque rupture and subsequent ischemic stroke 
or TIA. In addition, we showed that MRI has good sensitivity, but low specificity for 
the detection of plaque calcifications compared to MDCTA. There was an overall 
agreement in calcification volume assessed with MRI and MDCTA. However, due to 
substantial individual differences, MRI plaque imaging techniques presently cannot 
be recommended to estimate volume of plaque calcifications in individual patients 
with symptomatic carotid artery stenosis (Chapter 3.2). Finally, we found limited use 
for regular ultrasound in the detection of plaque ulcerations, however the addition 
of contrast-enhanced ultrasound (CEUS) can have additional value in the detection 
of ulcerations (Chapter 3.3). In conclusion, (CE)US, MDCTA and MRI have their 
own potentials and limitations and are not interchangeable. No clear choice of one 
preferred or superior image modality can be made at this point. Additional cross-sec-
tional and future prospective studies focusing on the evaluation of vulnerable plaque 
characteristics that increase the risk of ischemic stroke and TIA, should help clarify 
this question. 
An example of a study which hopefully help answer this question is the Plaque At 
RISK (PARISK); a large multicenter cohort study investigating if plaque imaging en-
ables us to better identify patients in the 30-69% carotid stenosis group with an in-
creased stroke risk (Chapter 4.2). In addition to the potential role of plaque imaging 
in risk stratification, imaging biomarkers may help expand our knowledge on plaque 
pathophysiology and ischemic stroke subtypes. We found no difference in extracranial 
and intracranial carotid artery calcifications between nonlacunar and lacunar isch-
emic strokes. However, a higher calcification volume in the aortic arch was associated 
with nonlacunar strokes (Chapter 4.1). These findings only partially confirm the no-
tion of distinct etiologies for nonlacunar and lacunar ischemic strokes. They suggest 
that the potential role of other plaque components, plaque morphology, and aortic 
arch calcifications in ischemic stroke subtypes needs further evaluation; a research 
question which we can also address in the PARISK-study or other future prospective 
plaque imaging studies.
In the final chapter (Chapter 5) the main findings, their implications, methodologi-
cal considerations and future perspectives are discussed. In conclusion, character-
ization of the atherosclerotic plaque by advanced imaging techniques gives unique 
and valuable insights in the association between atherosclerotic plaque composition 
and blood coagulation; between plaque composition and plaque pathophysiology; 
and between plaque composition and ischemic stroke subtypes. The association be-
tween VWF and ADAMTS13 and atherosclerosis remains unclear. In addition, CEUS, 
MDCTA and MRI each have their own advantages and limitations and do not allow 
an evidence based preference for one particular image modality at this point. The 
multicenter Plaque At RISK (PARISK) study will hopefully help answer the ques-
tion whether plaque imaging indeed can help clinical decision making. The PARISK 
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study is an example for future studies; cooperation between different academic and 
technical partners and reaching beyond the borders of your own expertise to achieve 
scientific and clinical progress. Future studies should focus on simplifying and stan-
dardization of plaque imaging protocols and analyses to enable the transition to the 
clinical situation. 
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Samenvatting
Hart- en vaatziekten, waaronder beroerte, zijn de tweede doodsoorzaak in Nederland 
met ongeveer 38.000 sterfgevallen per jaar.1 Daarnaast is beroerte de belangrijk-
ste oorzaak van invaliditeit. De meeste beroertes zijn herseninfarcten (87%)2; er is 
sprake van een zuurstoftekort in de hersenen doordat een bloedstolsel een bloe-
dvat in de hersenen heeft afgesloten. Bij een TIA (Transient Ischemic Attack) zijn 
deze onderbreking en de daaropvolgende neurologische symptomen tijdelijk, meestal 
uren, en is er geen permanente schade.3 Bij zowel herseninfarcten als TIA’s speelt 
slagaderverkalking (atherosclerose) een belangrijke rol en is de klinische behandeling 
vergelijkbaar.2
Atherosclerose is een chronische ontstekingsziekte van vooral de grote slagad-
ers. In eerste instantie verdikt de vaatwand, deze verdikking ontwikkelt zich tot een 
atherosclerotische plaque en kan een vernauwing (stenose) geven van het bloedvat. 
Eén van de grote gevaren van de atherosclerotische plaque is het scheuren van de 
plaque (plaque ruptuur) waardoor de inhoud van de plaque in contact komt met het 
bloed en er een stolsel kan ontstaan. Dit stolsel kan embolieën veroorzaken die een 
slagader van de hersenen kunnen afsluiten met als gevolg een herseninfarct. Echter, 
niet elke plaque ruptuur leidt tot klinisch symptomen (Hoofdstuk 1).4-6
Beeldvormende technieken zoals contrast-enhanced echografie (CEUS), mul-
tidetector-row computed tomografie angiografie (MDCTA) en magnetic resonance 
imaging (MRI) hebben het mogelijk gemaakt om de hoeveelheid atherosclerose te 
kwantificeren door middel van de stenosegraad, maximale vaatwand oppervlak of 
kalkvolume. Bovendien kunnen kenmerken van de kwetsbare, i.e. ruptuur gevoelige, 
plaque worden afgebeeld zoals plaque ulceratie, intraplaque bloeding (IPH) en de 
focale necrose en vetophoping. In dit proefschrift heb ik me geconcentreerd op de 
atherosclerotische plaque in de halsslagader afgebeeld met CEUS, MDCTA en MRI. 
De hoeveelheid atherosclerose en specifieke plaque kenmerken, ook wel beeldvor-
mende biomarkers genoemd, heb ik gebruikt om te proberen een beter begrip te 
krijgen van de plaque pathofysiologie en de rol van de bloedstolling. Daarnaast heb 
ik onderzocht welke beeldvormende technieken en biomarkers waardevol kunnen zijn 
in de klinische praktijk.
Bloedstolling speelt een rol bij atherosclerose en het ontstaan van herseninfarcten. 
We hebben een sterke correlatie gevonden tussen kalkvolume in de aortaboog en de 
halsslagaders en Von Willebrand Factor (VWF) levels bij patiënten met een hersen-
infarct of TIA; dit suggereert een positieve associatie tussen atherosclerose en VWF 
(Hoofdstuk 2.1). Net zoals in de huidige literatuur7,8 werden de hoogste VWF levels 
gevonden bij patiënten met atherosclerose in vergelijking met patiënten met een 
andere oorzaak van het herseninfarct of TIA (bijvoorbeeld een stolsel uit het hart of 
afwijkingen van de kleine vaatjes in de hersenen) (Hoofdstuk 2.1). Echter, als we 
specifiek kijken in een groep patiënten met atherosclerose van de halsslagaders of 
als we kijken naar kenmerken van de ruptuur gevoelige plaque zoals plaque ulcerat-
ies, intraplaque bloedingen en de focale necrose en vetophoping, vinden we geen 
associaties tussen de beeldvormende biomarkers en de stollingsfactoren VWF en AD-
AMTS13 (Hoofdstuk 2.2 en 2.3). Het precieze mechanisme van de associatie tussen 
de stollingsfactoren VWF en ADAMTS13 en het risico op hart- en vaatziekten is nog 
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onduidelijk; bloed biomarkers kunnen een marker zijn van wijdverspreide atheroscle-
rose of een meer complexe rol hebben in atherosclerotische plaque ontwikkeling.
US, MDCTA en MRI worden gebruikt in de huidige klinische praktijk om de stenoseg-
raad van de halsslagader te beoordelen. De stenosegraad wordt gebruikt om patiënt-
en met een herseninfarct of TIA te identificeren die het meest profijt hebben van een 
carotis-endarterectomie (CEA). De laatste decennia is er veel belangstelling voor het 
gedetailleerd afbeelden van de atherosclerotische plaque, zodat we op een andere 
manier naar de plaque kunnen kijken dan alleen met de stenosegraad, en meer 
kunnen leren over de plaque pathofysiologie. We hebben gevonden dat intraplaque 
bloedingen op MRI geassocieerd worden met onderbrekingen van het plaque opper-
vlak op MDCTA (Hoofdstuk 3.1). Omdat we voor dit onderzoek een dwarsdoorsnede 
hebben gebruikt, zijn er follow-up studies nodig om een  oorzakelijk verband tussen 
de intraplaque bloeding, plaque ruptuur en het herseninfarct en/of TIA te bevestigen. 
Verder hebben we aangetoond dat MRI een goede sensitiviteit, maar lage specificiteit 
heeft voor de detectie van kalk in de plaque vergeleken met MDCTA. Kalkvolume 
gemeten met MRI kwam over het algemeen overeen met kalkvolume gemeten met 
MDCTA. Er waren echter grote individuele verschillen, zodat MRI momenteel niet 
kan worden aanbevolen om kalkvolume in de atherosclerotische plaque te bepalen 
in individuele patiënten met een symptomatische vernauwing van de halsslagader 
(Hoofdstuk 3.2). Op de laatste plaats hebben we een beperkt nut gevonden voor het 
gebruik van “normale” echografie bij de detectie van plaque ulceraties. Het gebruik 
van contrastmiddel (CEUS) kan echter toegevoegde waarde hebben bij de detectie 
van ulceraties (Hoofdstuk 3.3). Concluderend, (CE)US, MDCTA en MRI hebben ieder 
hun eigen mogelijkheden en beperkingen en zijn niet uitwisselbaar. Op dit moment is 
er geen duidelijke voorkeur voor een bepaalde beeldvormende techniek. Extra studies 
gericht op de evaluatie van kenmerken van de ruptuur gevoelige plaque die het risico 
op het krijgen van een herseninfarct of TIA verhogen, moeten helpen om deze vraag 
te beantwoorden.
Een voorbeeld van een studie die hopelijk helpt bij het beantwoorden van deze vraag, 
is de Plaque at Risk (PARISK) studie; een grote multicenter cohortstudie die onder-
zoekt of gedetailleerde beeldvorming van de atherosclerotische plaque gebruikt kan 
worden om beter te identificeren welke patiënten met een 30-69% symptomatische 
stenose in de halsslagader een verhoogd risico hebben op het krijgen van een nieuw 
herseninfarct of TIA (Hoofdstuk 4.2). Naast de mogelijke rol van beeldvorming van 
de atherosclerotische plaque in risicoschatting, kunnen beeldvormende biomarkers 
ook helpen om onze kennis van plaque pathofysiologie en de oorzaken van hers-
eninfarcten te vergroten. We vonden geen verschil in kalk in de halsslagader tussen 
twee soorten herseninfarcten (niet-lacunaire en lacunaire herseninfarcten). Echter, 
een groter kalkvolume in de aortaboog was geassocieerd met niet-lacunaire infarc-
ten (Hoofdstuk 4.1). Dit bevestigt slechts gedeeltelijk de veronderstelde verschillende 
oorzaken van niet-lacunaire en lacunaire herseninfarcten. Het suggereert dat de rol 
van andere plaque kenmerken en aortaboog calcificaties in oorzakelijke subtypen 
van het herseninfarct verder moeten worden onderzocht. Een onderzoeksvraag die 
ook zal worden beantwoord in de PARISK-studie of andere toekomstige studies naar 
beeldvorming van de atherosclerotische plaque.
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In het laatste hoofdstuk (Hoofdstuk 5) worden de belangrijkste bevindingen, de 
implicaties, methodologische overwegingen en toekomstperspectieven besproken. 
Concluderend, karakterisering van de atherosclerotische plaque door middel van 
geavanceerde beeldvormende technieken geeft unieke en waardevolle inzichten in 
de relatie tussen atherosclerotische plaque samenstelling en de bloedstolling; tussen 
plaque samenstelling en plaque pathofysiologie; en tussen de plaque samenstelling 
en herseninfarct subtypen. De associatie tussen VWF en ADAMTS13 en atheroscle-
rose blijft onduidelijk. CEUS, MDCTA en MRI hebben elk hun eigen voor- en nadelen 
en er is op dit moment geen duidelijke voorkeur voor een bepaalde beeldvormende 
techniek. De multicenter Plaque at Risk (PARISK) studie zal hopelijk helpen bij het 
beantwoorden van de vraag of beeldvorming van de atherosclerotische plaque inder-
daad kan helpen bij de klinische besluitvorming. De PARISK studie is een voorbeeld 
voor toekomstige studies; een nauwe samenwerking tussen verschillende academi-
sche en technische partners en het integreren van verschillende expertisegebieden 
om wetenschappelijke en klinische vooruitgang te boeken. Toekomstig onderzoek 
moet zich richten op de vereenvoudiging en standaardisatie van protocollen en beel-
danalyses van de atherosclerotische plaque om de overgang van wetenschappelijk 
onderzoek naar de dagelijkse klinische praktijk mogelijk te maken.
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Dankwoord
Dit proefschrift was nooit tot stand gekomen zonder de steun, toewijding en hulp van 
natuurlijk de patiënten van de PARISK-studie en mijn promotoren, collega’s, vrienden 
en familie. Deze pagina’s wil ik graag gebruiken om jullie hiervoor te bedanken. Ik 
heb mijn best gedaan om niemand te vergeten, mocht je er onverhoopt toch niet tus-
sen staan, bij deze: “Excuses en bedankt!”.
Allereerst de patiënten van de PARISK-studie; net hersteld, of nog herstellend, van 
een herseninfarct of TIA kwamen jullie naar het Erasmus MC om allerlei extra onder-
zoeken te ondergaan voor de studie. Ik heb veel respect voor de tijd en energie die 
jullie erin hebben gestoken.
Mijn promotoren, prof. dr. Aad van der Lugt en prof. dr. Peter Koudstaal. 
Beste Aad, ruim zes jaar geleden kwam ik via de neurologie bij jou op gesprek. Na 
dat eerste gesprek wist ik eigenlijk nog niet zo goed wat me te wachten stond, maar 
ik besloot om de gok te wagen. Zoveel jaar later staan we hier en ik kijk met heel veel 
plezier terug op de afgelopen jaren. Je hebt me mijn eigen weg laten vinden en ik 
heb veel van je geleerd. Ik ben dan ook blij dat ik de komende jaren nog met je mag 
blijven werken als onderzoeker en als coördinator van het Erasmus MC Stroke Center. 
Beste Peter, omdat er op de neurologie niet direct een plek was, heb je me voorge-
steld aan Aad. Maar je bleef betrokken als mijn promotor en met alle praktische en 
klinische vragen op het gebied van de neurologie kon ik bij je terecht. Al was het wel 
even wennen om van prof. Koudstaal naar Peter te gaan. Ook heb je me geholpen 
met mijn twijfels t.a.v. de opleiding tot neuroloog. Inmiddels heb ik een ander pad 
gekozen, maar ik ben blij dat door mijn nieuwe functie, onze samenwerking blijft.
De leden van de leescommissie, Prof.dr. F.W.G. Leebeek, Prof.dr.ir. A.F.W. van der 
Steen en Prof.dr. J. Hendrikse, wil ik bedanken voor het beoordelen van mijn proef-
schrift. Beste Frank, dank voor de interessante discussies tijdens de hema-neuro-
radiologie overleggen. Beste Ton, dank voor de feedback op mijn papers en de dis-
cussies tijdens de PARISK semi-annual meetings. Beste Jeroen, dank voor de fijne 
samenwerking binnen de PARISK-studie.
De overige leden van de promotiecommissie, Prof.dr. W.J. Niessen, Prof.dr. H.J.M. 
Verhagen en dr. P.J. Nederkoorn, dank ik voor het plaatsnemen in de grote promotie-
commissie. Beste Paul, dank voor de fijne samenwerking binnen de PARISK-studie en 
de feedback op mijn papers.
Lieve Kim, toen ik in mijn examenjaar VWO zat, begon jij aan je MBRT-opleiding. 
Na een middelbare school tijd zonder exacte vakken was dat wel even pittig. Maar 
natuurlijk redde je het en ik ben dan ook super trots op hoe ver je bent gekomen. Mijn 
onderzoek op de radiologie heb je dan ook vanaf dag één super interessant gevon-
den. Daarnaast ben je mijn maatje en is het dan ook vanzelfsprekend dat je naast me 
staat als ik mijn proefschrift mag verdedigen.
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Lieve Rozanna, door de verhuizing naar het Na-gebouw kwamen we op dezelfde 
kamer terecht en hebben we elkaar beter leren kennen. Met de jaren is onze vriend-
schap alleen maar gegroeid. Je hebt altijd een luisterend oor en staat voor me klaar 
met een goed advies. Het is ook heel fijn dat we de laatste fase van onze promotie-
trajecten samen kunnen “doorstaan”. Ik weet zeker dat jij het super gaat doen op 31 
januari. Na januari gaat onze vriendschap een mooie nieuwe fase in! Ik kijk nu al uit 
naar het weekendje Edinburgh met Rebecca bij jou en Mat. 
En dan mijn andere kamergenootjes van “Room 13”; Rebecca, Taihra en Renske. 
Rebecca, we hebben zoveel leuke dingen gedaan de afgelopen jaren, te veel om op 
te noemen… En je stond ook altijd voor me klaar als vriendin. Des te leuker is het dan 
ook dat je inmiddels postdoc bent op de radiologie en we voorlopig kamergenootjes 
blijven! En laat de borrels, etentjes en uitstapjes naar Edinburgh maar komen :). 
Taihra, jij begon als student bij mij en Aad, net nadat ik gestart was als promovendus. 
Kalkscores, stenosegraden, TCD apparaten ophalen bij patiënten thuis, niks was een 
probleem. Inmiddels ben je alweer een tijdje zelf bezig als promovendus, erg leuk om 
zo samen te mogen blijven werken en ik wens je veel succes met je verdere traject. 
Renske, in veel dingen zijn we erg verschillend, toch hebben we ook genoeg gemeen. 
Je maakt zoveel ontwikkelingen mee, ga zo door en veel succes in je verdere promo-
tietraject en radiologie opleiding. 
En niet te vergeten mijn oud kamergenootjes en collega’s van de radiologie/BIGR, 
waaronder Kristina, Rinske, Carolina, Marjon, Martijn, Arna, Zaïd, Daniel en Sjel. 
Kristina, een jaar werken we nu ongeveer samen op de PARISK-studie. Je bent super 
enthousiast en wil graag alles weten. Ga vooral zo door en veel succes met je verdere 
traject. Rinske, het was altijd erg gezellig als je weer een keer kwam binnenvallen 
op kamer 13 en niet te vergeten in de Efteling en bij de film/spelletjesavonden. Veel 
succes in je verdere loopbaan en kom zeker nog eens binnenvallen. Carolina, we 
have missed you in Rotterdam for quite some time now, but is has been very nice to 
have you as a friend, roommate and fellow stroke researcher. Enjoy Chile and your 
beautiful family. Marjon, je bent degene die me wegwijs heeft gemaakt op de afdeling 
en in het onderzoek. Bovendien hadden we het ook nog eens erg gezellig samen in 
He. Inmiddels zit je alweer een tijd in de kliniek en ben je ook in de laatste fase van 
je onderzoek beland. Ik wens je veel succes met het afronden en laten we de bijklets 
etentjes vooral in ere houden. Martijn, eerst als student en toen als tijdelijke onder-
zoeker hebben we veelvuldig samen mogen werken en altijd met veel plezier. Heel 
veel succes met je verdere opleiding als radioloog. Arna, samen hebben we aan de 
PARISK-studie mogen werken, jij de technische kant en ik de klinische. Omdat we het 
goed konden vinden samen, kwamen deze werelden ook een stuk dichter bij elkaar. 
Erg leuk om, zelfs nu je alweer even in Londen zit, alsnog de samenwerking op te zoe-
ken. Zaïd, ook wij hebben samen mogen werken in de PARISK-studie en inmiddels 
ben je bezig met de huisartsopleiding. Veel succes en een mooie toekomst gewenst. 
Daniel, dank voor de gezelligheid en het sparren over statistiek dan wel de carotiden/ 
atherosclerose. Sjel, ook dank voor de gezelligheid de afgelopen jaren en succes met 
het afronden van je promotie.
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Als promovendus mocht ik ook samen werken met een aantal enthousiaste studenten 
waaronder Burhan, Nawid en Karlijn. Met jullie hulp zijn er mooie papers tot stand 
gekomen en ik wens jullie een mooie toekomst toe.
Dear Piotr, it has been a while since we were scanning the PARISK patients in room 
10. Sometimes the discrepancy between the interest of the patients and the interest 
of the research lead to a small discussion, but we always made it work. It was a real 
pleasure to work with you. Sylvia, Hanneke en Sita, dank voor jullie hulp bij de prak-
tische zaken rondom de MRI.
Voor de praktische zaken die komen kijken bij het opzetten en laten lopen van een 
studie zoals de PARISK en een promotietraject in het algemeen, was ik erg blij met de 
hulp van Laurens, Mart, Stefan, Naziha, Ton en Jolanda. Laurens, samen hebben we 
volgens mij één van de eerste “afdelings OpenClinica” databases opgezet (al was het 
met veel uitzoekwerk). En wat had, en heb, je toch altijd mooie vakantiefoto’s. Mart 
en Stefan, als ik het allemaal niet begreep qua servers, DICOM bestanden en andere 
te “technische” zaken, stonden jullie altijd klaar om het uit te leggen en me te helpen, 
dank daarvoor. Naziha, jij kreeg er zomaar even de PARISK follow-up bij… Voor mij 
was het wel een hele opluchting dat iemand, zo ervaren als jij, de follow-up gesprek-
ken op zich wilde nemen. Ton, met vragen over posters, figuren en photoshop, kon 
ik altijd even bij je binnenlopen. Bovendien heb je me geholpen met het maken van 
een mooi proefschrift, dank voor al je hulp. Jolanda, in de periode dat het even iets 
minder ging, heb jij me geholpen bij de zaken waar ik tegenaan liep en soms gewoon 
alleen geluisterd. Zonder die steun, stond ik hier nu niet.
Multicenter studies zoals de PARISK kunnen tot veel problemen leiden onder de ver-
schillende centra. Gelukkig was dit in de PARISK-studie niet zo, we hebben altijd met 
veel plezier samen gewerkt, getuige de verschillende “PARISK-etentjes” welke we 
hebben gehad met de promovendi. Martine, Floris, Anja, Alexandra, Madieke, Ge-
neviève, Remko, Jos, Jeire, Raf, Eline en Werner bedankt voor al die jaren aan mooie 
samenwerking. Ook de perifere centra in de regio mag ik natuurlijk niet vergeten. 
De afdelingen neurologie en radiologie van het Maasstad ziekenhuis (Ritu Saxena), 
Vlietland ziekenhuis (Hans Verhey), SFG (Stef Bakker) en IJsselland ziekenhuis (An-
nemarie Wijnhoud) wil ik graag bedanken voor hun deelname aan de PARISK-studie. 
In het bijzonder het Maasstad ziekenhuis, waar ik elke week welkom was om te zien 
of er nog potentiële deelnemers waren langs geweest.
Ook de andere PARISK-collega’s zoals bijvoorbeeld Stijn, Luit, Kim, Diego, Zeynettin, 
Guilleame, Ronald, Rob en Leander wil ik bedanken voor de fijne samenwerking. Ik 
wens jullie allen een mooie toekomst toe.
Natuurlijk wil ik ook mijn collega’s van de neurologie bedanken, de neurovasculaire 
groep in het bijzonder. Susanne, de kalkscores van de ESS patiënten hebben ons 
naast mooie papers, ook een mooie samenwerking opgeleverd. Inmiddels zit je in het 
HAGA als neuroloog, veel succes en een mooie toekomst. Inger, naast de gezellige 
neurologie congressen heb ik recent ook nog met je mogen samenwerken bij de or-
ganisatie van het “1st Erasmus MC conference on acute stroke treatment”. Er komen 
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spannende tijden voor je aan, eerst een klein wondertje op de wereld zetten en dan 
je eigen promotie- en opleidingstraject afronden. Veel succes en plezier toegewenst. 
Maaike en Dorien, we leerden elkaar kennen op de stroke preventie poli waar ik altijd 
jullie advies kon vragen, vervolgens een hoop gezelligheid op de congressen en nu 
werken we ook weer samen in het Stroke Center. Leuk om zo samen te blijven wer-
ken! Boudewijn, jou heb ik al leren kennen toen ik mijn keuzeonderzoek nog deed 
op de KNF. Toen ik terugkwam voor mijn promotie traject op de radiologie, zijn we 
altijd contact blijven houden. Bij onze lunches kwamen geregeld de hoogtepunten en 
tegenslagen van het promoveren voorbij… Veel succes in Utrecht.
Buiten de samenwerking met andere centra, was en is het ook heel prettig samenwer-
ken met de afdelingen in huis zoals de hematologie en cardiologie. Michelle, Moniek, 
dankzij jullie is de stolling veel meer voor mij gaan leven. Niet voor niks beslaat het 
een aanzienlijk deel van mijn proefschrift. Michelle, veel succes met je opleiding tot 
internist. Moniek, onze samenwerking houdt nog niet op, er liggen nog een paar 
mooie projecten in het verschiet. Anouchska, Heleen, het is helaas nog niet gelukt 
om ons gezamenlijk project af te ronden, maar daar zijn we druk mee bezig. Hopelijk 
kun jij dan ook toewerken naar de afronding van je promotietraject, Anouchska.
In januari 2016 ben ik gestart als coördinator van het Erasmus MC Stroke Center. Ik 
wil de directie (Peter Sillevis-Smit, Clemens Dirven, Peter Koudstaal, Diederik Dippel, 
Aad van der Lugt) en het dagelijks bestuur (Diederik Dippel, Aad van der Lugt, Ruben 
Dammer, Tilly van den Bout) van het Stroke Center bedanken voor de kans welke ik 
heb gekregen. Zeker het internationaal congres wat er aan zit te komen in maart, is 
een mooie kans om het Stroke Center nog meer op de kaart te zetten. Ik kijk uit naar 
alle mooie dingen die we nog mogen doen samen. Diederik, met de jaren hebben 
onze paden al diverse keren gekruist, binnen het Stroke Center werken we nu inten-
siever samen en met veel plezier. Dank voor alles wat ik hier nog kan en mag leren.
Ik heb geleerd dat een goede thuisbasis minstens net zo belangrijk is om een promo-
tietraject tot een goed einde te brengen als goede en fijne collega’s. Zonder de ge-
zellige (spelletjes) avonden, etentjes, dagjes weg, boswandelingen en zwemavondjes 
lag dit proefschrift er ook zeker niet. Bedankt lieve vrienden; Coen, Marleen, Adam, 
Wouter, Marlinde, Marnouk & …, Erwin, Annemieke, Saskia, Boaz, Liam en Elena. 
Lieve Mirjam en Myriam, in het eerste jaar van de geneeskunde opleiding kwamen we 
bij elkaar in de groep en zoveel jaren later kijk ik nog steeds uit naar onze etentjes en 
middagjes bij elkaar. Elk ons eigen pad gelopen, maar nog steeds nooit uitgepraat. 
Dank voor jullie geïnteresseerde vragen en steun de afgelopen jaren.
Soms is het lekker en nodig om alles om je heen even te vergeten, tekenen en schil-
deren helpt mij hierbij. Zeker als je dan midden in de Loonse en Drunense Duinen 
mag zitten met een ezel en een schildersdoek… Dank Jorg voor de fijne cursussen en 
je hulp bij het ontwerpen van de omslag van mijn proefschrift.
En natuurlijk wil ik mijn schoonfamilie, Robert, Mariëlla, Fender, Jolanda, Richard en 
Senn bedanken voor alle steun en gezonde afleiding. In het bijzonder mijn schoon-
ouders, Harrie en Wilma, jullie staan altijd voor ons klaar. Zeker nu met Bram en 
Processed on: 2-12-2016
506902-L-sub01-bw-vanDijk
5
Dankwoord
7
mijn werk in Rotterdam geeft het veel rust om te weten dat we op jullie terug kunnen 
vallen.
Lieve Robin en Samantha, ook al wonen we niet bij elkaar om de hoek, we weten 
elkaar altijd te vinden als het er om gaat. Zo veel mooie dingen hebben we al mogen 
delen, zoals bijvoorbeeld de geboorte van jullie prachtige dochter Nomi! Ik ben ook 
heel blij dat ik deze mijlpaal, mijn verdediging, met jullie mag delen en vieren.
Lieve pap en mam, ik ben ontzettend dankbaar dat ik de afronding van mijn promo-
tietraject met jullie beiden mag delen. Jullie staan altijd voor me klaar, of het nu gaat 
om “de nacht van Van Dijk”, het proefpersoon zijn in één of andere studie, oppassen 
op Bram of gewoon mijn verhaal aanhoren. Jullie hebben altijd in mijn kunnen ge-
looft en er alles aan gedaan om me te helpen mijn doelen te bereiken, dank jullie wel!
En dan als laatste, lieve Marcel, het duurde even voordat we elkaar leerde kennen, 
want het zou waarschijnlijk toch niet klikken tussen ons… En hier staan we dan zoveel 
jaren later: getrouwd en een prachtige zoon! Zonder jou, je onvoorwaardelijke steun 
en de stabiele basis die we samen hebben gecreëerd, had dit proefschrift hier nu niet 
gelegen, dankjewel voor alles. Lieve Bram, wat is het genieten om jou te zien groeien 
en ontwikkelen. Heerlijk om te zien hoeveel blijdschap zo’n kaboutertje kan geven. 
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